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 I 
Abstract 
Glial cells express a wide range of neurotransmitter receptors throughout the 
central nervous system (CNS). In this thesis, I have investigated glial 
neurotransmitter signaling mechanisms in CNS white matter, using the mouse 
optic nerve as a model white matter and with a particular focus on metabotropic 
glutamate receptors (mGluR). The transcriptomic profiling of postnatal, adult and 
ageing optic nerve identified a pre-eminence of glutamatergic neurotransmission 
in the optic nerve and highlighted a switch to GABAergic signaling in the ageing 
white matter, without a loss of glutamatergic neurotransmission. 
Immunostaining showed expression of group I and group II mGluR in optic nerve 
astrocytes and oligodendrocytes and their functionality was demonstrated by 
live cell calcium imaging. Activation of group I and group II mGluR is shown to 
protect both oligodendrocytes and astrocytes from hypoxia/ischaemia, using an 
oxygen and glucose deprivation (OGD) model in the isolated intact mouse optic 
nerve. A key finding is that mGluR were expressed by glia at all ages and were 
not developmentally downregulated, as had been suggested from previous in 
vitro studies. In addition, the genomic analysis indicated disruption of OPCs in 
ageing tissue, and significant age-related disruption of OPCs was confirmed in 
the triple transgenic mouse model of Alzheimer’s disease (3xTg AD). This study 
provides new insight into mGluR expression and function in white matter glia. 
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Section 1 
 
General Introduction 
  
 2 
1.1  CNS glial cells 
The central nervous system (CNS) is composed of two main cell types – 
neurones and neuroglia. The term ‘neuroglia’ was coined in 1856 by Rudolf 
Ludwig Karl Virchow, who described it as ‘nerve glue’, the mere connective 
tissue of the brain (comprehensively reviewed in Verkhratsky and Butt, 2013). In 
the following decades glial cells became the interest of the Nobel prize winning 
histologists Camillo Golgi and Santiago Ramon y Cajal, who clearly described the 
morphology of astrocytes using metal impregnation staining techniques. It was 
Cajal’s student, Pio Del Rio Hortega, who developed the metal staining 
technique further to provide the first descriptions of oligodendrocytes and 
microglia. Nowadays, CNS glia are broadly classified into astrocytes, 
oligodendrocytes, ependymal cells and microglia, in addition to a population of 
oligodendrocyte progenitor cells (OPCs), or NG2-glia, that populate the adult 
brain. The two main macroglial cell types, astrocytes and oligodendrocytes, 
have the same lineage as neurones and are derived from embryonic neural 
stem cells with a neuroectodermal origin. Ependymal cells are also 
neuroectodermal and line the ventricles of the brain and central canal of the 
spinal cord, where they assist in the production, monitoring and circulation of 
the cerebrospinal fluid (CSF). Microglia are not neural cells: they are derived 
from the yolk sac macrophages that seed the neuroepithelium during early fetal 
development. Embryonic microglia expand and colonise the whole CNS until 
adulthood, to serve as the resident macrophages and immune-competent cells 
of the so-called ‘immune privileged’ CNS (Ginhoux et al., 2013).  
 3 
1.1.1 General features of astrocytes 
Astrocytes, or astroglia, in general are star-shaped cells that can be 
identified by their expression of the intermediate filament glial fibrillary acidic 
protein (GFAP), the metabolic enzyme glutamine synthetase (GS) or the 
glutamate transporters GLAST and GLT-1. Astrocytes are broadly divided into 
two main subtypes according to their morphology and location - protoplasmic 
astrocytes of the grey matter and fibrous astrocytes of the white matter (Figure 
1.1). However, these are umbrella terms, and astrocytes display a very wide 
range of morphologies and highly varied expression of GFAP, in the rodent CNS 
(Figure 1.1) (Emsley & Macklis, 2006) and even more so in the human brain 
(Oberheim et al., 2012). One of the most established methods for identifying 
astrocytes is the use of transgenic reporter mice, in which GFAP drives the 
expression of a fluorescent reporter, such as enhanced green fluorescent 
protein (EGFP)(Nolte et al., 2001), as illustrated in Figure 1.2. 
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Figure 1.1 Morphological diversity of astrocytes throughout the CNS. Representative 
astrocytes from different regions of the brain and spinal cord of an adult transgenic 
mouse expressing enhanced green fluorescence protein under control of the GFAP 
astrocyte specific promoter (hGFAP-EGFP) (Emsley & Macklis, 2006). 
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Figure 1.2 CNS astrocytes in the GFAP-EGFP reporter mouse (Robel et al., 2011) 
 
Protoplasmic astrocytes are expressed throughout the grey matter and 
have highly branched fine processes that contact the basement membrane 
surrounding the blood vessels and enwrap synaptic connections (Figure 1.2a). 
White matter fibrous astrocytes have thicker and less branched processes that 
contact axons at nodes of Ranvier (Figure 1.2b). In addition, other astrocytes 
have a radial morphology and include the Bergmann glia in the cerebellum and 
the Müller glia in the retina. In the CNS there is no region devoid of astrocytes; 
which are organized in a contiguous, non-overlapping manner (Halassa et al., 
2007).  
Astrocytes perform a wide range of functions that are essential for CNS 
functioning and integrity (Table 1.1) (Verkhratsky and Butt, 2013). As well as 
providing the physical support and structure of the CNS, astrocytes provide for 
homeostasis of the extracellular environment, primarily through uptake of K+ 
and glutamate, which are constantly released by neurones and have 
pathological consequences if allowed to build up (Martinez-Hernandez et al., 
1977; Kimelberg et al., 1979; Levi et al., 1983; Ransom & Sontheimer, 1992; 
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Horio, 2001; Kofuji & Newman, 2004). Astrocytes also provide energy substrates 
to neurones (Pellerin & Magistretti, 1996; Suh et al., 2007), and help couple 
cerebral blood flow to neuronal activity (Iadecola & Nedergaard, 2007; Koehler 
et al., 2009). In addition, astrocytes express neurotransmitter receptors and are 
able to release neurotransmitters, and can directly modulate synaptic 
transmission (Haydon, 2001; Allen & Barres, 2005). Astrocytes play an 
important role in brain development, by providing a scaffold along which 
neurones can migrate and extend their axons (Powell & Geller, 1999), 
strengthening newly formed synapses (Ullian et al., 2001), regulating 
neurogenesis and gliogenesis (Doetsch, 2003), and playing an essential role in 
development and maintenance of the blood-brain barrier (BBB) (Araya et al., 
2008). Furthermore, astrocytes play a key role in CNS defence and 
neuroprotection, undergoing ‘reactive astrogliosis’ in response to CNS insults, 
characterised by formation of a ‘glial scar’, together with immune responses 
and secretion of inflammatory factors (Sofroniew, 2009). Thus, astrocytes can 
be described as homeostatic cells and their dysfunction can have dire 
consequences for neuronal function and integrity, and hence astrocytes are 
central to all neuropathologies (Verkhratsky and Butt, 2013). 
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Table 1.1 Major functions of astrocytes and references 
 
A defining physiological feature of astrocytes is that they are non-
excitable, i.e. they do not conduct action potentials as do neurones. However, 
astrocytes express voltage-gate sodium channels (Nav) and both voltage-gated 
potassium channels (Kv) and inward rectifying potassium channels (Kir) that 
carry inward and outward currents in response to shifts in the membrane 
potential, which in neurones is the molecular and ionic basis of the action 
potential (Nedergaard et al., 2003). Moreover, astrocytes express a very wide-
range of neurotransmitter receptors that on activation result in changes in the 
membrane potential, but unlike neurones these do not trigger action potentials 
because the density of Nav is too low and the density of Kv and Kir is very high in 
Regulation of extracellular environment: 
Homeostasis of H+ 
K+ buffering 
Glutamate and GABA uptake 
(Kimelberg et al., 1979) 
(Ransom & Sontheimer, 1992) 
(Martinez-Hernandez et al., 1977) 
(Levi et al., 1983) 
Support for neurons through the 
astrocyte-neuronal lactate shuttle 
(Pellerin & Magistretti, 1996) 
Control of cerebral blood flow and 
functional hyperaemia 
(Zonta et al., 2003b) 
Modulation of synaptic transmission (Haydon, 2001) 
Regulation of brain development: 
Neuronal migration 
Synapse formation 
Neurogenesis and gliogenesis 
(Powell & Geller, 1999) 
(Ullian et al., 2001) 
(Doetsch, 2003) 
Formation and maintenance of the blood 
brain barrier 
(Araya et al., 2008) 
Reaction to CNS injuries (reactive gliosis) (Sofroniew, 2009) 
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the astrocyte cell membrane, essentially clamping the astrocyte cell membrane 
close to the equilibrium potential for potassium (EK) (Kimelberg et al., 2006). 
Instead of electrical excitability, activation of astrocytes display regulated 
increases in intracellular calcium concentration ([Ca2+]i) in response to receptor 
activation (Figure 1.3), and this represents astroglial ‘calcium excitability’ and 
their mechanism of intracellular and intercellular communication (Cornell-Bell 
et al., 1990; Charles et al., 1991).  
 
 
 
 
 
Figure 1.3 Mechanisms of intercellular Ca2+ signaling in astrocytes. 
Intercellular Ca2+ signals can be propagated by the passage of IP3 through gap 
junctions (A), or release of neurotransmitters such as ATP (B), or a 
combination of both (adapted from Verkhrtasky and Butt, 2013)  
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1.1.2 General features of oligodendrocytes 
The main function of oligodendrocytes is the formation of myelin, the 
fatty multilamellar structure that insulates axons and guarantees high-speed 
conduction of action potentials. Each oligodendrocyte can myelinate up to 30 
axons within a short distance of the cell body (Butt & Ransom, 1989; Ransom et 
al., 1991) (Figure 1.4). Failure in myelin formation (dysmyelination) and myelin 
degradation (demyelination) affect neuronal activity; both of these processes 
are important in neuropathology, as observed in demyelinating diseases such as 
multiple sclerosis (MS) and leukodystrophies, as well as neurodegenerative 
diseases, such as Alzheimer’s disease, where myelin loss has been described 
(Bartzokis et al., 2003).  
 
Figure 1.4 Myelinating oligodendrocyte (Lundgaard et al., 2013) 
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Oligodendrocytes in the forebrain are derived from oligodendrocyte progenitor 
cells (OPCs) that originate from neural stem cells (NSC) of the subventricular 
zone (SVZ) (Richardson et al., 2006). During development, OPCs migrate to their 
destinations in the brain, where they proliferate and differentiate into 
oligodendrocytes in response to endogenous mechanisms and local 
environmental cues. OPCs are defined by their expression of the chondrotin 
sulphate proteoglycan (CSPG) neuron-glia 2 (NG2) and of the platelet-derived 
growth factor receptors of the  subtype (PDGFR) (Mudhar et al., 1993; 
Nishiyama et al., 1996a; b; Butt et al., 1997a; Butt et al., 1997b). The 
differentiation of OPCs into oligodendrocytes is characterized by a number of 
key stages that can be distinguished by expression of stage-specific 
transcription factors and myelin-related proteins (Figure 1.5); key stages are 
that once OPCs stop proliferating and begin to differentiate into 
oligodendrocytes they lose NG2 and PDGFR, and first express early markers 
such as galactocerebroside (GalC), and then the myelin-specific proteins myelin 
basic protein (MBP) and proteolipid protein (PLP). Proliferation and 
differentiation of OPCs is controlled by a large number of factors, some of the 
most important being PDGF, fibroblast growth factor (FGF2), Wnt signalling, 
insulin-like growth factor (IGF-I) and Sonic hedgehog (Chandran et al., 2003; 
Fancy et al., 2009; Kim et al., 2009; Azim & Butt, 2011). 
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Figure 1.5 Markers of oligodendrocyte lineage specification and maturation 
(Schumacher et al., 2012) 
 
1.1.3 Adult OPCs 
A substantial population of OPCs persists in the adult CNS after 
development and the main period of oligodendrocyte generation and 
myelination (Figure 1.6); adult OPCs have also been termed NG2-glia, since they 
are primarily identified by their expression of this CSPG, but NG2 is also 
expressed by pericytes in the CNS, and OPCs can be distinguished by their co-
expression of the classically defined OPC markers PDGFR and O4 (Nishiyama et 
al., 1996a; Reynolds & Hardy, 1997). Adult OPCs are found throughout the grey 
and white matter and form synaptic contacts with neurones and axons at nodes 
of Ranvier (Bergles et al., 2000; Butt et al., 2005; Kukley et al., 2007; Ziskin et al., 
2007). Adult OPCs generate new oligodendrocytes at a slow rate throughout life 
and this is increased following CNS injury and/or demyelination (Dimou et al., 
2008; Rivers et al., 2008; Zhu et al., 2008b; Kang et al., 2010). Adult OPCs 
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represent the largest proliferative cell population in the adult brain (Dawson et 
al., 2003; Butt et al., 2005), although their cell cycle time gets longer with 
ageing (Psachoulia et al., 2009; Simon et al., 2011). Like stem cells, OPCs divide 
asymmetrically to form ‘sister OPCs’, one for self-renewal of the OPC population 
and the other differentiates into an oligodendrocyte. OPCs are vital for restoring 
myelin, by proliferating in the injury site and giving rise to new oligodendrocytes 
(Tripathi et al., 2010; Guo et al., 2011). 
 
 
Figure 1.6 Oligodendrocyte progenitor cell (OPC) in the adult brain  
(Vanzulli, unpublished) 
 
1.2  Myelination  
Myelin is an electrical insulator composed of 70% lipids and 30% proteins. 
The most abundant proteins, and therefore myelin markers, are proteolipid 
protein (PLP), the myelin basic protein (MBP), the myelin oligodendrocyte 
 13 
glycoprotein (MOG), the myelin associated glycoprotein (MAG) and the 2’, 3’-
cyclic nucleotide 3’-phosphodiesterase (CNPase) (Dubois-Dalcq et al., 1986). In 
the mouse brain, myelination starts at birth in the hindbrain and proceeds 
caudally and rostrally (Foran & Peterson, 1992; Baumann & Pham-Dinh, 2001). 
Myelination in vivo requires neuron-glia recognition that can be organized in 
subsequent stages (Butt & Berry, 2000): 
 Contact between axon and immature oligodendrocyte 
 Induction phase: OPC extends initiator processes along a receptive axon 
 Remodeling phase: oligodendrocyte loses non-myelinating processes 
and myelin wraps around the axon initiate with the formation of 
internodal segments and the establishments of nodes of Ranvier 
 Maturation phase: myelin sheaths grow to establish the adult axonal 
diameter and myelin is compacted 
Several molecules control this process: integrins and adhesion molecules are 
believed to be involved in the initiation of myelination (Laursen & Ffrench-
Constant, 2007). Neuregulin is thought to be responsible for the decision of an 
oligodendrocyte to myelinate a particular axon (Sherman & Brophy, 2005), 
whereas Fyn kinase has been reported to promote oligodendroglial process 
growth and to initiate myelin wrapping (Klein et al., 2002).  
  
Myelination is not a process restricted to the postnatal age. White 
matter volume keeps increasing until the fourth decade of life in humans 
(Bartzokis et al., 2001) and around 70% of corpus callosum is still non-
myelinated in eight month-old mice (Sturrock, 1980). These evidences and the 
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existence of a pool of adult OPCs indicate that myelination is an active and 
plastic process throughout life (Rivers et al., 2008). The ‘myelin model’ proposes 
that myelin is the basis to vertebrate cognitive function and that in humans 
developmental deficits in myelin as well as injury or age-related breakdown and 
loss of myelin are a fundamental substance of psychiatric and 
neurodegenerative disorders, including schizophrenia, bipolar disease and 
Alzheimer’s disease (AD) (Bartzokis, 2002; Bartzokis et al., 2003; Bartzokis, 
2004; Bartzokis et al., 2007; Bartzokis, 2011a). It is known that CNS plasticity 
and repair decreases with age, and there is an age-related decline in the 
capacity for OPCs to regenerate new oligodendrocytes (Rivers et al., 2008; 
Psachoulia et al., 2009). This has led to the hypothesis that failure in recruiting 
OPCs and in their differentiation into myelinating oligodendrocytes is a central 
feature of the failure of myelination in the ageing brain and in demyelinating 
disease (Shields et al., 1999; Franklin, 2002; Sim et al., 2002). 
 
1.3   Neurotransmitter receptors in glial cells 
The purinergic and glutamatergic receptors are the main signaling systems 
that regulate glial functions, but glial cells express receptors for the main CNS 
neurotransmitters, neuropeptides, cytokines and chemokines (for detailed list 
see (Verkhratskiĭ & Butt, 2013)) and can release many signaling molecules 
(Figure 1.7).  
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Figure 1.7 Neurotransmitter receptors in glial cells. (Adapted from Verkhrtasky and 
Butt, 2013) 
 
In astrocytes, neurotransmitter receptors are the sensors by which 
astrocytes are able to respond to changes in neuronal synaptic signaling, for 
example activation of glutamate receptors stimulates Na+/K+ pumps, glutamate 
uptake, and astroglial metabolic support for neurones, by stimulating lactate 
release and regulating local blood supply (Figure 1.8).  
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Figure 1.8. Neurotransmitters in astrocyte functions. (1) Astrocytes uptake 
synaptically released glutamate via specific glutamate transporters. (2) Communication 
between astrocytes occurs via ATP release and binding to purinergic receptors, 
expressed on adjacent astrocytes, which elicits a downstream calcium mobilization. (3) 
Gap junctions allow the exchange of small molecules and therefore contribute to cell-
cell communication. (4) Astrocytes are responsible for the replenishment of neuronal 
glutamate via the glutamate-glutamine cycle and (5) for energy supply and storage 
thanks to their ability to transport glucose from the vasculature. (6) The release of 
vasoactive substances at the astrocyte end-feet regulates local blood flow. (7) Increase 
in intracellular calcium concentration might lead to the release of glutamate and other 
factors, i.e. prostaglandins. Glutamate release through hemichannels can be induced in 
vitro through lowering of extracellular calcium. (9) Glutamate binding to metabotropic 
glutamate receptors on astrocytes activates intracellular calcium, leading to the release 
of vasodilatatory substances. Abbreviations: Gln, glutamine; Glu, glutamate; IP3, 
inositol trisphosphate; PLC, phospholipase C. (Maragakis & Rothstein, 2006) 
 
Oligodendrocytes and OPCs also express a wide range of ion channels and 
neurotransmitter receptors, although with the exception of glutamate 
receptors, these are poorly defined (Verkhratsky and Butt, 2013). A common 
feature in oligodendrocytes is that neurotransmitters receptors are generally 
downregulated with differentiation, and numerous in vitro studies provide 
evidence they can regulate OPC proliferation, migration and differentiation 
(Figure 1.9). However, little is known about the physiological functions of 
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oligodendroglial neurotransmitter receptors and evidence they regulate 
myelination in vivo or in situ is lacking (for recent review, see (Butt et al., 
2014a)).  
 
Figure 1.9.  Neurotransmission and oligodendrocyte differentiation. Oligodendrocytes 
express a number of neurotransmitter receptors that are generally downregulated with 
age and are implicated in regulation of differentiation and myelination  (From 
Verkhratsky and Butt, 2013). 
 
1.4  The glutamatergic system  
A key feature of both astrocytes and oligodendrocytes is their expression 
of glutamate receptors. Glutamate is the main excitatory neurotransmitter in 
the mammalian CNS, and plays a crucial role in primary physiological neuronal 
and glial functions, and it is pivotal for higher brain functions such as learning, 
memory and cognition (Watkins & Evans, 1981). Furthermore, dysregulation of 
the glutamatergic signaling and glutamate excitotoxicity have been implicated 
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in an array of neuropathologies, with central roles in stroke and amyotrophic 
lateral sclerosis (ALS), as well as multiple sclerosis, epilepsy and schizophrenia 
(Nakanishi, 1992; 1994; Beneyto et al., 2007). Glutamate receptors are classified 
in ionotropic glutamate receptors (iGluRs) and metabotropic glutamate 
receptors (mGluRs). iGluRs are ligand-gated ion channels permeable to K+, Na+ 
and Ca2+ and are classified into three groups according to the name of the 
agonist that binds to them with highest specificity, namely NMDA (N-Methyl-D-
Aspartate), AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate), and 
Kainate (KA) receptors (Wisden & Seeburg, 1993; Lodge, 2009). AMPA receptors 
are assembled from four subunits, GluA1-4, all of which have been identified in 
astrocytes (Seifert & Steinhauser, 2001). The absence of the GluA2 subunit 
confers greater Ca2+ permeability on the AMPA receptor, which is a feature in 
OPCs (Hamilton et al., 2010), and it is suggested that oligodendroglial AMPA 
receptors comprise exclusively GluA3 and GluA4 (Itoh et al., 2002). Functional 
KA receptors have not been detected on astrocytes, but oligodendrocytes 
express GluK2-5 subunits (De Biase et al., 2010). Until quite recently, glial cells 
were not considered to express NMDA receptors, but physiological and 
immunocytochemical studies have identified functional NMDA receptors in 
astrocytes (Schipke et al., 2001) and oligodendrocytes (Káradóttir et al., 2005). 
NMDA receptors assemble as heteromers that require a GluN1 subunit and at 
least one GluN2 subunits (from GluN2A-D). Astrocyte and oligodendrocyte 
NMDA receptors are likely to be formed from two GluN1, one GluN2 and one 
GluN3 subunit, which reduces their Mg2+ block and makes them active at resting 
membrane potential (Káradóttir et al., 2005; Lalo et al., 2011). mRNA for all 
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NMDA receptor subunits have been detected in the optic nerve (Salter & Fern, 
2005) (Table 1.2).  
Table 1.2 Differential expression of ionotropic glutamate receptors in astrocytes, 
oligodendrocytes and OPCs. 
 Astrocytes Oligodendrocytes OPCs 
NMDA 
GluN1, 2A-D and 
GluN3A-B  
(Conti et al., 1996; 
Schipke et al., 2001; Lee 
et al., 2010) 
Functional expression of 
tri-heteromers of GluN1, 
GluN2C and GluN3A/B 
(Salter & Fern, 2005; 
Burzomato et al., 2010) 
GluN1, GluN2C and 
GluN3A/B 
(Karadottir et al., 2008; 
Domingues et al., 2011) 
AMPA 
All four known subunits 
GluA1-4 
(Seifert & Steinhauser, 
2001) 
GluA2, GluA3, GluA4 
(Itoh et al., 2002; De 
Biase et al., 2010) 
GluA3 and GluA4. 
GluA2 non edited or 
absent (Li & Stys, 2000) 
KA 
No functional expression 
detected yet 
GluK2-5 
(Kukley & Dietrich, 2009) 
GluK2-5 
(Sanchez-Gomez & 
Matute, 1999; De Biase 
et al., 2010) 
 
 
 
1.4.1  Metabotropic glutamate receptors 
mGluRs are members of the seven transmembrane domain G protein-
coupled receptor (GPCR) C family (Figure 1.10) and represented by three groups 
associated with distinct intracellular pathways. Eight different mGluRs have 
been cloned and they are divided in three groups, based on their second 
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messenger coupling, pharmacology and amino acid sequence (Pin & Bockaert, 
1995). Members of the same group share approximately 70% sequence 
homology, which is reduced to 45% between members of different groups 
(Conn & Pin, 1997). Group I mGluRs (mGluR1 and mGluR5) are positively 
coupled to phospholipase C (PLC) via Gq/11 and inositol triphosphate (IP3) 
formation. Their activation leads to an increase in intracellular calcium levels 
([Ca2+]i) by inducing calcium release from intracellular stores. Both group II 
(mGluR2 and mGluR3) and III (mGluR4, mGluR6, mGluR7 and mGluR8) are 
negatively coupled to adenylyl cyclase via Gi/G0 (Table 1.3). In addition, 
activation of group II mGluRs can lead to stimulation of K+ channels, inhibition 
of voltage-gated Ca2+ channels, and activation of the MAPK and PI3K signaling 
pathways (Pin & Duvoisin, 1995). 
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Figure 1.10 Generic mGluR structure. A schematic representation of a monomeric 
form of the metabotropic glutamate receptor; the N-terminal contains the binding site 
for glutamate and other competitive agonists/antagonists whilst non-competitive 
antagonists bind to the 7TM domain. (Spooren & Gasparini, 2004) 
 
 
 
Table 1.3 Group classification of metabotropic glutamate receptors. 
From IUPHAR database website 
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In situ hybridization analyses illustrate the expression mGluRs RNA in 
different brain regions (Figure 1.11). mGluR1 is highly expressed in cerebellum 
and olfactory bulb (Masu et al., 1991) and its expression is detected also in 
neuronal cells of the hippocampus and in cerebellar purkinje cells (Masu et al., 
1991), in the substantia nigra, lateral septum, globus pallidum and thalamic 
relay nuclei (Shigemoto et al., 1992; Baude et al., 1993). mGluR5 RNA has been 
detected most abundantly in the striatum and lower in the cerebellum and 
pons; it is expressed in hippocampus, striatum and lateral septal nucleus (Masu 
et al., 1991; Abe et al., 1992; Shigemoto et al., 1992). The expression of mGluR5 
is developmentally downregulated and different splice variants are expressed in 
different regions and at different time through life: mGlu5a isoform is expressed 
highly in all brain regions during early postnatal ages, whereas mGlu5b is highly 
expressed in the hippocampus, striatum and cerebral cortex in adult (Romano 
et al., 1996). mGluR2 and mGluR3 expression is widespread throughout the CNS 
(Nicoletti et al., 2011), highest in the cerebellar cortex and in the olfactory bulb 
(Ferraguti & Shigemoto, 2006), whereas group III subunits have more 
specialized expression, for example mGluR4 is abundant in the parallel fibers of 
cerebellar granule cells (Kinoshita et al., 1996). 
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Figure 1.11 Distribution of mGluR subunits in the mouse brain. In situ hybridization 
labeling of midline sagittal brain sections from a P56 male C57BL/6J mouse. OB: 
olfactory bulb; CTX: cortex; HP: hippocampus; CBL: cerebellum. Images from Allen 
Brain Atlas.  
 
 
At the cellular level, group I subunits are localised mainly at the 
postsynaptic membrane in the vicinity of NMDA and AMPA receptors (Baude et 
al., 1993; Petralia et al., 1996), whereas group I receptors, group II and III 
mGluRs are mainly located presynaptically (Ferraguti & Shigemoto, 2006). 
mGluR act as neuromodulators involving the generation of slow excitatory and 
inhibitory synaptic potentials, and hence modulation of synaptic transmission, 
synaptic integration, and plasticity (Figure 1.12) (Coutinho & Knopfel, 2002). 
mGluR-subtypes are implicated in multiple nervous system disorders, including 
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ischaemia-induced brain damage, traumatic brain injury, Huntington's and 
Parkinson's-like pathology, epilepsy, and Fragile-X syndrome (Flor et al., 2002). 
 
 
 
Figure 1.12 Distribution and synaptic modulatory function of mGluRs in excitatory 
synapses. (Benarroch, 2008) 
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Experimental studies have demonstrated that mGluRs can increase 
cellular survival during injury paradigms through the activation of the PI3-K/Akt 
pathway (Figure 1.13) (Chong et al., 2003). In rat hippocampal neuronal 
cultures, application of the group I mGluR agonists prevent neuronal injury 
during oxidative stress through increased Akt activity (Chong et al., 2005; Chong 
et al., 2006). In addition to Akt and PKC that have been previously discussed, 
protein kinase A (PKA) is another potential pathway that may offer control of 
synaptic plasticity as well as cytoprotection through the mGluR system (Figure 
1.13). During paradigms of cellular injury, activation of PKA can prevent 
apoptosis in a number of cell types, including neurons, neutrophils, and smooth 
muscle cells (Maiese et al., 1993; Rossi et al., 1995; Orlov et al., 1999). In 
addition, loss of PKA activity during toxic insults can lead to cell injury (Findik et 
al., 1995; Nishio & Watanabe, 1997). Protection by PKA is believed to reside 
upstream from the inhibition of caspase 3-like activity (Parvathenani et al., 
1998). Furthermore, PKA has been shown to phosphorylate Bad, a member of 
Bcl-2 protein family, which can prevent the induction of cell injury (Lizcano et 
al., 2000). Moreover, activation of group-II and group-III mGluR is 
neuroprotective, whereas group-I mGluR need to be antagonized in order to 
evoke protection, e.g. using the group-II mGluR agonist LY354740 and mGluR5-
selective antagonist MPEP. 
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Figure 1.13 Cytoprotective effects achieved through mGluRs activation. G-protein βγ 
in the mGluR system activates phospholipase β (PLC-β), diacylglycerol (DAG), and 
phosphoinositide 3 kinase (PI 3-K). These pathways lead to the activation of protein 
kinases A (PKA), B (Akt) and C (PKC) that can involve intracellular calcium (Ca2+). mGluRs 
can activate ERK2 through PKC. PKA can phosphorylate (p) Bad, a member of Bcl-2 
protein family, which can prevent apoptotic cell injury. Akt provides an anti-apoptotic 
survival signal through the phosphorylation and inactivation of Bad and also interfaces 
with the Wnt pathway. Interconnected pathways with Akt and Wnt involve the 
forkhead family members (FOXO), mitochondrial (Mito) membrane potential (ΔΨm), 
cytochrome c (Cyto-c), and caspases. If left unabated, these pathways converge to lead 
to apoptotic cell injury. (Maiese et al., 2008) 
 
 
Glial cells predominantly express mGluR1, mGluR3 and mGluR5. In 
astrocytes, activation of mGluR5 elicits a rise in [Ca2+]i  and can induce the 
release of glutamate and other neurotransmitters, which can evoke synaptic 
responses in neighbouring cells (Pasti et al., 1997; Bezzi et al., 1998). The in vivo 
 27 
expression of mGluR in oligodendrocytes is unclear. In vitro, OPCs express 
GluR1, mGluR2/3, mGluR4 and mGluR5 and they are developmentally 
downregulated, being high in OPCs and low or absent in immature and mature 
oligodendrocytes (Deng et al., 2003). One study has reported expression of 
mGluR1 and mGluR5 in premyelinating oligodendrocytes of postnatal day (P) 6 
rat cerebral white matter and in human postmortem preterm tissue (Jantzie et 
al., 2010). In addition, activation of mGluR5 in an OPC cell line has been shown 
to evoke Ca2+ oscillations and to be completely lost during differentiation (Luyt 
et al., 2006). These studies indicated that myelinating oligodendrocytes do not 
express mGluR, that in OPCs and premyelinating oligodendrocytes are 
considered to be potentially protective. 
 
1.5  Hypoxia/ischaemia and glutamate excitotoxicity 
The brain is amongst the most metabolically active organs in the body, 
together with heart and liver, despite accounting for only 2% of the body’s mass 
(Cunnane et al., 2011). The brain stores little energy in the form of glycogen and 
relies on circulating glucose and oxygen to meet its metabolic needs (Prins, 
2008). When the cerebral blood flow is disrupted (ischaemia) and the oxygen 
supply is reduced (hypoxia) for prolonged time, neuronal cell death occurs, 
resulting in a hypoxic brain injury. In adults, stroke is the leading cause of 
disability and is one of the most frequent causes of death. In neonates, 
prolonged hypoxia/ischaemia can cause injury resulting in mental retardation, 
seizures or motor disabilities (Vexler & Ferriero, 2001). One of the most 
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common outcomes is cerebral palsy, which is often caused by periventricular 
leukomalacia (PVL), an injury of the white matter structures surrounding the 
ventricles, characterized by early axonal and glial damage (Banker & Larroche, 
1962; Volpe, 2001; 2009). Ischaemia can be global or focal. Global ischaemia is 
the result of a heart arrest and leads to a complete interruption of the cerebral 
blood flow (CBF), with loss of consciousness. Ten minutes of global ischaemia 
are fatal for humans; at a cellular level, electrical activity disappears within 40 
seconds from the beginning of ischaemia, selective neuronal death can occur 
and astrocytes become reactive (Rossi et al., 2007; Hertz, 2008). In the case of 
focal ischaemia, the damage is confined to the area surrounding the occluded 
vessel. If the focal ischaemia is transient and CBF is restored, the damaged area 
is reperfused, which constitute a risk in itself because of the production and 
diffusion of reactive oxygen species (ROS).  
 
In hypoxia/ischaemia, the lack of oxygen and glucose causes a reduction 
of intracellular adenosine triphosphate (ATP) and cells undergo anoxic 
depolarization (Rossi et al., 2007). Neurones lose their excitability and all cells 
lose their capacity to maintain intracellular ion homeostasis (Hansen & 
Nedergaard, 1988). This results in a drop in pH, accumulation of extracellular K+, 
influx of NA+, Ca2+ and Cl- and a massive release of glutamate, result of synaptic 
release and uptake failure (Hansen & Nedergaard, 1988; Goldberg & Choi, 1993; 
Martinez-Sanchez et al., 2004; Bano & Nicotera, 2007). Calcium is pivotal in 
mediating cell death, whereas glutamate release amplifies the damage by 
glutamate excitotoxicity. Glutamate activates NMDA and AMPA receptors, 
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which depolarize the cell membrane and activate voltage-operated channels; 
this leads to further Ca2+ influx, aggravating the intracellular calcium overload. 
Increased intracellular Ca2+ promotes the release of additional glutamate, 
triggering a vicious cycle of glutamate excitotoxicity (Figure 1.14). The cytosolic 
Ca2+ is accumulated in the mitochondria, further compromising their ability to 
produce ATP. Moreover, Ca2+ can stimulate proteolytic enzymes, resulting in 
fatal damage to the cell membrane, cytoskeleton and DNA. 
 
 
Figure 1.14 Mechanisms of glutamate excitotoxicity. From Verkhratsky and Butt 
(2013). 
 
Within the infarcted core, excitotoxicity and necrotic death start after 
few minutes, whereas in the penumbra, the area surrounding the core, cell 
death occurs more slowly by apoptosis (Doyle et al., 2008; Hertz, 2008). Like 
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neurones, oligodendrocytes and OPCs are particularly sensitive to ischaemia, 
most likely because of their inadequate anti-oxidative defences and high levels 
of AMPA/kainite receptor expression (Fern & Möller, 2000; Back et al., 2001; 
Káradóttir et al., 2005; Karadottir et al., 2008). Astrocytes are generally 
considered to be less susceptible to ischaemia, although there is evidence of 
astrocytic dysfunction and death following ischaemia, with astrocytes in 
postnatal ages being particularly vulnerable (Fern, 1998; Zhao & Flavin, 2000; 
Bondarenko & Chesler, 2001; Shannon et al., 2007; Salter & Fern, 2008).  
 
1.6  The optic nerve as a model white matter 
The focus of this study is CNS white matter, because it is essential for higher 
brain function and is also disrupted in multiple neuropathologies, including 
multiple sclerosis, leukodystrophies, stroke, and AD (Bartzokis, 2011b; Butt et 
al., 2014a). Furthermore, there are numerous reports on the importance of 
neurotransmitters in white matter pathology, although the precise receptors 
and mechanisms are largely unresolved (Fern et al., 2014). The optic nerve is 
one of the most commonly studied white matter preparations and will be used 
throughout this thesis to study glial characteristics and functions. The optic 
nerve contains the axons of retinal ganglion cells and the glial cells that support 
them (Butt et al., 2004, Bolton and Butt, 2005). In tracts such as the optic nerve, 
most if not all axons are myelinated, whereas other tracts can contain both 
myelinated and small diameter unmyelinated axons. Developmentally, 
astrocytes appear first and guide axonal growth to reach their targets. OPCs 
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enter the optic nerve around birth and differentiate into myelinating 
oligodendrocytes during the first two weeks postnatal (Tsai & Miller, 2002). It is 
perhaps surprising that neurotransmitter-mediated signalling is prominent in 
the optic nerve, since there are no neuronal cell bodies or conventional neuron-
neuron synapses. However, there is abundant evidence for glutamate- and ATP-
mediated neurotransmission in the optic nerve, as well as other 
neurotransmitters such as GABA and norepinephrine (Figure 1.15). 
 
Figure 1.15 Diversity of neurotransmitters in the optic nerve. From (Butt et al., 
2014a). 
 
As described above, on the basis of in vitro studies, there are putative 
roles for neurotransmission in regulating OPC differentiation and myelination in 
the optic nerve. In addition, a great deal of our knowledge of the role for 
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glutamate and ATP in white matter pathology comes from the optic nerve (Butt 
et al., 2014a). However, most studies have been on postnatal optic nerves, and 
little is known about the precise neurotransmitters expressed in the adult or 
ageing optic nerve. In addition, the physiological function of neurotransmission 
in the optic nerve is unresolved, although extensive studies have shown that 
astrocytes, oligodendrocytes and OPCs make contacts with axons (Butt et al., 
1994a; Butt et al., 1994b; Butt et al., 1999), and that axonal activity activates 
glutamate and purine receptors on optic nerve OPCs and can trigger [Ca2+]i 
increase in astrocytes and OPCs (Kriegler & Chiu, 1993; James & Butt, 2001; Butt 
et al., 2004; Kukley et al., 2007; Ziskin et al., 2007; Hamilton et al., 2008; 
Hamilton et al., 2010). The sources of neurotransmitters in white matter and 
mechanisms of their release remain obscure, but the old dogma that chemical 
synaptic specializations occur exclusively between neurones has been 
overturned by studies over the past 20 years. First, there was the discovery that 
OPCs form functional glutamatergic and GABAergic synapses with neurones in 
hippocampus (Bergles et al., 2000; Lin & Bergles, 2004). Later, OPC were found 
to make occasional synapses with unmyelinated axons in an en passant fashion 
(Kukley et al., 2007; Ziskin et al., 2007), and in myelinated axons they contact 
nodes of Ranvier and respond to axonal activity (Hamilton et al., 2010). To add 
to the complexity, astrocytes can also have mechanisms of vesicular release of 
glutamate and ATP (Volterra & Meldolesi, 2005), and optic nerve axons contain 
glutamate-loaded vesicles and the machinery for vesicular release (Alix et al., 
2008). Combined with evidence that oligodendrocytes and myelin express 
glutamate receptors, this has led Stys to argue that potential communication 
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between axons and myelin may represent a new type of ‘axon-myelin synapse’ 
that regulates myelination even in adulthood (Stys, 2011). 
 
1.7  Hypothesis and aims 
There is abundant evidence of glutamate-mediated signaling in glial cells 
and of its importance in white matter neuropathology. However, the majority of 
studies have been on postnatal tissue and it is unclear whether 
neurotransmitter signaling mechanisms persists after maturation. Furthermore, 
despite evidence that glia express mGluR and that they may be therapeutic 
targets for neuroprotection, their expression and function in white matter glia is 
unknown. Thus, the hypothesis underpinning this thesis is that mGluR are 
expressed by white matter glia and may have a protective function against 
hypoxia/ischemia. The overall aim of the thesis is to test this hypothesis using 
the mouse optic nerve as a model CNS white matter. Moreover, towards the 
end of this project, a collaboration with a Spanish research group was 
established and, as a result, brain tissue from a triple transgenic mouse model 
of Alzheimer’s disease became available. Therefore, the specific objectives of 
this study are to: 
1. Identify age-related changes in the neurotransmitter profile of the 
mouse optic nerve. 
2. Examine the expression of functional group I and group II mGluR in 
astrocytes and oligodendrocytes in the optic nerve. 
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3. Determine whether mGluR are protective for white matter glia in 
hypoxia/ischemia 
4. Examine the changes in mGluR5 expression, myelin and OPCs in ageing 
and pathology, using a triple transgenic mouse model for Alzheimer’s 
disease.   
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Section 2 
Materials and methods 
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2.1  Animals 
2.1.1  Declaration 
Animals were humanely killed by cervical dislocation, in accordance with 
the regulations issued by the Home Office of the United Kingdom under the 
Animals (Scientific Procedures) Act (ASPA), 1986. 
 
2.1.2  Animal Strains 
Several different strains of mice were used; C57BL/6J (Wild type black) 
and transgenic strains;  
 SOX10-lox-GFP-4xPolyA-lox-DTA, which expresses the enhanced green 
fluorescent protein (EGFP) under transcriptional control of the SOX10 
gene (Stolt et al., 2006). The SOX10-EGFP transgenic line was a gift from 
William D Richardson and Nikoleta Kessaris’ lab (UCL).  
 TgN (GFAP-EGFP) GFEC-FKi, expressing EGFP under the control of the 
GFAP gene promoter, resulting in green astrocytes (Nolte et al., 2001).  
 TgN (PLP-DsRed1), expressing enhanced red fluorescent protein (DsRed - 
drFP583, from Discosoma species) under the control of the PLP gene 
promoter, resulting in red myelin (Hirrlinger et al., 2005). The GFAP-
EGFP and PLP-DsRed transgenic lines were a generous gift from Dr. 
Frank Kirchhoff (Max Planck Institute for Experimental Medicine, 
Gottingen, Germany). 
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 NG2-DsRed BAC, in which DsRed is expressed under the control of the 
NG2 promoter (Zhu et al., 2008a). The NG2-DsRed transgenic line was a 
gift from Dr. Akiko Nishiyama (University of Connecticut, USA). 
 3xTg AD, which harbours the APP Swedish mutations K670N/M671L, the 
presenilin-1 M146V mutation and the tau P301L mutation in the C57BL6 
mice background (Oddo et al., 2003) and is a model for Alzheimer’s 
disease. 6 months and 24 months 3xTgAD and age-matched brain tissue 
was kindly provided by Prof JJ Rodriguez (Ikerbasque, Bilbao, Spain). 
 
2.1.3  Animal Ages 
Mice of both sexes but different ages were used throughout this study. 
P10-12 (i.e. post natal day 10-12), 1 month or 18 months old mice were used for 
optic nerve microarray analysis; old optic nerve tissue wasn’t available for the 
qRT-PCR experiments, therefore the analysis focused on early myelinating tissue 
(P7), myelinated tissue (P12) and P30. For the expression studies, P8-9 mice 
were used for brain/optic nerve sections and optic nerve explants, since the 
protocol for the latter technique is optimised for pre-myelinated tissue. P7-13 
optic nerves were analysed in calcium imaging experiments because of 
inadequate loading of the calcium sensing dye in older optic nerves. Optic 
nerves from P8-11 mice were used for the oxygen and glucose deprivation study 
in order to explore the cytoprotective effect of the activation of mGluR. Finally, 
in section 6, 6 months and 24 months old 3xTg AD and age-matched control 
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male mice brain tissue was kindly provided by Prof. JJ Rodriguez (Ikerbasque, 
Bilbao, Spain), who suggested these two age points as early and late stages of 
pathology in the triple transgenic mouse model for Alzheimer’s disease. 
 
2.1.4  Tissue Fixation Protocols 
Three different fixation protocols have been used in the duration of this 
project:  
a) 1% PFA with 15% Picric acid for 10 mins to fix optic nerve explant 
cultures  
b) 4% PFA with 15% Picric acid to plunge-fix mouse brains (24 hrs) and 
optic nerves (1 hr) for immunohistochemistry. The fixed tissue was then 
cryoprotected in 30% sucrose.  
c) 4% PFA to plunge-fix optic nerves for 1 hr after oxygen glucose 
deprivation. 
 
2.2  Molecular Biology 
2.2.1  Total RNA Extraction 
All tissues, except the P30 optic nerve samples, were disrupted and 
homogenized using the TissueRuptor and disposable probes of approximately 
10 mm diameter (Qiagen, Crawley, West Sussex, UK). Extraction of RNA was 
performed using the RNeasy Micro Kit (Qiagen) following the manufacturer’s 
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instructions, from approximately 5 mg of mouse cortex, cerebellum and optic 
nerve. When extracting RNA from P30 optic nerves, the tissue was placed in 500 
µL of ice cold Trizol (Sigma) and mechanically disrupted using a sterile plastic 
pestle (Fisher) and homogenised by being passed through a 23G syringe 10 
times on ice. Homogenate was allowed to rest for 5 mins and then passed 
through a QIAshredder column (Qiagen) for further homogenisation. 100 µL 
chloroform (Sigma) was added and the homogenate shaken vigorously for 15 
secs before being allowed to rest for 3 mins at room temperature. Then, 
samples were centrifuged at 12000 g for 5 mins at 4°C. Finally, the top clear, 
aqueous phase containing the RNA was aspirated and transferred into a new 1.5 
ml eppendorf where it was mixed at 1:1 ratio with 70% ethanol. The RNeasy 
Micro Kit procedure was followed from that point onwards. Approximately 5 mg 
of tissue was placed in RNA later until it was disrupted and homogenized using 
the TissueRuptor in a round bottomed collection tube containing a guanidine 
thiocyanate (GITC) lysis buffer (RLT) and then centrifuged for 3 mins at 13000 
rpm. GITC is a chaotropic salt, i.e. a potent protein denaturant, which 
inactivates RNases thus allowing for the RNA to be isolated intact. The 
supernatant was carefully removed and placed in a new collection tube before 
adding 70% molecular grade ethanol at 1:1 ratio. It was then transferred onto 
an RNeasy spin column containing a silica-gel membrane upon which the RNA 
would bind during subsequent centrifugation at 10000 rpm for 15 secs. A 
further wash with 350 µl of a chaotropic salt containing buffer (RW1) was 
performed at 10000 rpm for 15 secs in order to wash away any remaining 
contaminating impurities such as degraded proteins and a last was with ethanol 
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was utilised to wash away the salts. A dry spin for 5 mins at full speed was 
performed to remove all ethanol residues from the membrane. Complete 
removal of ethanol is essential for high yields of clean eluent. If there is ethanol 
remaining on the column then the nucleic acids will not be completely 
rehydrated and elution will result in low yields. Finally, high quality total RNA 
was eluted in 10µl RNA-free water by centrifuging for 1 min at full speed. 
An extra DNase digestion step using DNase I (Qiagen) was performed in 
order to eliminate genomic DNA that was released in the lysate, as the 
homogenisation protocol disrupted the nucleic as well as the cell membranes. 
All RNA samples were stored at -80°C. 
The purity and concentration of isolated total RNA was assessed using a 
ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) to 
measure the UV absorption of samples. The absorption at 260nm (A260) was 
used to determine the concentration of RNA in undiluted samples. The ratio of 
absorptions at 260 nm and 280 nm (A260/A280 ratio) was used to determine the 
samples’ purity, where a ratio of >1.8 indicated high RNA purity. As RNA 
optimally absorbs light at a wavelength of 260 nm due to its high content of 
nucleotides, while proteins and other impurities that might be contaminating 
the isolated RNA absorb best at 280 nm, the A260/A280 ratio is the preferred 
way to assess if an RNA sample is pure.  
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2.2.2  Quantitative real time PCR (qRT-PCR) 
The RT2 First Strand Kit (Qiagen) was used for in vitro transcription of 
extracted RNA into cDNA to be used for qRT-PCR, following the manufacturer’s 
instructions. The quantity of RNA that was transcribed was the same for all 
samples (500 ng). 1350 µl of 2x SYBR Green qPCR Mastermix (Qiagen) was 
mixed with 102 µL cDNA and 1248 µl ultra-pure water (Ambion) and 25 µL was 
pipetted in each well of the 96 well-plate arrays. The custom mGluR array used 
was purchased from SABiosciences (Qiagen) and thermocycled on a Roche 
Lightcycler 96 instrument (Roche). The protocol used was the following; 95 °C 
for 15 secs (1 cycle), followed by 60 °C for 1 min (45 cycles). Data normalisation 
was performed using the best housekeeping genes for each experiment. 
Optimal housekeeping genes were chosen using the NormFinder logarithm 
(Andersen et al., 2004) and the standard deviation (SD) method (Mane et al., 
2008). The method of Comparative Quantitation was used to study the 
expression of metabotropic glutamate receptors with the following formula; 
Ct Sample – Ct Calibrator = ∆Ct 
Relative quantity = Av(2-∆Ct) 
The fold change in mRNA transcript levels between different ages was 
calculated using the -∆Ct method and tested for significance using ANOVA and 
post hoc Bonferroni’s tests. Statistical analysis was performed using the Prism 6 
software (GraphPad).  
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2.2.3  Microarray 
 The microarray profiling presented in Section 3 is the result of my 
analysis on microarrays performed by two of my colleagues, Dr. Virginia 
Hawkins and Dr. Andrea Rivera, who collected the postnatal/ageing and adult 
samples respectively, and carried out the RNA extraction following the Trizol 
method. Then the samples were sent to the ATLAS-Biolabs company (Germany). 
Briefly, 1g of total RNA was used to generate biotinylated cRNA samples, 
which were hybridized to a GeneChip Mouse Genome 430_2.0 Arrays 
(Affymetrix) and visualized using a Affimetryx GeneChip Scanner 3000. This 
platform contains oligonucleotide probe sets complimentary to the 3’ end of 
the mRNA transcripts (a 3’-array), with each array containing 45,000 probe sets, 
corresponding to over 34,000 well-characterized mouse genes. Quality control 
analysis and data analysis produced .CEL image and >CHP image files for further 
analysis using an Affymetrix Genechip Operating Software. All samples passed 
quality control (QC), as reported by Atlas Biolabs (Germany).  
 Data analysis was performed using the GeneSpring GX 12 Software 
(Agilent). Data normalisation was carried out using the MAS-5 algorithm. 
GeneSpring GX software was used to profile genes of interest and obtain 
dataset from samples. 
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2.3  Cell Culture 
All cell cultures were completed within a routinely sterilized room 
containing a laminar flow cabinet (Life Technologies) and cell culture incubator 
(Fisher). 
 
2.3.1  Cover Slip Preparation 
13mm diameter glass cover-slips were sterilised by immersion in 70% 
ethanol and placed in 24-well plates (Greiner Bio-One, Manchester, UK) and left 
to dry in the culture hood. 100 µl of 1% poly L-lysine (Sigma-Aldrich, Dorset, UK) 
in double distilled sterilised water (ddH2O) was placed on each cover-slip and 
left overnight at 37°C. Poly L-lysine was removed and replaced with 25 µL of 
0.5% laminin (Life Technologies, Paisley, UK) in sterile ddH2O. After two hours, 
laminin was replaced with 30 µl of sterile ddH2O and the cover-slips were left in 
the incubator until required. Poly L-lysine coated cover-slips and slides provide 
higher adhesion, reducing the chance of tissue or cell loss during processing. 
This pre-preparation of cover-slips is required when culturing cells that do not 
adhere well. 
 
2.3.2  Optic Nerve Explant Cultures 
Optic nerve explants were cultured as previously described (Greenwood 
& Butt, 2003). Briefly, optic nerves were dissected from P8 mice and placed 
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directly into 50µl dissecting medium consisting of high glucose Dulbecco’s 
Modified Eagle Medium (DMEM) (Sigma-D5671) containing 10% Fetal Calf 
Serum (FCS; Life Technologies), L-Glutamine (Sigma) and 0.1% Gentamycin (Life 
Technologies). Next, they were finely chopped with a scalpel blade and 
triturated with pipettes of decreasing diameter (P1000 then P200) to further 
break up the tissue. After adding 50 µl more dissecting medium, the solution 
was pipetted evenly between cover slips (approx. 1 nerve per cover-slip) and 
left for the initial stick down period. After approximately 24 hrs the dissecting 
medium was replaced with a low serum (0.5%) modified Bottenstein and Sato 
(B&S) culture medium (Bottenstein & Sato, 1979) without thyroid hormones in 
which 10 ng/ml of recombinant human PDGF-a (R&D Systems) was added to 
encourage OPC proliferation. After 3-4 days in vitro (DIV) the medium was 
replaced with B&S medium supplemented with 0.5 mM dbc-AMP (Sigma) until 
DIV10.  
 
2.4  Immunostaining techniques 
2.4.1  Antibodies 
All antibodies used during this project are listed in Table 2.1 and 2.2, 
along with information concerning host species reactivity, working 
concentration and source. 
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The secondary antibodies must be raised in the same species as the 
serum used for blocking, and against the type of animal from which the primary 
antibody is derived. 
 
Table 2.1 Primary antibodies 
Antibody Host Dilution Source Reference 
mGluR5 Rabbit 1:1000 Neuromics (Lohith et al., 2013) 
mGluR2/3 Rabbit 1:300 Upstate 
Millipore 
(Meek et al., 2008) 
GFAP Chicken 1:500 Chemicon (Yoshioka et al., 
2010) 
NG2 Rabbit 1:400 Millipore (Gritti et al., 2009) 
MBP Rat 1:400 Millipore (Li et al., 2006) 
Aβ Mouse 1:1000 Covance (Olabarria et al., 
2010) 
 
Table 2.2 Secondary antibodies 
Conjugate Reactivity Dilution Source 
AlexaFluor® 
488 
Gt-a-Rb, Gt-a-
Ck, Gt-a-
Ms,Gt-a-Rat 
1:400 
Life 
Technologies 
AlexaFluor® 
568 
Gt-a-Rb, Gt-a-
Ck, Gt-a-Ms, 
Gt-a-Rat 
1:400 
Life 
Technologies 
 
Gt: goat; Rb: rabbit; Ck: chicken; Ms: mouse 
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2.4.2  Immunocytochemistry 
Cultured cells were fixed for 10 mins with 1% paraformaldehyde (PFA-
TAAB Laboratories Equipment, UK) dissolved with 15% Picric Acid in 0.2 M 
Phosphate Buffer. After washing 3 x10 mins with PBS (Sigma), cells were 
blocked for 75 mins at room temperature using blocking solution containing 5% 
Normal Goat Serum (NGS; Invitrogen) in order to prevent non-specific binding 
of both the primary and secondary antibodies (Abs) to other antigens on the 
cells. Where primary antibodies targeted an intracellular epitope of a protein, 
0.01% detergent (Triton X, Sigma) was incorporated into the blocking solution, 
for cell membrane permeabilisation. After blocking, cells were not washed 
again. Primary antibodies were diluted in PBS. Incubation was performed 
overnight according to manufacturer’s recommendations at 4°C. Cells were 
then washed 3 x 10 mins with PBS. The secondary antibody conjugates were 
diluted in PBS and added to the cells for 1 hr at room temperature on an orbital 
shaker and protected from light by wrapping the 24-well plate in foil. During 
this step, the DNA dye Hoechst Blue (Molecular Probes) was added at a 
concentration of 1:500. After completion of immuno-staining, the cells were 
once again washed 3 x10 mins with PBS and cover-slips were mounted on clean 
slides, using mounting medium (Vectashield, Vector Labs, or Fluoromount G, 
Southern Biotech). 
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2.4.3  Immunohistochemistry 
For the immunohistochemical analysis presented in Section 4, mouse 
brains and optic nerves were dissected and fixed with submersion in 4% PFA 
with 15% picric acid for 24 hrs and 1 hr respectively. After fixation, tissues were 
washed 3 times in PBS and stored in 30% sucrose in PBS at 4°C for 24-48 hrs. 
Brains and optic nerves were embedded in cryo-m-bed on a cork board and 
stored at -80C until required for use. Coronal brain sections and longitudinal 
optic nerve sections (14μm) were cut using a Leica cryostat and collected onto 
poly-l-lysine coated slides. Samples were stored at -80C until assayed. Tissue 
was blocked with 10% serum (NGS or NDS) for 1-2 hrs, washed 3 times in PBS, 
and incubated overnight in the antibody solution, which comprised of the 
primary antibody diluted in blocking solution containing Triton-X. Tissues were 
then washed 3 times again in PBS and incubated with secondary antibody 
diluted in blocking solution for 1 hr at room temperature on an orbital shaker 
and protected from the light. Following secondary antibody incubation, tissues 
were washed 3 times with PBS before being covered with mounting medium 
and glass coverslips ready for imaging. 
The 3xTgAD and age-matched control brains were kindly provided by 
Prof. JJ Rodriguez (Ikerbasque, Bilbao, Spain) and required another protocol for 
immunohistochemistry, due to a different method of perfusion, as described in 
(Noristani et al., 2012). Male 3xTgAD and non-transgenic control mice were 
anaesthetized with intra-peritoneal injection of sodium pentobarbital (50 mg 
kg) at 6 and 24 months of age. The mice were perfused through the aortic arch 
 48 
with 3.75% acrolein (TAAB, Berkshire, UK) in a solution of 2% paraformaldehyde 
(Sigma, Cambridge, UK) and 0.1 M phosphate buffer (PB) pH 7.4, followed by 2% 
paraformaldehyde. Brains were then removed and cut into 4- to 5-mm coronal 
slabs of tissue containing the entire rostrocaudal extent of the hippocampus. 
The brain sections were postfixed in 2% paraformaldehyde for 24 h and kept in 
0.1 M PB, pH 7.4. Coronal sections of the brain were cut into 40 m thickness 
using a vibrating microtome (VT1000S; Leica, Milton Keynes, UK). Free floating 
brain sections in 0.1 M PB, pH 7.4, were collected and stored in cryoprotectant 
solution containing 25% sucrose and 3.5% glycerol in 0.05 M PB at pH 7.4. 
Coronal sections at levels -1.58 ⁄ -2.46 mm (hippocampus) posterior to bregma 
were selected for immunohistochemistry according to the mouse brain atlas of 
Paxinos & Franklin. The sections were incubated for 30 min in 30% methanol in 
0.1 M PB and 3% hydrogen peroxide (H2O2) (Sigma). Sections were then rinsed 
with 0.1 M PB for 5 min and placed in 1% sodium borohydride (Sigma) for 30 
min. The sections were then washed with PB profusely before rinsing in 0.1 M 
Trizma base saline (TS) for 10 min. Brain sections were then incubated in 0.5% 
bovine serum albumin (BSA) (Sigma) in 0.1 M TS and 0.25% Triton (Sigma) for 30 
min. Sections were incubated for 24 h at room temperature in primary 
antibody. Tissues were then washed 3 times again in TS and incubated with 
secondary antibody diluted in blocking solution for 1 hr at room temperature on 
an orbital shaker and protected from the light. Following secondary antibody 
incubation, tissues were washed 2 times with TS and 3 times with PB before 
being covered with mounting medium and glass coverslips ready for imaging.  
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2.4.4  Confocal Microscopy 
Fluorescence-stained cells and sections were examined under a confocal 
microscope with the following characteristics (Table 2.3); 
Table 2.3 Confocal microscope characteristics 
Microscope 
Zeiss Axiovert LSM 710 
VIS405, 
Zeiss LSM 5 Pascal 
Axioskop 2 
Laser confocal system 
and LED Light Source 
(Colibri) 
Lasers 
Argon, helium-neon 
(HeNe1) and diode 
lasers 
Sequential excitation at 
wavelengths 488nm, 
568nm and 405nm 
Image Acquisition 
Zeiss LSM 510NLO 
confocal scan head 
x20 (air), or x40, x63 and 
x100 (oil immersed) 
objectives 
Image analysis Zeiss Software 
LSM and Zen 9000 
Software 
 
2.4.5  Immunohistochemistry negative controls 
Immunohistochemistry is a powerful investigative tool that can provide 
supplemental information to the routine morphological assessment of tissues. 
The application of antibodies requires adaptation and refinement of 
immunohistochemical protocols, particularly for use in fixed tissues. In contrast 
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to solution-based immunoassays that detect relatively abundant native 
proteins, in fixed tissues the preservation of antigen is variable and 
unpredictable. In order to avoid non-specific staining, well-characterised 
antibodies were used throughout this study (see references in Table 2.1). 
Moreover, a negative control, omitting the primary antibody, was performed in 
every essay (Figure 2.1). 
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Figure 2.1 Negative controls for immunohistochemistry. Representative images of 
negative controls, in which primary antibodies were omitted. Panels A and B show 
negative controls for mGluR2/3 and mGluR5 respectively, on optic nerve sections from 
a P8 GFAP-EGFP reporter mouse. Negative controls for GFAP, NG2 and MBP were 
carried out on brain slices from 6 months old non transgenic mouse (C, D and E), whilst 
the control for the A antibody was performed on 24m 3xTgAD brain tissue. Scale bars: 
50 m.  
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2.4.6  Morphological analysis of OPCs 
The volume and the surface of individual NG2 labeled OPCs was 
estimated on 3-dimentional reconstructed images obtained with confocal 
scanning microscopy (Zeiss 710), recording optical sections at 0.2 µm steps. 
Parallel confocal planes were superimposed and morphological analysis was 
carried out by Cell analyst software (Chvátal et al., 2007). Digital filters (average 
3x3, convolution, gauss 5x5, despeckle, simple objects removal) were used to 
determine surface and volume of the NG2-stained oligodendrocyte progenitor 
cells, as well as the surface and the volume of their soma.  
 
2.4.7 Statistical analysis 
Data are expressed as mean ± SEM. The Gaussian distribution of the 
data was analysed with the D’Agostino & Pearson’s normality test. Unpaired t-
test analysis was used to examine the differences in the surface area and 
volume of NG2 labeled cells between the 3xTg-AD and non-transgenic animals. 
Difference between the groups were considered as significant if p≤0.05. The 
statistical analysis was performed using Prism 6.0 Software (GraphPad Software 
Inc.). 
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2.5  Calcium Imaging 
2.5.1  Optic nerve dissection and dye loading 
Optic nerves were excised from P7-P13 wild type C57BL/6 mice and 
incubated for 1 hr in aCSF containing 4 µM Fluo-4 AM (Molecular Probes) which 
is a green-fluorescent Ca2+ dye in its acetoxymethyl ester form. In this form, an 
acetoxymethyl ester group renders the dye membrane permeable. Once taken 
up by a cell, cytosolic esterases remove this ester group and the dye remains 
intracellular (Garaschuk et al., 2006).  
 
2.5.2  Imaging parameters 
 Dye loaded nerves were washed in aCSF to remove excess dye, and then 
placed in a perfusion chamber under a Zeiss LSM 5 Pascal Axioskop 2 confocal 
microscope and continuous perfusion with aCSF in the bath was established. A 
20x/0.50 WPh2 Achroplan water immersion lens objective was used to visualise 
the intracellular Ca2+ changes after excitation of the optic nerves at 488 nm for 
Fluo4. Optical z-sections (typically 7-8 sections at 2–3 µm intervals) were 
obtained using the Zeiss LSM Image Examiner software (Zeiss, Germany). 
Regions of interest (ROI) covering single-cell bodies were selected within the z-
stacks and the change in fluorescence intensity was measured.  
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2.5.3  Typical experiment 
The nerve was continuously bathed in aCSF via a multitap system that 
allowed rapid turnover to solutions containing agents of interest (listed in Table 
2.4). The health of the optic nerves was assessed by briefly (30 secs) inducing an 
ATP response at the beginning and end of each experiment and in the cases that 
[Ca2+]i increase was not observed in response to ATP, the nerve was excluded 
from analysis. In any given cell, the response to ATP provided a measure of the 
maximal rise of glial [Ca2+]i, irrespective of the level of Fluo4 loading (Hamilton 
et al., 2008). Thus, quantification of the change in glial [Ca2+]i could be 
measured as the change in fluorescence from baseline (∆F/F), and data 
expressed relative to the ATP response in the same cell, so that comparison can 
be made between treatments.  
 
2.5.4  Solutions 
 aCSF (in mM): NaCl,133; KCl, 3; CaCl2, 1.5; NaH2PO4, 1.2; MgCl2, 1.0; 
D-glucose. 10; HEPES, 10; pH 7.3 NaOH. 
 See Table 2.4 for agonists and antagonists. 
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Table 2.4 List of pharmacological agents used in calcium imaging 
Name Concentration used Function Company 
ATP 
Adenosine 5'-triphosphate 
disodium salt 
100µM P2 purinoceptor 
agonist. 
Sigma 
ACPD 
(±)-1-Aminocyclopentane-
trans-1,3-dicarboxylic acid 
100µM 
Selective agonist for 
both group I and 
group II mGlu 
receptors 
Tocris 
DHPG 
(RS)-3,5-
Dihydroxyphenylglycine 
100µM 
Selective group I 
metabotropic 
glutamate receptor 
agonist 
Tocris 
AIDA 
(RS)-1-Aminoindan-1,5-
dicarboxylic acid 
 
100µM 
A relatively potent 
and selective 
antagonist of group I 
metabotropic 
glutamate receptors 
Tocris 
 
2.5.5  Statistical analysis 
Measurements were made from multiple cells (n>15 ROIs) in each nerve 
and experiments were replicated in n4. Data were then expressed as mean  
SEM, where n represents the number of cells, and tested for significance using 
the paired t-test (Graphpad 6.0 software, Prism). 
 
2.6  Oxygen and Glucose Deprivation (OGD) 
Optic nerves from P8-11 wild type C57BL/6 and transgenic GFAP-EGFP, 
Sox10-EGFP, PLP1-dsRed mice were isolated intact and immediately placed in 
aCSF for 30 mins at 37°C in a normoxic incubator (95% air/5% CO2) and allowed 
to stabilise. Control groups were incubated for a further 1 hr in normal aCSF 
containing glucose with 5% CO2/95% O2 (oxygenated, O2). Oxygen-glucose 
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deprivation (OGD) was achieved using the method of Fern and colleagues 
(Salter & Fern, 2005), by incubating nerves for 1 hr at 37 °C in glucose-free aCSF 
(osmolarity was maintained by replacing glucose with sucrose), and switching 
the chamber atmosphere to 5% CO2/95% N2.  
Pharmacological modulators added to the aCSF solution during O2 and 
OGD incubations are listed in Table 2.4. 
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Table 2.5 List of pharmacological agonists and antagonists used in OGD  
 
Name Concentration used Function Company 
ACPD 
(±)-1-Aminocyclopentane-trans-
1,3-dicarboxylic acid 
100µM 
Selective agonist for 
both group I and group II 
mGlu receptors 
Tocris 
DHPG 
(RS)-3,5-Dihydroxyphenylglycine 
100µM 
Selective group I 
metabotropic glutamate 
receptor agonist 
Tocris 
LY 379268 
 
(1R,4R,5S,6R)-4-Amino-2-
oxabicyclo[3.1.0]hexane-4,6-
dicarboxylic acid 
100µM Highly selective group II 
mGlu receptor agonist 
Tocris 
Go6976 
5,6,7,13-Tetrahydro-13-methyl-
5-oxo-12H-indolo[2,3-
a]pyrrolo[3,4-c]carbazole-12-
propanenitrile 
10µM 
Potent protein kinase C 
(PKC) inhibitor; 
selectively inhibits 
PKCα and PKCβ1 
Tocris 
MRS2365 
[[(1R,2R,3S,4R,5S)-4-[6-Amino-2-
(methylthio)-9H-purin-9-yl]-2,3-
dihydroxybicyclo[3.1.0]hex-1-
yl]methyl] diphosphoric acid 
mono ester trisodium salt 
100µM Highly potent, selective 
P2Y1 receptor agonist 
Tocris 
MRS2279 
(1R*,2S*)-4-[2-Chloro-6-
(methylamino)-9H-purin-9-yl]-2-
(phosphonooxy)bicyclo[3.1.0]hex
ane-1-methanol dihydrogen 
phosphate ester diammonium 
salt 
100µM 
Selective, high affinity 
competitive antagonist 
of the P2Y1 receptor 
Tocris 
dbcAMP 
N6,2′-O-Dibutyryladenosine 3′,5′-
cyclic monophosphate sodium 
salt 
100 µM 
Cell-permeable cAMP 
analog that activates 
cAMP dependent 
protein kinase (PKA). 
Sigma 
Forskolin 
[3R-
(3α,4aβ,5β,6β,6aα,10α,10aβ,10b
α)]-5-(Acetyloxy)-3-
ethenyldodecahydro-6,10,10b-
trihydroxy-3,4a,7,7,10a-
pentamethyl-1H-naphtho[2,1-
b]pyran-1-one 
100µM Cell-permeable activator 
of adenylyl cyclase 
Sigma 
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2.6.1  Quantification of glia 
At the end of the 60 mins incubation period, optic nerves were fixed and 
whole-mounted for image capture using a Zeiss LSM 710 metaconfocal 
microscope (as previously described). Cells expressing the GFAP-EGFP and 
SOX10-EGFP or PLP1-dsRed reporters were visualised at 488 nm or 568 nm, 
respectively, using an argon laser and x40 oil immersion lens with high 
numerical aperture (1.3 nm); images were captured maintaining the acquisition 
parameters constant between samples. In each nerve, the total number of cells 
was counted in two FOV along the length of the optic nerve. The FOV comprised 
a constant volume of 20 x 20 µm in the x-y-plane and 15 x 1 µm optical sections 
in the z-plane, in the centre of the optic nerve. Cell counts are expressed as 
mean number of cells per FOV + SEM (n>5, where ‘n’ represents the number of 
nerves). The Gaussian distribution of the data was analysed with the D’agostino 
& Pearson’s normality test and the Bartlett’s test was performed to investigate 
whether all the populations had the same standard deviation. The significance 
was determined using the parametric One-way ANOVA and, in order to 
compare more than three samples, the Newman–Keuls multiple comparison 
post-hoc analysis was performed,  (as published in (Hawkins & Butt, 2013), using 
Graphpad Prism 6.0. 
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Section 3 
 
Microarray Analysis of Age-Related 
Changes in Neurotransmitter Signalling 
Mechanisms in the Mouse Optic Nerve  
 60 
3.1  Introduction and aims 
CNS white matter comprises tracts of myelinated axons that 
interconnect neurones from one area of the brain to another. One of the most 
commonly studied white matter preparations is the optic nerve, which connects 
the retina to the brain and contains the axons of retinal ganglion cells (RGC) that 
synapse in the superior colliculus in the mouse and lateral geniculate nucleus in 
human. The vast majority of optic nerve axons are myelinated in the adult, and 
the main cells associated with them are the myelinating oligodendrocytes and 
astrocytes, which make up over 90% of the total cells, together with small 
populations of OPCs (~5%) and microglia (Butt et al., 2004). Astrocytes appear 
first in development, followed by OPCs that differentiate into myelinating 
oligodendrocytes mainly during the first two weeks postnatal, although they 
continue to generate oligodendrocytes slowly throughout adult life (Butt & 
Ransom, 1993; Rivers et al., 2008). Notably, the optic nerve does not contain 
neuronal cell bodies or synapses, although this is not the case for all white 
matter structures (von Engelhardt et al., 2011). It is surprising, therefore, that 
neurotransmitter-mediated signalling is prominent in the optic nerve and other 
white matter areas studied, since neurotransmitter signalling is generally 
considered to be an exclusive function of neurones confined to synapses (Butt 
et al., 2014b).  
 
The primary physiological functions of neurotransmitters in white 
matter remain elusive, although there are reported roles for glutamate, ATP, 
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and GABA in regulating oligodendrocyte differentiation and myelination (Butt, 
2006; 2011; Butt et al., 2014b). Moreover, clear roles for ATP and glutamate 
have been demonstrated in oligodendrocyte pathology, most notably in 
multiple sclerosis (MS) and hypoxia/ischaemia (Matute, 2011). However, the 
majority of studies on white matter are during development and details of 
neurotransmitter signalling mechanisms in adult and ageing white matter are 
lacking. Studies in primates and rodents provide indirect evidence of myelin loss 
in the ageing brain, which may be due to deregulation of oligodendrocyte 
generation from OPCs (Peters & Sethares, 2004; Rivers et al., 2008). Notably, 
MRI and post-mortem human studies have identified myelin loss as a key 
feature of the normal ageing brain and there is evidence this is accelerated in 
dementia (Ihara et al.; Bartzokis et al., 2004; Bowley et al., 2010).  These studies 
raise the possibility that neurotransmitter signalling, which is proposed to 
regulate oligodendrocyte differentiation and integrity, may be deregulated in 
ageing white matter.  
 
The aim of this section is to use Affymetrix GeneChip arrays to profile 
genes involved in neurotransmitter signaling during development and in the 
ageing mouse optic nerve.  
 62 
3.2  Results 
3.2.1  Microarray analysis of gene expression in mouse optic nerve 
To better understand the potential age-related changes in 
neurotransmitter signaling in white matter, a three-way Affymetrix GeneChip 
analysis was used to profile mRNA isolated from optic nerves from mice aged 
10-12 days (P10-12, postnatal), 1-month (adult) and 18-month (ageing). 
Following the protocol of Barres and colleagues (Zamanian et al., 2012), total 
RNA was extracted from acutely dissected optic nerves pooled from n=6-12 
animals for each sample. Total RNA concentration was determined by 
spectrophotometry and samples were sent to Atlas Biolabs (Germany) for 
microarray analysis. Briefly, 1g of total RNA was used to generate biotinylated 
cRNA samples, which were hybridized to a GeneChip Mouse Genome 430_2.0 
Arrays (Affymetrix) and visualized using a Affimetryx GeneChip Scanner 3000. 
This platform contains oligonucleotide probe sets complimentary to the 3’ end 
of the mRNA transcripts (a 3’-array), with each array containing 45,000 probe 
sets, corresponding to over 34,000 well-characterized mouse genes. All samples 
passed quality control (QC), as reported by Atlas Biolabs (Germany). For 1-
month tissue, two samples were available and replicates were performed, but 
this was not feasible for P10-12 and 18-month tissue, due to the availability of 
tissue. The generated CEL file was analysed with Genespring GX 12 (Agilent) 
software, using the MAS-5 algorithm to generate expression values and 
absent/present (A/P) calls (Hubbell et al., 2002). Expression profiles were then 
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analysed using fold change (FC), A/P calls and profile plots, all within Genespring 
GX 12 software (Agilent). 
 
Data analysis using the MAS-5 algorithm showed expression values for 
45,101 entities (probe sets) per sample, of which at least 28,302 were present 
in one or more of the samples. Expression values (E, Absolute value) are 
summarized by baseline transformation to the median of all samples as 
demonstrated in Figure 3.1, with the box and whisker plot showing the spread 
of the values (Figure 3.1A) and the Venn diagram illustrating the number of A/P 
entities common and exclusive to the three age groups (Figure 3.1B). Lists of all 
entities present or absent in each group were then generated for further 
analysis. For example: 24,369 entities present in all samples; only 707 entities 
were specific to ageing nerves, whilst 3455 were specific to adult nerves and 
1345 to postnatal nerves; 4136 entities were common to adult and ageing 
nerves, but absent in postnatal nerves, whilst only 179 entities were common to 
both postnatal and ageing nerves and absent in adult nerves. The profile plot 
illustrates these changes in entity expression between the samples, with all 
entities illustrated in Figure 3.1C, and 20,736 entities identified by filtering on 
fold-change (FC), with a cut-off value of  1.5 FC (Figure 3.1D).  
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Figure 3.1 Gene expression analysis of P10-12, 1-month and 18-month mouse optic 
nerve. Pooled optic nerves from 6-12 animals per group were assessed, using the 
genome wide Mouse Affymetrix GeneChip microarray and scanned intensity values 
were normalized using the MAS-5 algorithm. (A) Box-whisker plot of the data range of 
all probes in P10-12, 1-month and 18-month samples. (B) Venn diagram of the probes 
catalogued by their presence in each group. (C, D) Profile plots of changes in probe 
intensity values between the samples, with all probes (C) and probes with  1.5 fold-
change (FC) across the groups (D). 
  
 65 
3.2.2  Macroglial genes expression in optic nerve samples 
The bulk of RNA extracted from optic nerves is from astrocytes and 
oligodendrocytes, which represent >90% of the cells, with low levels of RNA 
from OPC, microglial and vascular cells and axons (Salter & Fern, 2005). To 
confirm this, the expression levels of well-described glial markers are compared 
with neurone/axon and endothelial markers in postnatal, adult and ageing optic 
nerves (Figure 3.2) and the P/A calls given in Table 3.1. In all the groups, the 
probes with the highest level of expression were for astrocyte- and 
oligodendrocyte-specific genes, while the expression of non-glial markers was 
marginal. Neuronal and axonal markers were mainly called absent or were 
present at negligible levels (E<50), although the presence of the axoskeletal 
Ank3 (Ankyrin3G) and Nefl (Neurofilament, light chain) are consistent with 
axonal mRNA being present in the optic nerve (Salter & Fern, 2005), and these 
were particularly prominent in the postnatal nerve. Furthermore, although the 
nodal axonal sodium and potassium channels Kcnq2 (Kv7.2) and Scn8a (Nav1.6) 
were called absent at all ages, the synaptic vesicle marker Sv2b was prominently 
expressed in the postnatal nerve, consistent with evidence of axonal vesicular 
release mechanisms described in the developing optic nerve (Alix et al., 2008). 
Similarly, the endothelial marker Cldn5 (Claudin5), an important component of 
endothelial tight junctions in the blood-brain barrier (BBB), was highly 
expressed in the postnatal nerve; indeed, all endothelial markers were more 
highly expressed in the postnatal nerve, consistent with increased 
vascularization during the major period of nerve growth. Notably, in the 
 66 
postnatal nerve the levels of expression of Cldn5 and Ank3 are similar to the 
levels of Kcnj10 (Kir4.1), the main astrocyte potassium channel, indicating axonal 
and vascular transcripts are major components of the postnatal nerve. 
Interestingly, the microglial markers tested were not expressed at high levels, 
with the notable exceptions of Mrc1 (CD206), which was highly expressed in the 
postnatal nerve and downregulated thereafter, and Fcgr3 (CD16), which was 
low in postnatal and adult nerves, but markedly upregulated in ageing nerves. 
These results suggest an age-related shift in the microglial function, although 
this did not appear to be a clear-cut shift between the M1 (activated, or pro-
inflammatory) and M2 (alternatively activated or anti-inflammatory, involved in 
restoring tissue homeostasis) phenotypes; Mrc1 and Fcgr3 are both phagocytic 
markers, whilst Arg1 and iNOS, important markers of M2 and M1 microglial 
activation, respectively, were called absent, and the M1 markers Cd86 and 
Fcgr2b (CD32) were expressed at varying levels in the different age group (Kigerl 
et al., 2009).  
 
In addition to evident age-related changes in the expression of axonal, 
endothelial and microglial markers, expression levels of the main astrocyte, 
oligodendrocyte and OPC markers were also at their highest in the postnatal 
nerve (Figure 3.2; Table 3.1). Further analysis of the overall proportion of 
entities in the different cell types indicates an overall trend in the reduction of 
oligodendrocyte genes with age, together with proportional increases in 
astrocyte genes between the postnatal and adult nerves, and in microglial 
genes in ageing nerve (Figure 3.3). The myelin- and OPC-related genes were 
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highest in the postnatal optic nerve, during the period of maximum active 
myelination, decreasing in adulthood and then diminishing further in the ageing 
nerves; a notable feature was the downregulation of OPC genes Pdgfra and 
Nkx2.2 in the ageing nerve, and that Cspg4 (NG2) was called absent in all 
samples.  
 
 
 
 
 
 6
8
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Gene expression analysis of well described cell specific marker in P10-12, 1-month and 18-month mouse optic nerve. Pooled optic nerve 
transcript from 6-12 mice was assessed using a genome wide microarray and scanned intensity values were normalized using the MAS-5 algorithm. See 
Table 3.1 for protein names.
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Table 3.1 Gene expression levels of well described cell markers for astrocytes, 
oligodendrocytes, OPCs, neurons, microglia and endothelial cells. 
 
 
  
Gene	Symbol P10-12 1mo 18mo Name Cell	type
E Call E Call E Call
Kcnj10 1505.75 P 1014.27 P 1084.17 P Kir4.1 Astrocyte
Aqp4 2154.99 P 594.41 P 584.36 P Aquaporin	4 Astrocyte
Gfap 7788.83 P 1798.69 P 2110.47 P GFAP Astrocyte
Gja1 2740.18 P 1551.12 P 1349.98 P Cx43 Astrocyte
Slc1a3 2112.81 P 395.78 P 431.36 P GLAST/EAAT1 Astrocyte
Cnp 9261.22 P 1645.40 P 1652.92 P Cnpase Oligodendrocyte
Mag 7159.49 P 940.08 P 583.02 P MAG Oligodendrocyte
Plp1 8534.50 P 2243.87 P 2274.25 P PLP Oligodendrocyte
Mbp 7316.75 P 1694.00 P 2013.73 P MBP Oligodendrocyte
Mobp 7069.88 P 1606.95 P 1674.88 P MOPBP Oligodendrocyte
Mog 4026.13 P 2010.19 P 1495.71 P MOG Oligodendrocyte
Ugt8a 5394.73 P 936.74 P 780.83 P UDP	glycosyltransferase Oligodendrocyte
Cspg4 233.98 P 37.85 A 34.00 A NG2 OPC
Pdgfra 657.60 P 221.11 P 80.95 P PDGFRa OPC
Nkx2-2 1259.47 P 196.29 P 86.28 P Transcription	factor OPC
Sox10 1317.37 P 466.09 P 444.52 P Transcription	factor OPC/OL
Olig2 1207.22 P 299.41 P 125.87 P Transcription	factor OPC/OL
Kcnq2 15.97 A 2.94 A 23.48 A Kv7.2,	nodal	K+	channel Axon
Scn8a 44.75 A 18.53 A 33.47 A Nav1.6,	nodal	Na+	channel Axon
Cntnap1 9.30 A 4.22 A 7.01 A Caspr/Contactin Axon
Ank3 989.48 P 275.20 P 139.77 P Ankyrin	3G,	nodal	protein Axon
Nefl 466.09 P 152.02 P 364.95 P Neurofilament,	light	chain Axon
Slc12a5 51.11 P 7.99 A 130.78 P K+/Cl-	transporter Neuron
Sv2b 111.52 P 35.68 A 71.83 P Synaptic	vesicles Neuron
Syt1 55.81 P 4.67 A 132.26 P Synaptotagmin	1 Neuron
Mrc1 1036.07 P 116.24 P 96.56 P CD206 Microglia/M2
Arg1 5.11 A 4.46 A 8.10 A Arginase	1 Microglia/M2
Fcgr3 309.30 P 328.40 P 1079.64 P CD16 Microglia/M2
Nos2 2.75 A 1.00 A 1.00 A iNOS Microglia/M1
Cd86 66.06 P 26.60 A 121.34 P CD86 Microglia/M1
Fcgr2b 196.23 P 93.58 P 175.11 P CD32 Microglia/M1
Cldn5 1638.45 P 204.13 P 205.19 P Claudin	5	(tight	junctions) Endothelium
Ocln 204.02 P 50.12 A 14.16 A Occludin	(tight	junction) Endothelium
Pecam1 165.14 P 8.28 P 6.02 A adhesion	molecule Endothelium
Tek 231.34 P 116.33 P 47.17 A tyrosine	kinase Endothelium
Vwf 455.64 P 239.24 P 164.16 P Von	Willebrandt	factor Endothelium
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Figure 3.3 Age-related changes in the proportional expression of markers for 
astrocytes, oligodendrocytes, OPCs, axons, microglia and endothelial cells in mouse 
optic nerve. The expression values of the top five markers were summed for each cell 
type and expressed as a percentage. 
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3.2.3  Most expressed genes by glial cells throughout aging 
Microarray data were analysed to obtain the top 100 genes that are most 
expressed in young, adult and aging optic nerves. Figure 3.4 shows how some of 
the most expressed entities are exclusive to a particular age group, suggesting a 
specific functional role of their coding protein at that age, whilst others are 
highly expressed in two or all three age groups. Gene symbols, expression levels 
and coding protein role for the top 100 probes expressed in P10-12, 1-month and 
18-month optic nerves are listed respectively in Tables 3.2, 3.3 and 3.4. The 
genes were classified in categories according to their coding protein biological 
function, summed and then expressed as percentage in Figure 3.5. This analysis 
shows that the majority (35-63%) of the top 100 expressed genes at all three 
ages are involved in gene expression itself, having a role in transcription, 
translation and protein folding. In all three groups, many of the most expressed 
genes have a role in the primary glial functions of myelination, control of cellular 
homeostasis and metabolism, cytoskeleton and intermediate filament formation 
and protein degradation. The proportion of genes involved in myelination and 
protein degradation is at its highest at P10-12 (15% and 4%) and decreases 
markedly in ageing optic nerves (5% and 1%), consistent with a transition from 
an actively developing and remodelling environment in the postnatal nerve to a 
less plastic and more stable mature tissue. 
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Figure 3.4 Venn diagram illustrating the distribution of the top 100 most expressed 
entities in P10-12, 1-month and 18-month optic nerve.  
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Table 3.2 Expression levels of the top 100 genes in P10-12 optic nerves. 
  
Probe	Set	ID Gene	Symbol E Coding	protein	role/function
1456228_x_at Mbp 12737.34 myelination
1416589_at Sparc 11961.59 ossification
1450641_at Vim 11353.2 intermediate	filament
1424635_at Eef1a1 11042.74 translational	elongation/protein	homooligomerization
1433785_at Mobp 10785.7 intracellular	protein	transport/nervous	system	development
1437341_x_at Cnp 10768.35 myelin	associated	enzyme
1433472_x_at Rpl38 10659.44 regulation	of	translation	90S	preribosome	assembly
1416642_a_at Tpt1 10366.71 cell	survival
1449436_s_at Ubb 10302.05 protein	degradation
1433443_a_at Hmgcs1 10271.65 ketogenesis/metabolism
1422156_a_at Rps2 10235.47 ribosomal	small	subunit	assembly/formation	of	translation	preinitiation	complex/translation
1415906_at Tmsb4x 10137.1 regulation	of	actin	polymerization
1437413_x_at Rps29 10113.04 translation
1460008_x_at Rpl31-ps12 9990.166 translation/	protein	folding
1428792_at Bcas1 9868.191 breast	carcinoma-amplified	sequence	1
1436722_a_at Actb 9831.437 actin	formation
1423860_at Ptgds 9805.28 prostaglandin	biosynthetic	process
1417184_s_at Hbb-bs/Hbb-bt 9756.646 hemoglobin
1436924_x_at Rpl31-ps12 9698.184 translation/protein	folding
1451961_a_at Mbp 9680.358 myelination
1425467_a_at Plp1 9643.99 axon	ensheathment/myelination
1432827_x_at Ubc 9643.519 protein	degradation
1416624_a_at Kxd1/Uba52 9621.252 translation	
1418884_x_at Tuba1a 9507.544 microtubule	formation
1417451_a_at Ppia 9471.375 protein	peptidyl-prolyl	isomerization/protein	folding
1438859_x_at Rps29 9437.384 translation
1431765_a_at Rps2 9436.734 ribosomal	small	subunit	assembly/formation	of	translation	preinitiation	complex/translation
1415833_x_at Rps29 9400.983 translation
1426508_at Gfap 9327.452 intermediate	filament
1422475_a_at Rps3a1 9264.441 translation
1451718_at Plp1 9257.401 axon	ensheathmen/myelination
1415879_a_at Rplp2 9206.688 translational	elongation
1449296_a_at Cnp 9188.181 microtubule	cytoskeleton	organization/axonogenesis
1455578_x_at Rpl41 9136.645 translation
1437185_s_at Tmsb10 9128.296 cytoskeleton	organization
1415822_at Scd2 9125.701 lipid	metabolic	process/fatty	acid	metabolic	process/myelination
1450857_a_at Col1a2 9073.227 collagen	formation
1415701_x_at Rpl23 9054.395 translation
1460175_at Rps23 9021.685 translation
1422613_a_at Rpl7a 9002.883 ribosome	biogenesis
1428361_x_at Hba-a1/Hba-a2 8986.983 hemoglobin
1436995_a_at Rpl26 8951.73 rRNA	processing/translation
1455976_x_at Dbi 8920.191 triglyceride	metabolic	process
1454859_a_at Rpl23 8907.353 translation
1418625_s_at Gapdh 8882.264 glucose	metabolic	process/glycolysis
1433532_a_at Mbp 8866.951 myelination
1459986_a_at Rps17 8857.918 ribosomal	small	subunit	assembly/translation
1416277_a_at Rplp1 8833.914 translational	elongation
1416141_a_at Rps6-ps4 8823.625 G1/S	transition	of	mitotic	cell	cycle
1418000_a_at Itm2b 8790.517 apoptotic	process/negative	regulation	of	amyloid	precursor	protein	biosynthetic	process
1419646_a_at Mbp 8754.418 myelination
1415812_at Gsn 8695.245 actin	assembly	and	disassembly
1426088_at ND5 8688.919 electron	transport	chain
1416420_a_at Rpl9 8639.12 translation
1454651_x_at Mbp 8635.563 myelination
1417275_at Mal 8632.116 induction	of	apoptosis/myelination
1451101_a_at Rps28 8631.813 rRNA	export	from	nucleus/translation
1416330_at Cd81 8628.887 activation	of	MAPK	activity
1438649_x_at Pebp1 8624.359 MAPK	cascade/regulation	of	neurotransmitter	levels/negative	regulation	of	protein	phosphorylation
1448771_a_at Fth1 8611.063 iron	ion	transport	and	homeostasis
1436263_at Mobp 8570.687 intracellular	protein	transport/nervous	system	development
1436201_x_at Mbp 8496.671 myelination
1423763_x_at Rps28 8489.383 rRNA	export	from	nucleus/translation
1423507_a_at Sirt2 8421.868 protein	deacetylation
1453723_x_at Ubb 8412.609 protein	degradation
1450840_a_at Rpl39 8392.408 translation
1450088_a_at Mobp 8392.092 intracellular	protein	transport/nervous	system	development
1416404_s_at Rps16-ps2 8386.945 rRNA	processing/translation
1455789_x_at Hspa8 8371.99 cell	morphogenesis/ATP	catabolic	process/transcription,	DNA-dependent
1436064_x_at Rps24 8367.11 maturation	of	SSU-rRNA	from	tricistronic	rRNA	transcript/rRNA	processing
1455662_x_at Rps17 8365.075 ribosomal	small	subunit	assembly/translation
1415942_at Rpl10 8361.41 translation
1423846_x_at Tuba1b 8352.836 microtubule	formation
1448152_at Igf2 8313.95 development	and	growth
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1449323_a_at Rpl3 8307.013 translation/cellular	response	to	interleukin-4
1435151_a_at Rps3 8296.515 translation/induction	of	apoptosis/response	to	DNA	damage	stimulus
1425742_a_at Tsc22d1 8286.702 TGF	beta	1	induced	trascriptional	repressor
1454778_x_at Rps28 8283.73 rRNA	export	from	nucleus/translation
1455997_a_at Uqcrb 8283.022 mitochondrial	electron	transport
1455485_x_at Rpl13a 8280.98 transcription,	DNA-dependent/regulation	of	translation
1437005_a_at Rpl18 8278.179 translation/oxidation-reduction	process
1455106_a_at Ckb 8251.615 energy	homeostasis
1435643_x_at Ubb 8231.305 protein	degradation
1416099_at Rpl27 8224.691 translation
1432466_a_at Apoe 8209.396 lipid	metabolism
1456142_x_at Morf4l1 8208.23 chromatin	remodeling/transcriptional	activation
1449196_a_at Rps27a 8187.117 translation/ubiquitin	homeostasis
1433721_x_at Rps21 8145.562 translation/ribosomal	small	subunit	biogenesis
1423665_a_at Rpl5 8123.343 rRNA	processing/translation
1437706_x_at Rps14 8119.005 ribosomal	small	subunit	assembly/regulation	of	translation
1434396_a_at Myl6 8105.839 regulatory	light	chain	of	myosin
1428161_a_at Chchd2 8096.821 Coiled-Coil-Helix-Coiled-Coil-Helix	Domain-Containing	Protein	2
1416074_a_at Rpl28 8093.007 translation
1428212_x_at Rpl31-ps12 8038.415 translation
1448739_x_at Rps18 8025.492 translation/ribosome	biogenesis
1420830_x_at Ywhaq 8007.406 protein	targeting/small	GTPase	mediated	signal	transduction
1416219_at Rpl19 7980.535 translation
1419441_at Rplp0 7979.316 translational	elongation/ribosome	biogenesis/cellular	response	to	interleukin-4
1454661_at Atp5g3 7974.935 ATP	synthesis	coupled	proton	transport
1423221_at Tubb4a 7969.454 microtubule	formation
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Table 3.3 Expression levels of the top 100 genes in 1-month optic nerves. 
  
Probe	Set	ID Gene	Symbol E Coding	protein	role/function
1433532_a_at Mbp 2989.54 myelination
1433785_at Mobp 2947.40 intracellular	protein	transport/nervous	system	development
1448771_a_at Fth1 2939.68 	iron	ion	transport	and	homeostasis
1455976_x_at Dbi 2647.00 triglyceride	metabolic	process
1433432_x_at Rps12 2626.77 translation
1438118_x_at Vim 2618.58 intermediate	filament
1456292_a_at Vim 2608.81 intermediate	filament
1433472_x_at Rpl38 2580.65 skeletal	system	development/ossification/regulation	of	translation	90S	preribosome	assembly
1437341_x_at Cnp 2577.62 myelin	associated	enzyme
1435873_a_at Rpl13a 2577.15 transcription,	DNA-dependent/regulation	of	translation
1418884_x_at Tuba1a 2550.18 microtubule	formation
1423859_a_at Ptgds 2546.28 prostaglandin	biosynthetic	process
1451718_at Plp1 2532.85 axon	ensheathment/myelination
1434670_at Kif5a 2531.08 microtubule-based	transport
1425468_at Plp1 2493.37 axon	ensheathment/myelination
1438859_x_at Rps29 2479.96 translation
1436201_x_at Mbp 2465.44 myelination
1418273_a_at Rpl30 2448.88 translation
1455439_a_at Lgals1 2432.62 cell	adhesion
1455693_x_at Rps6-ps4 2427.72 G1/S	transition	of	mitotic	cell	cycle
1460561_x_at Sepw1 2420.65 cell	redox	homeostasis
1416178_a_at Plekhb1 2420.34 synapse	formation/axon	guidance
1416496_at Mrfap1 2409.47 T-Cell	Activation	Protein
1460581_a_at Rpl13 2400.75 translation
1448344_at Rps12 2398.96 translation
1455138_x_at Cfl1 2372.17 actin	PH-dependent	polymerization/depolymerization
1419646_a_at Mbp 2369.59 myelination
1433991_x_at Dbi 2367.62 triglyceride	metabolic	process
1428212_x_at Rpl31-ps12 2360.56 translation
1438986_x_at Rps17 2357.14 ribosomal	small	subunit	assembly/translation
1454651_x_at Mbp 2356.82 myelination
1455485_x_at Rpl13a 2355.27 transcription,	DNA-dependent/regulation	of	translation
1436924_x_at Rpl31-ps12 2353.32 translation
1434872_x_at Rpl37 2333.66 translation
1454620_x_at Rps6-ps4 2330.06 G1/S	transition	of	mitotic	cell	cycle
1415906_at Tmsb4x 2329.73 regulation	of	actin	polymerization
1416453_x_at Rps12 2329.64 translation
1448392_at Sparc 2329.64 ossification
1437976_x_at Rpl23a 2318.12 translation/cell	proliferation
1417275_at Mal 2313.86 myelination
1419734_at Actb 2311.81 actin	formation
1437992_x_at Gja1 2311.46 gap	junction	formation
1426661_at Rpl27a 2310.13 translation
1454849_x_at Clu 2301.05 response	to	oxidative	stress/cell	death
1426195_a_at Cst3 2286.90 inhibitor	of	cysteine	proteinases
1456174_x_at Ndrg1 2272.00 cellular	response	to	hypoxia/stress
1450840_a_at Rpl39 2266.40 translation
1437666_x_at Ubc 2249.80 protein	degradation
1443823_s_at Atp1a2 2241.20 cation	transport	ATPase
1415964_at Scd1 2231.29 lipid	metabolic	process
1438649_x_at Pebp1 2230.26 MAPK	cascade/regulation	of	neurotransmitter	levels/negative	regulation	of	protein	phosphorylation
1418209_a_at Pfn2 2225.22 cytoskeleton	organization
1433443_a_at Hmgcs1 2221.52 ketogenesis/metabolism
1423860_at Ptgds 2219.19 prostaglandin	biosynthetic	process
1460008_x_at Rpl31-ps12 2216.88 translation
1437993_x_at Qdpr 2208.01 L-phenylalanine	catabolic	process
1416624_a_at Kxd1/Uba52 2195.34 translation
1456373_x_at Rps20 2188.32 translation
1452209_at Pkp4 2187.63 cell-cell	junction	assembly/cell	adhesion
1451101_a_at Rps28 2182.10 rRNA	export	from	nucleus/translation
1456228_x_at Mbp 2178.42 myelination
1434377_x_at Rps6-ps4 2172.54 G1/S	transition	of	mitotic	cell	cycle
1425546_a_at Srprb 2156.02 GTPase
1438650_x_at Gja1 2139.54 gap	junction	formation
1416219_at Rpl19 2126.57 translation
1426660_x_at Rpl23a 2122.98 translation/cell	proliferation
1438958_x_at Fkbp1a 2114.83 protein	peptidyl-prolyl	isomerization/negative	regulation	of	protein	phosphorylation
1438093_x_at Dbi 2103.06 triglyceride	metabolic	process
1415822_at Scd2 2100.66 lipid	metabolic	process/myelination
1416371_at Apod 2096.55 lipid	metabolism
1448729_a_at Sept4 2093.88 filament-forming	cytoskeletal	GTPase
1451586_at Tmbim6 2092.92 anti	apoptotic	process/response	to	unfolded	protein
1456436_x_at Rps20 2089.95 translation
1434369_a_at Cryab 2076.43 molecular	chaperone
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1416642_a_at Tpt1 2069.15 response	to	virus/stem	cell	maintenance
1455422_x_at Sept4 2063.26 filament-forming	cytoskeletal	GTPase
1436691_x_at Prdx1 2062.82 cell	redox	regulation
1456196_x_at Fkbp1a 2060.74 protein	peptidyl-prolyl	isomerization/negative	regulation	of	protein	phosphorylation
1427021_s_at Fth1 2057.13 iron	ion	transport/cellular	iron	ion	homeostasis
1417463_a_at Lamtor1 2049.74 regulation	of	receptor	recycling/endosome	organization/lysosome	organization
1433445_x_at Hmgcs1 2040.65 ketogenesis/metabolism
1425966_x_at Ubc 2040.17 protein	degradation
1423091_a_at Gpm6b 2039.09 protein	transport
1436991_x_at Gsn 2036.18 actin	assembly	and	disassembly
1415716_a_at Rps27 2026.99 translation
1437729_at Rpl27a 2024.12 translation
1437171_x_at Gsn 2023.92 actin	assembly	and	disassembly
1460175_at Rps23 2020.43 translation
1434892_x_at Rbbp4 2019.72 DNA	replication/chromatin	remodeling
1448157_s_at Rpl10 2018.71 translation
1437211_x_at Elovl5 2017.57 lipid	metabolic	process
1438655_a_at Rpl34-ps1 2017.39 translation
1448768_at Mog 2010.19 cell	adhesion	
1436064_x_at Rps24 2008.82 maturation	of	SSU-rRNA	from	tricistronic	rRNA	transcript/rRNA	processing
1415849_s_at Stmn1 2004.60 microtubule	depolymerization
1453723_x_at Ubb 1998.50 protein	degradation
1438839_a_at Ywhae 1984.53 protein	targeting/small	GTPase	mediated	signal	transduction
1424635_at Eef1a1 1953.51 translational	elongation/protein	homooligomerization
1436992_x_at Vdac1 1926.39 mitochondrial	anion	channel
1421375_a_at S100a6 1902.97 calcium	binding
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Table 3.4 Expression levels of the top 100 genes in 18-month optic nerves.   
Probe	Set	ID Gene	Symbol E Coding	protein	role/function
1435873_a_at Rpl13a 4013.13 transcription,	DNA-dependent/regulation	of	translation
1455439_a_at Lgals1 4001.13 cell	adhesion
1460581_a_at Rpl13 3866.90 translation
1448771_a_at Fth1 3865.98 iron	ion	transport	and	homeostasis
1433432_x_at Rps12 3799.24 translation
1418273_a_at Rpl30 3754.28 translation
1455976_x_at Dbi 3736.73 triglyceride	metabolic	process
1433472_x_at Rpl38 3736.10 skeletal	system	development/ossification/regulation	of	translation	90S	preribosome	assembly
1448344_at Rps12 3716.20 translation
1433532_a_at Mbp 3714.41 myelination
1438986_x_at Rps17 3706.89 ribosomal	small	subunit	assembly/translation
1417184_s_at Hbb-bs/Hbb-bt 3687.28 hemoglobin
1438859_x_at Rps29 3682.26 translation
1433785_at Mobp 3668.36 intracellular	protein	transport/nervous	system	development
1416453_x_at Rps12 3659.59 translation
1455485_x_at Rpl13a 3604.31 transcription,	DNA-dependent/regulation	of	translation
1436924_x_at Rpl31-ps12 3576.59 translation/protein	folding
1437976_x_at Rpl23a 3525.91 translation/cell	proliferation
1437726_x_at C1qb 3521.90 complement	activation,	classical	pathway/innate	immune	response
1456292_a_at Vim 3487.19 intermediate	filament
1438118_x_at Vim 3484.26 intermediate	filament
1460008_x_at Rpl31-ps12 3478.28 translation/protein	folding
1456373_x_at Rps20 3463.71 translation
1455693_x_at Rps6-ps4 3456.92 G1/S	transition	of	mitotic	cell	cycle
1418884_x_at Tuba1a 3442.92 microtubule	formation
1460561_x_at Sepw1 3439.24 cell	redox	homeostasis
1428212_x_at Rpl31-ps12 3439.02 translation
1438649_x_at Pebp1 3434.10 MAPK	cascade/regulation	of	neurotransmitter	levels/negative	regulation	of	protein	phosphorylation
1434872_x_at Rpl37 3430.83 translation
1450840_a_at Rpl39 3430.83 translation
1455245_x_at Rpl13 3411.19 translation
1416219_at Rpl19 3394.11 translation
1454620_x_at Rps6-ps4 3383.28 G1/S	transition	of	mitotic	cell	cycle
1426661_at Rpl27a 3373.43 translation
1456436_x_at Rps20 3364.97 translation
1436996_x_at Lyz1 3360.50 immune	system/cytolysis
1415906_at Tmsb4x 3355.44 regulation	of	actin	polymerization
1423859_a_at Ptgds 3350.44 prostaglandin	biosynthetic	process
1433991_x_at Dbi 3339.14 triglyceride	metabolic	process
1438655_a_at Rpl34-ps1 3319.75 translation
1438093_x_at Dbi 3319.74 triglyceride	metabolic	process
1434231_x_at Rpl35 3316.48 translation
1426195_a_at Cst3 3308.23 inhibitor	of	cysteine	proteinases
1460637_s_at Pfdn5 3294.99 protein	folding
1460175_at Rps23 3294.82 translation
1415716_a_at Rps27 3291.18 translation
1451101_a_at Rps28 3286.67 rRNA	export	from	nucleus/translation
1416970_a_at Cox7a2 3282.66 oxidation-reduction	process
1436201_x_at Mbp 3264.41 myelination
1454856_x_at Rpl35 3264.39 translation
1448157_s_at Rpl10 3260.17 translation
1434670_at Kif5a 3258.49 microtubule-based	transport
1449196_a_at Rps27a 3256.17 translation/ubiquitin	homeostasis
1416178_a_at Plekhb1 3209.54 synapse	formation/axon	guidance
1437975_a_at Rpl23a 3199.25 translation/cell	proliferation
1437729_at Rpl27a 3185.40 translation
1454627_a_at Rpl29 3167.92 translation/cell	proliferation
1437510_x_at Rps17 3167.31 ribosomal	small	subunit	assembly/translation
1416624_a_at Kxd1/Uba52 3157.99 translation
1449289_a_at B2m 3157.73 positive	regulation	of	T	cell	mediated	cytotoxicity/immune	response
1452701_x_at Uba52 3154.04 translation
1426659_a_at Rpl23a 3149.88 translation/cell	proliferation
1454651_x_at Mbp 3122.80 myelination
1416519_at Rpl36 3109.20 translation
1454778_x_at Rps28 3104.65 rRNA	export	from	nucleus/translation
1436757_a_at Cox6b1 3099.89 oxidation-reduction	process
1417317_s_at Rpl35a 3095.91 mitotic	sister	chromatid	segregation/DNA	repair/chromatin	remodeling
1454849_x_at Clu 3094.87 response	to	oxidative	stress/cell	death
1422557_s_at Mt1 3084.14 melatonin
1436840_x_at Rpl35 3068.62 translation
1437341_x_at Cnp 3063.82 myelin	associated	enzyme
1426660_x_at Rpl23a 3051.40 translation/cell	proliferation
1436064_x_at Rps24 3049.70 maturation	of	SSU-rRNA	from	tricistronic	rRNA	transcript/rRNA	processing
1455138_x_at Cfl1 3049.26 actin	PH-dependent	polymerization/depolymerization
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1451068_s_at Rps25 3049.08 ribosomal	small	subunit	assembly
1455950_x_at Rpl35 3045.98 translation
1460590_s_at Ywhaq 3039.46 protein	targeting/small	GTPase	mediated	signal	transduction
1423754_at Ifitm3 3018.19 interferon	inducible	protein/response	to	biotic	stimulus
1439374_x_at Rps10 3018.02 ribosomal	small	subunit	assembly
1423763_x_at Rps28 3013.49 rRNA	export	from	nucleus/translation
1456628_x_at Rps24 3012.54 maturation	of	SSU-rRNA	from	tricistronic	rRNA	transcript/rRNA	processing
1436691_x_at Prdx1 3011.81 cell	redox	regulation
1423860_at Ptgds 3003.08 prostaglandin	biosynthetic	process
1416056_a_at Ndufb11 2994.84 electron	transport	chain
1436822_x_at Rpl17 2985.86 cellular	glucose	homeostasis
1454859_a_at Rpl23 2977.48 translation
1434377_x_at Rps6-ps4 2975.12 G1/S	transition	of	mitotic	cell	cycle
1416371_at Apod 2970.05 lipid	metabolism
1416088_a_at Rps15 2965.07 ribosomal	small	subunit	assembly
1435151_a_at Rps3 2941.60 translation/induction	of	apoptosis/response	to	DNA	damage	stimulus
1455767_x_at Rpl21 2926.72 translation
1437413_x_at Rps29 2921.03 translation
1416277_a_at Rplp1 2920.96 translational	elongation
1435791_x_at Rpl17 2914.41 cellular	glucose	homeostasis
1416496_at Mrfap1 2913.15 T-Cell	Activation	Protein
1449436_s_at Ubb 2911.61 protein	degradation
1425183_a_at Rpl4 2911.11 translation
1436995_a_at Rpl26 2906.62 rRNA	processing/translation
1437610_x_at Rps8 2896.87 translational	elongation
1455789_x_at Hspa8 2888.59 cell	morphogenesis/ATP	catabolic	proces/transcription,	DNA-dependent
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Figure 3.5 Top 100 most expressed entities in P10-12, 1-month and 18-month mouse 
optic nerve, classified according to their coding protein biological function and 
expressed as percentage.  
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3.2.4  Most prominent genes enriched in the P10-12 mouse optic nerve 
The three-way comparison of the top 100 genes in each age-group 
identified 60 that were specifically enriched in the P10-12 mouse optic nerve 
(Figure 3.4), which is an indication of the functionally most important genes at 
this age. Their gene symbols, expression levels and coding protein role/function 
are listed in Table 3.5. The vast majority of these genes are involved in 
transcription, translation and protein folding, myelination, glial intermediate 
filaments and cytoskeleton organization and cellular metabolism. These are 
consistent with developmental myelination and growth at this age. Notable 
amongst the remaining genes was Sparc (Osteonectin), which was the most 
expressed and encodes for a cysteine-rich acidic matrix associated protein that is 
required for the collagen in bone to calcify and is involved in extracellular matrix 
synthesis (Brekken & Sage, 2001). High levels of Sparc mRNA are found in the 
developing and mature brain (Vincent et al., 2008; Eroglu, 2009); astrocyte-
secreted SPARC can negatively regulate CNS synaptogenesis in vitro and in vivo 
and control synaptic AMPA receptor levels (Jones et al., 2011). Other notable 
genes include Bcas1 (Breast Cancer Amplified Sequence 1), which was the fourth 
most expressed and is associated with aggressive tumour phenotypes. In the 
brain, Bcas1 has been found to be regulated in the subthalamic nucleus of mice 
exposed to MPTP (Lauridsen et al., 2011). Col1a2 (Collagen type 1 alpha 2) is also 
enriched in the postnatal nerve and encodes for a fibril-forming collagen found 
in most connective tissue, and has been suggested in human neuroblastoma 
cultures as a marker for differentiation of these cells into glial cells in vitro 
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(DeClerck et al., 1987), but has not been directly reported in glia. Interestingly, 
there is high level of expression of Hba-a1/Hba-a2 (Haemoglobin alpha1/alpha2), 
iron-containing proteins associated with oxygen transport in the blood, which 
colocalise with mitochondria in the brain (Shephard et al., 2014). 
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Table 3.5 Most prominent genes enriched in the P10-12 mouse optic nerve 
 
  
Probe	Set	ID Gene	Symbol E Coding	protein	role/function
1416589_at Sparc 11961.59 ossification
1450641_at Vim 11353.20 intermediate	filament
1422156_a_at Rps2 10235.47 ribosomal	small	subunit	assembly/formation	of	translation	preinitiation	complex/translation
1428792_at Bcas1 9868.19 breast	carcinoma-amplified	sequence	1
1436722_a_at Actb 9831.44 actin	formation
1451961_a_at Mbp 9680.36 myelination
1425467_a_at Plp1 9643.99 axon	ensheathment/myelination
1432827_x_at Ubc 9643.52 protein	degradation
1417451_a_at Ppia 9471.38 protein	peptidyl-prolyl	isomerization/protein	folding
1431765_a_at Rps2 9436.73 ribosomal	small	subunit	assembly/formation	of	translation	preinitiation	complex/translation
1415833_x_at Rps29 9400.98 translation
1426508_at Gfap 9327.45 intermediate	filament
1422475_a_at Rps3a1 9264.44 translation
1415879_a_at Rplp2 9206.69 translational	elongation
1449296_a_at Cnp 9188.18 microtubule	cytoskeleton	organization/axonogenesis
1455578_x_at Rpl41 9136.65 translation
1437185_s_at Tmsb10 9128.30 cytoskeleton	organization
1450857_a_at Col1a2 9073.23 collagen	formation
1415701_x_at Rpl23 9054.40 translation
1422613_a_at Rpl7a 9002.88 ribosome	biogenesis
1428361_x_at Hba-a1/Hba-a2 8986.98 hemoglobin
1418625_s_at Gapdh 8882.26 glucose	metabolic	process/glycolysis
1459986_a_at Rps17 8857.92 ribosomal	small	subunit	assembly/translation
1416141_a_at Rps6-ps4 8823.63 G1/S	transition	of	mitotic	cell	cycle
1418000_a_at Itm2b 8790.52 apoptotic	process/negative	regulation	of	amyloid	precursor	protein	biosynthetic	process
1415812_at Gsn 8695.25 actin	assembly	and	disassembly
1426088_at ND5 8688.92 electron	transport	chain
1416420_a_at Rpl9 8639.12 translation
1416330_at Cd81 8628.89 activation	of	MAPK	activity
1436263_at Mobp 8570.69 intracellular	protein	transport/nervous	system	development
1436201_x_at Mbp 8496.67 myelination
1423507_a_at Sirt2 8421.87 protein	deacetylation
1450088_a_at Mobp 8392.09 intracellular	protein	transport/nervous	system	development
1416404_s_at Rps16-ps2 8386.95 rRNA	processing/translation
1455662_x_at Rps17 8365.08 ribosomal	small	subunit	assembly/translation
1415942_at Rpl10 8361.41 translation
1423846_x_at Tuba1b 8352.84 microtubule	formation
1448152_at Igf2 8313.95 development	and	growth
1449323_a_at Rpl3 8307.01 translation/cellular	response	to	interleukin-4
1425742_a_at Tsc22d1 8286.70 TGF	beta	1	induced	trascriptional	repressor
1455997_a_at Uqcrb 8283.02 mitochondrial	electron	transport
1437005_a_at Rpl18 8278.18 translation/oxidation-reduction	process
1455106_a_at Ckb 8251.62 energy	homeostasis
1435643_x_at Ubb 8231.31 protein	degradation
1416099_at Rpl27 8224.69 translation
1432466_a_at Apoe 8209.40 lipid	metabolism
1456142_x_at Morf4l1 8208.23 chromatin	remodeling/transcriptional	activation
1433721_x_at Rps21 8145.56 translation/ribosomal	small	subunit	biogenesis
1423665_a_at Rpl5 8123.34 rRNA	processing/translation
1437706_x_at Rps14 8119.01 ribosomal	small	subunit	assembly/regulation	of	translation
1434396_a_at Myl6 8105.84 regulatory	light	chain	of	myosin
1428161_a_at Chchd2 8096.82 Coiled-Coil-Helix-Coiled-Coil-Helix	Domain-Containing	Protein	2
1416074_a_at Rpl28 8093.01 translation
1448739_x_at Rps18 8025.49 translation/ribosome	biogenesis
1420830_x_at Ywhaq 8007.41 protein	targeting/small	GTPase	mediated	signal	transduction
1419441_at Rplp0 7979.32 translational	elongation/ribosome	biogenesis/cellular	response	to	interleukin-4
1454661_at Atp5g3 7974.93 ATP	synthesis	coupled	proton	transport
1423221_at Tubb4a 7969.45 microtubule	formation
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3.2.5  Most prominent genes enriched in the 1-month mouse optic nerve 
The three-way comparison of the top 100 genes in each age-group 
identified 31 that were specifically enriched in the 1-month mouse optic nerve 
(Figure 3.4), which is an indication of the functionally most important genes at 
this age. Their gene symbols, expression levels and coding protein role/function 
are listed in Table 3.6. The vast majority of these probes are for genes involved in 
glial intermediate filaments and cytoskeleton organization, control of cellular 
homeostasis and metabolism. One of the most expressed genes was Gja1 (Gap 
Junction Protein alpha 1), which encodes for the main astroglial connexin Cx43; 
connexins are components of gap junctions, which are ubiquitous structures 
connecting cells, and are particularly abundant in CNS astrocytes (Dermietzel & 
Spray, 1998). Ndrg1 (N-myc Downstream Regulated Gene 1) belongs to the 
alpha/beta hydrolase superfamily and encodes for a cytoplasmic protein 
involved in stress responses, hormone responses, cell growth and differentiation 
(Melotte et al., 2010). Ndrg1 is upregulated with myelination of Schwann cells 
(Heller et al., 2014) and its deficiency leads to progressive PNS demyelination in 
mice (Okuda et al., 2004). Pkp4 (Plakophilin-4) encodes for a member of the 
Armadillo-like protein that regulates cell adhesion and cytoskeletal organization 
(Keil et al., 2013); Pkp4 mRNA has been localized in primary astrocyte cultures 
(Thomsen & Lade Nielsen, 2011). Tmbim6 (transmembrane BAX Inhibitor Motif 
Containing 6) encodes for the protein BAX inhibitor 1 that acts as a suppressor of 
apoptosis and has been shown to modulate calcium homeostasis in mouse 
cortical cultures (Hunsberger et al., 2011). 
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Table 3.6 Most prominent genes enriched in the 1-month mouse optic nerve 
 
  
Probe	Set	ID Gene	Symbol E	1mo Coding	protein	role/function
1425468_at Plp1 2493.37 axon	ensheathment/myelination
1448392_at Sparc 2329.64 ossification
1419734_at Actb 2311.81 actin	formation
1437992_x_at Gja1 2311.46 gap	junction	formation
1456174_x_at Ndrg1 2272.00 cellular	response	to	hypoxia/stress
1437666_x_at Ubc 2249.80 protein	degradation
1443823_s_at Atp1a2 2241.20 cation	transport	ATPase
1415964_at Scd1 2231.29 lipid	metabolic	process
1418209_a_at Pfn2 2225.22 cytoskeleton	organization
1437993_x_at Qdpr 2208.01 L-phenylalanine	catabolic	process
1452209_at Pkp4 2187.63 cell-cell	junction	assembly/cell	adhesion
1425546_a_at Srprb 2156.02 GTPase
1438650_x_at Gja1 2139.54 gap	junction	formation
1438958_x_at Fkbp1a 2114.83 protein	peptidyl-prolyl	isomerization/negative	regulation	of	protein	phosphorylation
1448729_a_at Sept4 2093.88 filament-forming	cytoskeletal	GTPase
1451586_at Tmbim6 2092.92 anti	apoptotic	process/response	to	unfolded	protein
1434369_a_at Cryab 2076.43 molecular	chaperone
1455422_x_at Sept4 2063.26 filament-forming	cytoskeletal	GTPase
1456196_x_at Fkbp1a 2060.74 protein	peptidyl-prolyl	isomerization/negative	regulation	of	protein	phosphorylation
1427021_s_at Fth1 2057.13 iron	ion	transport/cellular	iron	ion	homeostasis
1417463_a_at Lamtor1 2049.74 regulation	of	receptor	recycling/endosome	organization/lysosome	organization
1433445_x_at Hmgcs1 2040.65 ketogenesis/metabolism
1425966_x_at Ubc 2040.17 protein	degradation
1423091_a_at Gpm6b 2039.09 protein	transport
1436991_x_at Gsn 2036.18 actin	assembly	and	disassembly
1437171_x_at Gsn 2023.92 actin	assembly	and	disassembly
1434892_x_at Rbbp4 2019.72 DNA	replication/chromatin	remodeling
1437211_x_at Elovl5 2017.57 lipid	metabolic	process
1448768_at Mog 2010.19 cell	adhesion	
1415849_s_at Stmn1 2004.60 microtubule	depolymerization
1438839_a_at Ywhae 1984.53 protein	targeting/small	GTPase	mediated	signal	transduction
1436992_x_at Vdac1 1926.39 mitochondrial	anion	channel
1421375_a_at S100a6 1902.97 calcium	binding
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3.2.6  Most prominent genes enriched in the 18-month mouse optic nerve 
The three-way comparison of the top 100 genes in each age-group 
identified 31 that were specifically enriched in the 18-month mouse optic nerve 
(Figure 3.4), which is an indication of the functionally most important genes at 
this age. Their gene symbols, expression levels and coding protein role/function 
are listed in Table 3.7. The majority of these probes are for genes involved in 
transcription, translation, protein folding and cellular metabolism. Moreover, the 
enrichment of genes involved in the immune response was specific to this group: 
C1qb (Complement Component C1q, B chain) encodes a major constituent of the 
complement system and is expressed in rat striatal microglia (Pasinetti et al., 
1999), and in macrophage-like cells in the infarct core of a mouse model of 
cortical focal ischemia (Van Beek et al., 2000); lysozyme, encoded by Lyz1, is an 
enzyme with bacteriolytic function and is usually found in body fluids; B2m 
(Beta-2-microglobulin) encodes a component of the major histocompatibility 
complex (MHC) class I, which is involved in the presentation of peptide antigens 
to the immune system; Ifitm3 (Interferon Induced Transmembrane Protein) has 
antiviral properties by disrupting intracellular cholesterol homeostasis. While 
there is no evidence supporting glial expression of Lyz1 and B2m, Ifitm3 is 
expressed by astrocytes, but its function in the CNS is still largely unknown (Ibi et 
al., 2013).  
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Table 3.7 Most prominent genes enriched in the 18-month mouse optic nerve 
 
  
Probe	Set	ID Gene	Symbol E	18mo Coding	protein	role/function
1437726_x_at C1qb 3521.90 complement	activation,	classical	pathway/innate	immune	response
1455245_x_at Rpl13 3411.19 translation
1436996_x_at Lyz1 3360.50 immune	system/cytolysis
1434231_x_at Rpl35 3316.48 translation
1460637_s_at Pfdn5 3294.99 protein	folding
1416970_a_at Cox7a2 3282.66 oxidation-reduction	process
1454856_x_at Rpl35 3264.39 translation
1437975_a_at Rpl23a 3199.25 translation/cell	proliferation
1454627_a_at Rpl29 3167.92 translation/cell	proliferation
1437510_x_at Rps17 3167.31 ribosomal	small	subunit	assembly/translation
1449289_a_at B2m 3157.73 positive	regulation	of	T	cell	mediated	cytotoxicity/immune	response
1452701_x_at Uba52 3154.04 translation
1426659_a_at Rpl23a 3149.88 translation/cell	proliferation
1416519_at Rpl36 3109.20 translation
1436757_a_at Cox6b1 3099.89 oxidation-reduction	process
1417317_s_at Rpl35a 3095.91 mitotic	sister	chromatid	segregation/DNA	repair/chromatin	remodeling
1422557_s_at Mt1 3084.14 melatonin
1436840_x_at Rpl35 3068.62 translation
1451068_s_at Rps25 3049.08 ribosomal	small	subunit	assembly
1455950_x_at Rpl35 3045.98 translation
1460590_s_at Ywhaq 3039.46 protein	targeting/small	GTPase	mediated	signal	transduction
1423754_at Ifitm3 3018.19 interferon	inducible	protein/response	to	biotic	stimulus
1439374_x_at Rps10 3018.02 ribosomal	small	subunit	assembly
1456628_x_at Rps24 3012.54 maturation	of	SSU-rRNA	from	tricistronic	rRNA	transcript/rRNA	processing
1416056_a_at Ndufb11 2994.84 electron	transport	chain
1436822_x_at Rpl17 2985.86 cellular	glucose	homeostasis
1416088_a_at Rps15 2965.07 ribosomal	small	subunit	assembly
1455767_x_at Rpl21 2926.72 translation
1435791_x_at Rpl17 2914.41 cellular	glucose	homeostasis
1425183_a_at Rpl4 2911.11 translation
1437610_x_at Rps8 2896.87 translational	elongation
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3.2.7  Genes enriched in more than one age group 
The list of genes enriched in P10-12 and 1-month old mouse optic nerve 
is given in Table 3.8 and clearly shows the importance of the myelination process 
at these two ages. In contrast, P10-12 and 18-month optic nerves share high 
levels of expression for genes involved in transcription and translation, protein 
degradation and oxygen transport (Table 3.9). One of the genes enriched in P10-
12 and 1-month old nerves is notable because it has not been reported in glia: 
Tpt1 (Tumor Protein, Translationally Controlled 1) encodes for the protein 
fortilin, which regulates apoptosis and is over-expressed in cancer cells, and 
fortilin knock-out severely compromises the formation of neural tissue and is 
embryonically lethal (Koide et al., 2009).  
 
Amongst the genes enriched in 1-month and 18-month mouse optic 
nerves, three that stand out because of their function are Lgals1, Plekhb1 and 
Clu. Lgals1 (Lectin, Galactoside-Binding, Soluble 1) encodes for the protein 
galectin-1, which belongs to the family of beta-galactoside-binding proteins 
implicated in modulating cell-cell and cell-matrix interactions; a recent study 
suggests that galectin-1 might have a neuroprotective role (Qiao et al., 2013). 
Plekhb1 (Pleckstrin homology Domain Containing Family B Member1) encodes 
PHR1, protein required for proper localization of retinogeniculate projections 
during development (Culican et al., 2009); the fact that Plekhb1 is one of the 
most enriched genes in adult and ageing optic nerve suggests a persistent role in 
maintaining these projections. Clusterin, the protein encoded by Clu, is a 
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secreted chaperone suggested to be involved in several basic biological events, 
including cell death, tumor progression and neurodegenerative disorders; 
studies indicate an important role of clusterin in the pathogenesis of Alzheimer’s 
Disease (Holtzman, 2004; Thambisetty et al., 2010), while, in the optic nerve, 
clusterin upregulation in astrocytes leads to complement activation following 
crush injury (Ohlsson et al., 2003). 
 
Unsurprisingly, the genes enriched in all age groups are encoding proteins 
involved in essential biological functions, such as transcription and translation 
(ribosomal subunits), myelin and cytoskeleton organization (MBP, actin), and 
cellular metabolism (Table 3.11). Notably, Pebp1 (phosphatidylethanolamine 
binding protein 1, also known as PBP) is a phospholipid binding protein and 
serine protease inhibitor, and to my knowledge there is only one report of its 
expression in the cytoplasm of oligodendrocytes, describing a role in the 
organization of phospholipids in the myelin sheath (Moore et al., 1996). 
 
Table 3.8 Enriched genes common to P10-12 and 1-month mouse optic nerves 
 
 
 
 
Probe	Set	ID Gene	Symbol E	P10-12 E	1mo Coding	protein	role/function
1456228_x_at Mbp 12737.34 2178.42 myelination
1424635_at Eef1a1 11042.74 1953.51 translational	elongation/protein	homooligomerization
1416642_a_at Tpt1 10366.71 2069.15 cell	survival
1433443_a_at Hmgcs1 10271.65 2221.52 ketogenesis/metabolism
1451718_at Plp1 9257.40 2532.85 axon	ensheathmen/myelination
1415822_at Scd2 9125.70 2100.66 lipid	metabolic	process/myelination
1419646_a_at Mbp 8754.42 2369.59 myelination
1417275_at Mal 8632.12 2313.86 myelination
1453723_x_at Ubb 8412.61 1998.50 protein	degradation
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Table 3.9 Enriched genes common to P10-12 and 18-month mouse optic nerves 
 
 
Table 3.10 Enriched genes common to 1-month and 18-month mouse optic nerves 
 
 
  
Probe	Set	ID Gene	Symbol E	P10-12 E	18mo Coding	protein	role/function
1449436_s_at Ubb 10302.05 2911.61 protein	degradation
1437413_x_at Rps29 10113.04 2921.03 translation
1417184_s_at Hbb-bs/Hbb-bt 9756.65 3687.28 hemoglobin
1436995_a_at Rpl26 8951.73 2906.62 rRNA	processing/translation
1454859_a_at Rpl23 8907.35 2977.48 translation
1416277_a_at Rplp1 8833.91 2920.96 translational	elongation
1423763_x_at Rps28 8489.38 3013.49 rRNA	export	from	nucleus/translation
1455789_x_at Hspa8 8371.99 2888.59 cell	morphogenesis/ATP	catabolic	process/transcription,	DNA-dependent
1435151_a_at Rps3 8296.52 2941.60 translation/induction	of	apoptosis/response	to	DNA	damage	stimulus
1454778_x_at Rps28 8283.73 3104.65 rRNA	export	from	nucleus/translation
1449196_a_at Rps27a 8187.12 3256.17 translation/ubiquitin	homeostasis
Probe	Set	ID Gene	Symbol E	1mo E	18mo Coding	protein	role/function
1433432_x_at Rps12 2626.77 3799.24 translation
1438118_x_at Vim 2618.58 3484.26 intermediate	filament
1456292_a_at Vim 2608.81 3487.19 intermediate	filament
1435873_a_at Rpl13a 2577.15 4013.13 transcription,	DNA-dependent/regulation	of	translation
1423859_a_at Ptgds 2546.28 3350.44 prostaglandin	biosynthetic	process
1434670_at Kif5a 2531.08 3258.49 microtubule-based	transport
1418273_a_at Rpl30 2448.88 3754.28 translation
1455439_a_at Lgals1 2432.62 4001.13 cell	adhesion
1455693_x_at Rps6-ps4 2427.72 3456.92 G1/S	transition	of	mitotic	cell	cycle
1460561_x_at Sepw1 2420.65 3439.24 cell	redox	homeostasis
1416178_a_at Plekhb1 2420.34 3209.54 synapse	formation/axon	guidance
1416496_at Mrfap1 2409.47 2913.15 T-Cell	Activation	Protein
1460581_a_at Rpl13 2400.75 3866.90 translation
1448344_at Rps12 2398.96 3716.20 translation
1455138_x_at Cfl1 2372.17 3049.26 actin	PH-dependent	polymerization/depolymerization
1433991_x_at Dbi 2367.62 3339.14 triglyceride	metabolic	process
1438986_x_at Rps17 2357.14 3706.89 ribosomal	small	subunit	assembly/translation
1434872_x_at Rpl37 2333.66 3430.83 translation
1454620_x_at Rps6-ps4 2330.06 3383.28 G1/S	transition	of	mitotic	cell	cycle
1416453_x_at Rps12 2329.64 3659.59 translation
1437976_x_at Rpl23a 2318.12 3525.91 translation/cell	proliferation
1426661_at Rpl27a 2310.13 3373.43 translation
1454849_x_at Clu 2301.05 3094.87 response	to	oxidative	stress/cell	death
1426195_a_at Cst3 2286.90 3308.23 inhibitor	of	cysteine	proteinases
1456373_x_at Rps20 2188.32 3463.71 translation
1434377_x_at Rps6-ps4 2172.54 2975.12 G1/S	transition	of	mitotic	cell	cycle
1426660_x_at Rpl23a 2122.98 3051.40 translation/cell	proliferation
1438093_x_at Dbi 2103.06 3319.74 triglyceride	metabolic	process
1416371_at Apod 2096.55 2970.05 lipid	metabolism
1456436_x_at Rps20 2089.95 3364.97 translation
1436691_x_at Prdx1 2062.82 3011.81 cell	redox	regulation
1415716_a_at Rps27 2026.99 3291.18 translation
1437729_at Rpl27a 2024.12 3185.40 translation
1448157_s_at Rpl10 2018.71 3260.17 translation
1438655_a_at Rpl34-ps1 2017.39 3319.75 translation
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Table 3.11 Enriched genes common to P10-12, 1-month and 18-month mouse optic 
nerves 
 
 
 
  
Probe	Set	ID Gene	Symbol E	P10-12 E	1mo E	18mo Coding	protein	role/function
1433785_at Mobp 10785.70 2947.40 3668.36 intracellular	protein	transport/nervous	system	development
1437341_x_at Cnp 10768.35 2577.62 3063.82 myelin	associated	enzyme
1433472_x_at Rpl38 10659.44 2580.65 3736.10 regulation	of	translation	90S	preribosome	assembly
1415906_at Tmsb4x 10137.10 2329.73 3355.44 regulation	of	actin	polymerization
1460008_x_at Rpl31-ps12 9990.17 2216.88 3478.28 translation/	protein	folding
1423860_at Ptgds 9805.28 2219.19 3003.08 prostaglandin	biosynthetic	process
1436924_x_at Rpl31-ps12 9698.18 2353.32 3576.59 translation/protein	folding
1416624_a_at Kxd1/Uba52 9621.25 2195.34 3157.99 translation	
1418884_x_at Tuba1a 9507.54 2550.18 3442.92 microtubule	formation
1438859_x_at Rps29 9437.38 2479.96 3682.26 translation
1460175_at Rps23 9021.69 2020.43 3294.82 translation
1455976_x_at Dbi 8920.19 2647.00 3736.73 triglyceride	metabolic	process
1433532_a_at Mbp 8866.95 2989.54 3714.41 myelination
1454651_x_at Mbp 8635.56 2356.82 3122.80 myelination
1451101_a_at Rps28 8631.81 2182.10 3286.67 rRNA	export	from	nucleus/translation
1438649_x_at Pebp1 8624.36 2230.26 3434.10 MAPK	cascade/regulation	of	neurotransmitter	levels/negative	regulation	of	protein	phosphorylation
1448771_a_at Fth1 8611.06 2939.68 3865.98 iron	ion	transport	and	homeostasis
1436201_x_at Mbp 8496.67 2465.44 3264.41 myelination
1450840_a_at Rpl39 8392.41 2266.40 3430.83 translation
1436064_x_at Rps24 8367.11 2008.82 3049.70 maturation	of	SSU-rRNA	from	tricistronic	rRNA	transcript/rRNA	processing
1455485_x_at Rpl13a 8280.98 2355.27 3604.31 transcription,	DNA-dependent/regulation	of	translation
1428212_x_at Rpl31-ps12 8038.42 2360.56 3439.02 translation
1416219_at Rpl19 7980.54 2126.57 3394.11 translation
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3.2.8  “Neurotransmission machinery” in young, adult and old optic nerve 
There is abundant evidence of neurotransmission in the optic nerve and 
glial cells express an array of neurotransmitter receptors and have the capacity 
to synthesize and release neurotransmitters (Butt et al., 2014b). However, most 
studies have focused on the developing optic nerve, and little is known about 
age-related changes in the various aspects of the ‘neurotransmission machinery’. 
To address this, I analysed 516 genes involved in cell-to-cell signaling, 
neurotransmitter production, storage and release, and filtered for an absolute 
expression value, E, 50 and displaying a fold change (FC) 1.5 between at least 
2 age groups (Figure 3.6). In this way 230 genes of interest were identified and 
are presented in the following sections according to the official IUPHAR/BPS 
target classification (http://www.guidetopharmacology.org). 
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Figure 3.6 Venn diagram showing the number of entities for neurotransmission in 
filtered for E50 and FC 1.5 between at least 2 age groups 
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3.2.9  Class A G-protein coupled receptors (GPCRA) in the mouse optic nerve 
The expression of genes for GPCRA is summarized in Table 3.12. Most of 
the GPCRA are called absent or expressed at barely detectable levels, and the 
most evident feature is a general downregulation of GPCRA after postnatal 
development (Figure 3.7). Most prominent in the optic nerve are the adenosine 
receptor Adora1 and purine receptor P2yr12. Only 13 genes are altered in 
expression by FC  1.5 between at least 2 age groups: Adora2a, Adora2b, 
Adra1b, Adra2a, Adrb2, Chrm1 are detectable in P10-12 optic nerve only, 
suggesting that adrenergic and cholinergic receptors have a role in the 
development of young tissue. In addition, there is an apparent developmental 
switch in expression of 5-HT receptors, in particular Htr1b, which is enriched in 
postnatal nerves. The expression profile of purinergic receptors indicates a pre-
eminence for P2ry12, which is highly expressed at P10-12 and then 
downregulated, but persists in 1-month and 18-month nerves, whilst P2ry13 
shows an antithetical expression profile, with the highest expression detected in 
the ageing optic nerve. 
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Table 3.12 GPCRA in P10-12, 1-month and 18-month mouse optic nerve. 
Downregulation with age is depicted in red.  
 
 
  
Gene	Symbol FC	P10-12	vs	1mo FC	1mo	vs	18mo Official	IUPHAR	receptor	name
E Call E Call E Call
Adora1 377.64 P 181.05 P 143.09 P 2.09 1.27 A1	receptor
Adora2a 171.25 P 31.61 A 29.46 A 5.42 1.07 A2A	receptor
Adora2b 68.73 P 10.55 A 11.40 A 6.52 0.93 A2B	receptor
Adora3 8.27 A 3.08 A 4.81 A 2.68 0.64 A3	receptor
Adra1a 4.53 A 2.57 A 6.18 A 1.76 0.42 α1A-adrenoceptor
Adra1b 82.85 P 7.31 A 6.84 A 11.33 1.07 α1B-adrenoceptor
Adra2a 207.85 P 30.04 A 16.39 A 6.92 1.83 α2A-adrenoceptor
Adra2b 12.83 A 5.34 A 3.81 A 2.40 1.40 α2B-adrenoceptor
Adra2c 21.64 A 2.40 A 2.76 A 9.01 0.87 α2C-adrenoceptor
Adrb1 17.17 A 7.96 A 7.31 A 2.16 1.09 β1-adrenoceptor
Adrb2 104.20 P 30.95 A 6.62 A 3.37 4.68 β2-adrenoceptor
Adrb3 1.51 A 1.89 A 6.06 A 0.80 0.31 β3-adrenoceptor
Chrm1 73.20 P 7.84 A 14.84 A 9.34 0.53 M1	receptor
Chrm3 5.13 A 1.07 A 1.00 A 4.81 1.07 M3	receptor
Chrm4 1.00 A 1.00 A 1.00 A 1.00 1.00 M4	receptor
Cnr1 32.90 A 4.09 A 10.53 A 8.05 0.39 CB1	receptor
Cnr2 7.75 A 5.71 A 13.75 A 1.36 0.42 CB2	receptor
Drd1a 5.34 A 3.27 A 2.93 A 1.63 1.12 D1	receptor
Drd2 16.40 A 1.40 A 4.99 A 11.71 0.28 D2	receptor
Drd3 9.34 A 1.18 A 1.27 A 7.89 0.93 D3	receptor
Drd4 13.37 A 4.52 A 3.40 A 2.96 1.33 D4	receptor
Hrh1 28.69 A 8.42 A 22.97 A 3.41 0.37 H1	receptor
Hrh2 15.72 A 3.51 A 3.95 A 4.48 0.89 H2	receptor
Hrh3 12.52 A 1.84 A 6.55 A 6.82 0.28 H3	receptor
Hrh4 1.40 A 1.00 A 1.74 A 1.40 0.57 H4	receptor
Htr1a 21.34 A 1.53 A 3.43 A 13.93 0.45 5-HT1A	receptor
Htr1b 115.68 P 8.77 A 5.92 A 13.19 1.48 5-HT1B	receptor
Htr1d 11.62 A 3.65 A 3.84 A 3.18 0.95 5-HT1D	receptor
Htr1f 1.24 A 1.22 A 6.16 A 1.01 0.20 5-HT1F	receptor
Htr2b 6.26 A 75.34 P 57.78 P 0.08 1.30 5-HT2B	receptor
Htr2c 22.19 A 1.07 A 5.54 A 20.68 0.19 5-HT2C	receptor
Htr4 6.62 A 1.38 A 1.00 A 4.80 1.38 5-HT4	receptor
Htr5a 8.87 A 1.59 A 4.94 A 5.59 0.32 5-HT5a	receptor
Htr5b 12.59 A 1.48 A 1.64 A 8.51 0.91 5-HT5b	receptor
Htr6 13.09 A 2.54 A 2.19 A 5.15 1.16 5-HT6	receptor
Htr7 11.01 A 1.64 A 2.74 A 6.71 0.60 5-HT7	receptor
Oprd1 2.76 A 1.05 A 1.00 A 2.62 1.05 δ	receptor
Oprk1 22.69 A 1.08 A 1.56 A 20.94 0.70 κ	receptor
Oprl1 41.70 A 2.41 A 4.89 A 17.32 0.49 NOP	receptor
Oprm1 8.29 A 1.30 A 2.27 A 6.36 0.58 μ	receptor
P2ry1 20.66 A 14.58 A 10.94 A 1.42 1.33 P2Y1	receptor
P2ry12 928.45 P 148.44 P 108.84 P 6.25 1.36 P2Y12	receptor
P2ry13 281.07 P 208.78 P 474.68 P 1.35 0.44 P2Y13	receptor
P2ry14 67.31 P 54.79 P 83.56 P 1.23 0.66 P2Y14	receptor
P2ry2 1.91 A 2.01 A 2.82 A 0.95 0.71 P2Y2	receptor
P2ry4 24.24 A 1.20 A 1.00 A 20.22 1.20 P2Y4	receptor
P2ry6 210.28 P 52.93 P 141.49 P 3.97 0.37 P2Y6	receptor
P10-12 1mo 18mo
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Figure 3.7 Age-related changes of the most prominent GPCRA in the mouse optic nerve. 
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3.2.10  Class C G -protein-coupled receptors (GPCRC) in the mouse optic nerve 
The expression of genes for GPCRC is summarized in Table 3.13. Most of 
the GPCRC are called absent or expressed at barely detectable levels, and the 
most evident feature is a general downregulation of GPCRC after postnatal 
development (Figure 3.8). Most prominent is the calcium sensing receptor CASR, 
which appears to be expressed only in the postnatal optic nerve. The 
metabotropic GABAergic GABAB receptor is highly expressed in all 3 age groups, 
suggesting a prominent and persistent role for GABA in the optic nerve. The 
metabotropic glutamate receptors (mGluR) show a varied expression profile, 
with Grm4 being the most expressed subunit at P10-12 and then it is 
downregulated, whereas Grm5 is most highly expressed in the ageing optic 
nerve. 
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Table 3.13 GPCRC in P10-12, 1-month and 18-month mouse optic nerve. 
Downregulation with age is depicted in red.  
 
 
 
Figure 3.8 Age-related changes of the most prominent GPCRA in the mouse optic 
nerve. 
  
Gene	Symbol	(	GPCR	C	) FC	P10-12	vs	1mo FC	1mo	vs	18mo Official	IUPHAR	receptor	name
E Call E Call E Call
Casr 93.81 P 2.21 A 1.00 A 42.48 2.21 CASR
Gabbr1 409.90 P 350.12 P 332.48 P 1.17 1.05 GABAB1
Gprc6a 3.94 A 1.48 A 1.00 A 2.65 1.48 GPRC6	receptor
Grm1 26.04 A 4.90 A 27.53 A 5.31 5.61 mGlu1	receptor
Grm2 14.56 A 2.28 A 24.34 A 6.38 10.66 mGlu2	receptor
Grm3 78.49 P 91.32 P 88.21 P 1.16 1.04 mGlu3	receptor
Grm4 235.43 P 7.70 A 43.71 A 30.58 5.68 mGlu4	receptor
Grm5 47.50 A 33.61 A 86.77 P 1.41 2.58 mGlu5	receptor
Grm7 26.24 A 17.92 A 41.68 A 1.46 2.33 mGlu7	receptor
Grm8 13.05 A 2.14 A 16.51 A 6.09 7.70 mGlu8	receptor
P10-12 1mo 18mo
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3.2.11  Expression of ligand-gated ion channels in the mouse optic nerve 
The expression of ligand-gated ion channels (LGIC) is summarized in Table 
3.14. Many LGIC are called absent or expressed at barely detectable levels, but a 
prominent feature is the expression of multiple iGluR and P2XR in postnatal 
nerves, whereas nAChR are not prominently expressed at any age, and 
GABAA1/3, GABAA2 and GABA2 are upregulated in the 18-month nerve, 
whereas others are more prominent in the postnatal nerve (Figure 3.9). The gene 
for the glycine receptor  is one the most expressed in all 3 groups. The most 
expressed genes in the postnatal nerve encode the AMPA receptor subunit 
GluA1, whose mRNA level is downregulated but still high in the adult and ageing 
nerves. Kainate receptor genes (Grik1-3 and 5) appear to be most expressed, 
even though at low levels and downregulated after postnatal development, 
except for Grik5. The NMDA receptor subunit GluN2B appears to be expressed 
only in the old optic nerve. P2X4 and P2X7 are the purinergic receptors, whose 
mRNA are expressed the most at P10-12, and are downregulated thereafter. 
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Table 3.14 LGIC in P10-12, 1-month and 18-month mouse optic nerve. Downregulation 
with age is depicted in red.  
  
Gene	Symbol FC	P10-12	vs	1mo FC	1mo	vs	18mo Official	IUPHAR	receptor	name
E Call E Call E Call
Chrna1 5.90 A 1.00 A 1.00 A 5.90 1.00 α1
Chrna2 7.03 A 1.00 A 2.52 A 7.03 2.52 α2
Chrna3 9.80 A 1.95 A 4.70 A 5.02 2.41 α3
Chrna4 38.75 A 8.30 A 6.90 A 4.67 1.20 α4
Chrna5 14.51 A 3.03 A 1.46 A 4.79 2.07 α5
Chrna6 6.04 A 2.60 A 4.67 A 2.32 1.79 α6
Chrna7 13.38 A 3.25 A 3.74 A 4.12 1.15 α7
Chrna9 3.74 A 1.94 A 1.75 A 1.93 1.11 α9
Chrnb1 53.58 P 49.17 A 14.64 A 1.09 3.36 β1
Chrnb2 20.57 A 3.48 A 14.95 A 5.91 4.30 β2
Chrnb3 3.94 A 1.66 A 2.03 A 2.38 1.23 β3
Chrnb4 13.77 A 1.31 A 4.90 A 10.50 3.74 β4
Chrnd 2.47 A 1.00 A 1.00 A 2.47 1.00 δ
Chrne 14.06 A 2.92 A 1.00 A 4.82 2.92 ε
Chrng 6.88 A 1.07 A 1.00 A 6.41 1.07 γ
Gabra1 21.18 A 4.84 A 182.36 P 4.37 37.65 α1
Gabra2 15.80 A 2.78 A 43.16 A 5.67 15.50 α2
Gabra3 35.89 A 22.97 A 138.97 P 1.56 6.05 α3
Gabra4 37.73 A 7.31 A 32.36 A 5.16 4.43 α4
Gabra5 10.48 A 2.69 A 111.87 P 3.90 41.62 α5
Gabra6 6.92 A 1.12 A 1.51 A 6.18 1.35 α6
Gabrb1 208.34 P 246.72 P 402.99 P 0.84 1.63 β1
Gabrb2 30.28 A 16.66 A 185.11 P 1.82 11.11 β2
Gabrb3 165.60 P 32.11 A 84.40 P 5.16 2.63 β3
Gabrd 14.29 A 3.60 A 20.44 A 3.97 5.69 δ
Gabre 6.78 A 1.32 A 1.92 A 5.15 1.46 ε
Gabrg1 69.54 A 7.55 A 13.36 A 9.21 1.77 γ1
Gabrg2 23.24 A 2.30 A 103.48 P 10.12 45.06 γ2
Gabrg3 26.58 A 47.15 A 17.92 A 1.77 2.63 γ3
Gabrp 21.00 A 1.37 A 1.56 A 15.39 1.15 π
Gabrq 2.59 A 1.00 A 1.00 A 2.59 1.00 θ
Gabrr1 2.63 A 1.00 A 1.00 A 2.63 1.00 ρ1
Gabrr2 6.72 A 41.36 A 5.68 A 6.15 7.28 ρ2
Glra1 8.86 A 1.27 A 1.50 A 6.96 1.18 α1
Glra2 8.12 A 1.76 A 8.12 A 4.62 4.62 α2
Glra3 1.01 A 1.00 A 1.97 A 1.01 1.96 α3
Glra4 1.04 A 1.00 A 1.00 A 1.04 1.00 α4
Glrb 435.84 P 405.05 P 405.30 P 1.08 1.00 β
Gria1 1185.38 P 496.67 P 528.29 P 2.39 1.06 GluA1
Gria2 248.16 P 59.95 P 208.64 P 4.14 3.48 GluA2
Gria3 79.38 P 47.63 A 87.95 P 1.67 1.85 GluA3
Gria4 254.42 P 91.87 P 70.05 P 2.77 1.31 GluA4
Grid1 43.16 A 14.72 A 11.51 A 2.93 1.28 GluD1
Grid2 96.82 A 31.52 A 9.89 A 3.07 3.19 GluD2
Grik1 17.91 A 103.96 A 38.05 A 5.80 2.73 GluK1
Grik2 68.58 P 53.41 P 45.32 A 1.28 1.18 GluK2
Grik3 53.97 A 14.61 A 21.20 A 3.69 1.45 GluK3
Grik4 48.61 A 26.93 A 17.85 A 1.81 1.51 GluK4
Grik5 387.40 A 28.77 A 32.59 A 13.46 1.13 GluK5
Grin1 65.66 A 5.98 A 49.95 A 10.98 8.35 GluN1
Grin2a 1.00 A 1.00 A 1.00 A 1.00 1.00 GluN2A
Grin2b 20.45 A 4.64 A 116.94 P 4.41 25.21 GluN2B
Grin2c 2.34 A 1.06 A 22.81 A 2.20 21.49 GluN2C
Grin2d 54.42 A 23.80 A 40.60 A 2.29 1.71 GluN2D
Grin3a 95.39 A 22.11 A 19.76 A 4.31 1.12 GluN3A
Grin3b 6.11 A 12.23 A 13.89 A 0.50 1.14 GluN3B
Htr3a 26.91 A 2.17 A 5.26 A 12.40 2.42 5-HT3A
Htr3b 1.00 A 1.18 A 1.00 A 0.85 1.18 5-HT3B
P2rx1 20.29 A 2.92 A 2.13 A 6.96 1.37 P2X1
P2rx2 2.43 A 1.16 A 1.00 A 2.10 1.16 P2X2
P2rx3 2.37 A 3.70 A 4.16 A 0.64 1.12 P2X3
P2rx4 311.92 P 89.09 P 74.63 P 3.50 1.19 P2X4
P2rx5 11.84 A 5.71 A 4.98 A 2.07 1.15 P2X5
P2rx6 46.38 A 31.94 A 27.42 A 1.45 1.16 P2X6
P2rx7 178.53 P 115.55 P 51.92 P 1.55 2.23 P2X7
P10-12 1mo 18mo
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Figure 3.9 Age-related changes of the most prominent LGIC in the mouse optic nerve. 
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3.2.12  Expression of genes involved in neurotransmission in the mouse optic 
nerve 
The expression of genes that are essential for neurotransmission were 
examined in brief and are summarized in Figures 3.10-3.12, and the key point is 
that the optic nerve contains the machinery for neurotransmission, and in 
general this is downregulated with age. The neurotransmitter transporters, 
enzymes and SNAREs are summarized in Figure 3.10, and the most evident 
feature is that neurotransmitter transporters are expressed at their highest level 
in the postnatal optic nerve. Slc1a3 is the most highly expressed gene and 
encodes EAAT1/GLAST, the main astrocytic glutamate transporter. The genes for 
glutamate and GABA transporters (Slc1a1-3 and Slc6a1/6/8/11/12/13) are highly 
expressed at P10-12 and then are downregulated. On the other hand, the glycine 
transporter GlyT1 (Slc6a9) is prominently expressed at all ages. The vesicular 
glutamate and ATP transporters are not evident, although VGLUT1 (Slcc17a7) 
appears to be expressed in the 18-month nerve. Slc18b1 is a paralog of Slc18a1, 
which encodes vesicular monoamine transporter 1 (VMAT1), and is expressed at 
all ages. 
 
The expression of enzymes associated with neurotransmission is 
summarized in Figure 3.11. Notably Adk (adenosine kinase) was prominent at all 
ages and encodes for an enzyme that catalyzes ATP to adenosine, both 
intracellularly and extracellularly, consistent with the prominent role for ATP-
mediated signaling in the optic nerve (Butt, 2011).  In addition, Aldh9a1 
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(Aldehyde Dehydrogenase 9, member A1) and Aldh5a1 (Aldehyde 
Dehydrogenase 5, member A1) are expressed at all ages and important in the 
breakdown of GABA, whereas Gad 1 and Gad2 (glutamate decarboxylase 1 and 
2) were most highly expressed in the ageing nerve and convert GABA to 
glutamate, a function of astrocytes. Notably, Mg11 (Monoglyceride lipase) is 
highly expressed in the postnatal nerve, and Gaglb (Diaglycerol Lipase, beta) 
appears to be upregulated with age, both playing a critical role in the formation 
of the endocannabinoid 2-arachidonoylglycerol (2-AG), the most abundant 
endocannabinoid in tissues. 
 
The expression of the most prominent genes that encode synaptic 
proteins is summarized in Figure 3.12, which suggests highly active synaptic 
transmission in the optic nerve. Notable amongst these were the high levels of 
transcripts for Vamp3 (Vesicle associated membrane protein 3, or 
synaptobrevin-3) and Vapa (Vesicle associated protein A), which functions are 
related to vesicle trafficking, docking and fusion, and were highest in the 
postnatal nerve, suggesting they may be primarily axonal (Alix et al., 2008). 
Vesicular release in astrocytes usually involves synaptobrevin-2 (Vamp2), which 
was present at all ages in the optic nerve, and snap-23, which was most 
prominent in the postnatal optic nerve.  Syntaxins were also prominent, with an 
apparent developmental shift from syntaxin 6/7/16 (Stx6/7/16) in postnatal 
nerves to syntaxin 12 (Stx12) in ageing nerves; the syntaxins are part of the 
SNARE complex that also contains VAMPs and regulate synaptic vesicles and 
endosomes, a feature of astrocyte neurotransmitter release. 
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Figure 3.10 Age-related changes of the most prominent neurotransmitter transporters in the mouse optic nerve. 
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Figure 3.11 Age-related changes of the most prominent enzymes involved in neurotransmission in the mouse optic nerve. 
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Figure 3.12 Age-related changes of the most prominent SNARE and synaptic proteins involved in neurotransmission in the mouse optic nerve. 
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3.3  Discussion 
 Astrocytes and oligodendrocytes have been shown to express a 
wide range of neurotransmitter receptors in vitro and in vivo (Verkhratskiĭ & 
Butt, 2013). Furthermore, there is abundant evidence that neurotransmitter-
mediated signalling is a prominent feature of CNS white matter, even though it 
does not contain neuronal cell bodies, dendrites or synapses (see (Butt et al., 
2014a) for recent review). In this section, I have provided a profile of 
neurotransmitter signalling in the optic nerve and how it changes with age 
(Figure 3.13). Notably, the optic nerve is enriched in the machinery for 
neurotransmission, with a prominence for glutamate > ATP > GABA > Glycine > 
Adenosine > Adrenergic. A key finding is that neurotransmitter systems were 
highest in the postnatal nerve, supporting evidence of important roles in 
oligodendrocyte differentiation and myelination. Some notable exceptions were 
GABA signalling, mGluR5 and P2Y13 receptors, which were increased in the 18-
month optic nerve and hence may be important in the neuropathology of white 
matter loss, which is a feature of the ageing brain and dementia. To this end, I 
also examined key oligodendrocyte genes and the main change in the ageing 
optic nerve was a decrease in OPC genes and transcription factors that regulate 
their differentiation, suggesting OPC function may be deregulated in ageing 
white matter. In addition, my analysis identified a number of genes that have no 
reported function in CNS glia and were specifically enriched in the ageing optic 
nerve. This study helps to shed new light on the key neurotransmitter systems 
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and potential molecular and cellular targets that may be important in regulating 
changes in glial functions with age.  
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Figure 3.13 Summary of age-related changes in the main neurotransmitter receptors in 
the mouse optic nerve. 
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3.3.1  Age-dependent changes in glial genes 
Microarray analysis confirmed that the bulk of gene expressed in the 
optic nerve at all ages is specific to astrocytes and oligodendrocytes, which make 
up the vast majority of cells in the optic nerve, with relatively lower levels of 
expression of OPC, microglia, vascular and axonal genes (Salter & Fern, 2005). A 
three-way analysis in postnatal, adult and ageing optic nerve shows that the 
most highly expressed genes are involved in the primary glial functions of 
myelination, homeostasis and metabolism, in addition to cell growth, e.g. 
cytoskeleton and intermediate filament formation and protein degradation. A 
key finding is the decline in genes associated with myelination, 
homeostasis/metabolism and cell growth. My analysis highlighted a reduction of 
oligodendrocyte and OPCs markers from postnatal to adult and further still in 
ageing tissue (Figure 3.14). As predicted, the P10-12 optic nerves is enriched in 
myelin and OPC genes, since it is undergoing highly active myelination, which 
commences around P7 and the majority of axons are myelinated by P15 (Foran & 
Peterson, 1992). Notably, compared to the adult nerve at 1-month, there was an 
apparent loss of the OPC marker Pdgfra in the aging 18-month optic nerve, as 
well as a striking decrease in transcription factors that regulate OPC 
differentiation, Nkx2.2, Sox10 and Olig2 (Figure 3.14B), which are essential for 
initiating oligodendrocyte differentiation (Zhu et al., 2014). The decline in OPCs 
regenerative capability in the ageing brain has been suggested to be a key factor 
in the age-dependent loss of white matter and decline in cognitive function (Sim 
et al., 2002; Bartzokis, 2011a; b). The results of my study indicate this may be 
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related to a loss of PDGF-mediated signalling, which regulates OPC proliferation, 
and key transcription factors that regulate their subsequent differentiation into 
oligodendrocytes. 
 
In contrast to the decline in genes regulating myelination, there is a 
marked increase in genes associated with transcription/translation/protein 
folding in the 18-month optic nerve, indicative of altered proteostasis which is 
associated with stress and ageing (Hipp et al., 2014). The maintenance of the 
proteome is regulated by a complex proteostasis network that is essential to 
preserve cell function and the ability to respond and adapt to the changing 
environment (Hipp et al., 2014). My results in the ageing optic nerve require 
further investigation, but may identify genes and/or pathways that underlie the 
decline in protein homeostasis that is a feature of ageing and is likely to 
contribute to white matter disruption during ageing.  
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Figure 3.14 Age-related changes in the main oligodendrocyte and OPC genes in the 
mouse optic nerve.  
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3.3.2  Microglial genes and ageing mechanisms in the optic nerve  
Although only a small number of microglial genes were examined, 
proportionally they comprised 3% of genes in the postnatal and adult nerve, 
which is consistent with number of microglia in relation to astrocytes and 
oligodendrocytes. Interestingly, the microglial markers Mrc1 (CD206) and Fcgr3 
(CD16) exhibited opposite developmental shifts, with Mrc1 being high in the 
postnatal nerve and CD16/FcR3 being increased in the ageing optic nerve. Both 
Mrc1 and Fcgr3 are considered markers of the M2 phenotype (Kigerl et al., 
2009), and in my analysis there did not appear to be a clear-cut shift between 
the M1 (activated, or pro-inflammatory) and M2 (alternatively activated or anti-
inflammatory, involved in restoring tissue homeostasis) phenotypes. The M1 
phenotype, or classical activation, is associated with defence and attack and 
induces the release of pro-inflammatory cytokines (Mantovani et al., 2004; 
Mosser & Edwards, 2008). The M2 phenotypes are termed alternative activation 
and include the M2a, M2b and M2c states. The M2a phenotype is characterized 
by wound healing and high levels of arginase 1 (ARG1) and the chitinase-like 
protein YM1 (Edwards et al., 2006). The M2b phenotype is a combination of an 
M1 and M2a state and is associated with high levels of CD86 and the Fc gamma 
receptors 1 and 3 (FcγR1 and FcγR3) (Edwards et al., 2006). Finally, the M2c 
phenotype is a deactivation state accompanied by high levels of transforming 
growth factor beta and sphingosine kinase 1 (Sternberg, 2006; Mosser & 
Edwards, 2008).  
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Senescent CD16+ macrophages also exhibit proinflammatory activity and 
their accumulation could have a role in the development of chronic inflammation 
and atherosclerosis in elderly subjects (Merino et al., 2011). Moreover, a 
transition from M1 to a mixed phenotype increases amyloid deposition in a 
double transgenic model of AD (Weekman et al., 2014). In the 18-month optic 
nerve there was an apparent enrichment in genes involved in the innate 
immunity, most notably C1qb (Complement Component C1q, B chain) and 
lysozyme, encoded by Lyz1, the MHCI co-factor B2m (Beta-2-microglobulin), and 
Ifitm3 (Interferon Induced Transmembrane Protein). MHCI is localized on all 
nucleated cells and the MHCI cofactor B2m has been shown to be upregulated in 
the hippocampus with advanced aging (Vanguilder et al., 2012). C1qb encodes a 
major constituent of the complement system in microglia (Pasinetti et al., 1999), 
which is increased in response to axonal injury (Byrnes et al., 2006) and in AD 
(Johnson et al., 1992). Lysozyme is important in inflammasome activation in 
macrophages, and indicates increased phagocytic activity is 
microglia/macrophages in the ageing optic nerve. In contrast, upregulation of 
Ifitm3 in astrocytes mediates neuronal impairments (Ibi et al., 2013) and it is 
implicated in the immune disturbance in schizophrenia and autism (Garbett et 
al., 2008a; Garbett et al., 2008b). Overall, the results suggest that multiple genes 
may contribute to altered immune homeostasis and white matter disruption in 
the ageing optic nerve. 
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3.3.3  Age-dependent changes in neurotransmitter receptors in the optic 
nerve 
 The analysis on neurotransmitter receptors provides evidence for the 
presence of diverse signalling in white matter, primarily glutamatergic and 
purinergic systems, which have been extensively described, but also GABAergic, 
adrenergic, cholinergic, dopaminergic, serotoninergic and glycinergic signalling 
mechanisms were all detected, although their function is unclear (Figure 3.15). 
Neurotransmitter receptors were most highly expressed during development, 
but the main ones continued to be expressed in the adult and ageing nerve. 
However, adenosine receptors 2A (Adora2a) and 2B (Adora2b), the 2, 1, and 
2 adrenergic receptors (Adra1b, Adra2a, Adrb2), and mAChR M1 (Chrm1) were 
detectable in P10-12 optic nerve only, suggesting they have a specific role in 
optic nerve development. Most of these neurotransmitters have been shown to 
affect OPCs and their differentiation in one manner or other, e.g. adenosine 
acting via A1 receptors regulates the migration, proliferation and differentiation 
of OPCs (Othman et al., 2003; Agresti et al., 2005a), and mAChR activation 
significantly increases OPC proliferation and inhibits their differentiation into 
myelinating oligodendrocytes (De Angelis et al.). In comparison, GABA signalling 
was highest in the ageing nerve and inhibits OPC proliferation (Yuan et al., 1998). 
Interestingly, transcripts for glutamate receptors predominated by far in the 
postnatal optic nerve, whereas P2Y and P2XR are always most dominant in 
functional studies using calcium imaging (Hamilton et al., 2008; Hamilton et al., 
2010). This illustrates that glutamate receptors, like GABA receptors, do not play 
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a major role in mediating calcium signalling in optic nerve glia, but instead have 
other effects, such as sodium movement and intracellular signalling through 
second messengers other than calcium (Verkhratsky and Butt, 2013).   
 
 Transcripts for AMPA, Kainate and NMDA receptors are present in the 
optic nerve, in agreement with their expression by astrocytes and 
oligodendrocytes (Matute et al., 2007a; Bakiri et al., 2009; Matute, 2011). AMPA 
receptors are composed of GluRA1-4 subunits, and all four were detected at all 
ages analysed, although GluA1 and GluA4 were higher in the postnatal nerve, 
consistent with evidence that AMPA receptors help control the timing of 
myelination, by inhibiting OPC proliferation and differentiation (reviewed in 
(Mangin & Gallo, 2011)). Interestingly, OPCs and myelin express NMDA-R that 
lack the NR2 subunit, which bears the glutamate binding site and instead they 
are activated exclusively by glycine or D-serine, and they display reduced Ca2+ 
permeability and Mg2+ sensitivity (reviewed in (Stys, 2011)). In contrast, 
transcripts in the optic nerve would indicate an upregulation of GluN2B in the 
ageing optic nerve, suggesting there may be a change in NMDA-R function to 
increased sensitivity to glutamate and Ca2+ permeability, which may have 
pathological consequences (Salter & Fern, 2005). The GluN2B subunit is reduced 
with age in hippocampus and cerebral cortex (Low & Wee, 2010), and when 
enhanced in aged mice can rescue memory (Brim et al., 2013). The high level of 
expression observed in the ageing optic nerve could be related to its reported 
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expression in astrocytes after ischaemia and anoxia in vivo and in vitro (Krebs et 
al., 2003).  
 
 
 
Figure 3.15 Age-related changes in the neurotransmitter receptor expression in the 
mouse optic nerve.   
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Metabotropic glutamate receptors (mGluRs) were also prominent in the 
optic nerve, with the mGluR5 (group I), mGluR3 (group II), and mGluR4 (group III) 
being the most expressed. Expression of mGluR5 and mGluR3 is a common 
feature of glial cells throughout the CNS and they regulate multiple functions, 
such as inhibition of K+ currents, proliferation and survival (Verkhratsky and Butt, 
2013). In contrast, mGluR4 is surprisingly the most expressed mGluR transcript in 
the postnatal optic nerve, although it has been described in cultured astrocytes 
(Yao et al., 2005) and in a subpopulation of reactive astrocytes in human MS 
lesions (Geurts et al., 2005), and is relatively recently come to light as a potential 
therapeutic target in Parkinson’s disease (Amalric et al., 2013). Furthermore, 
while it is generally held that mGluR5 is downregulated in astrocytes and 
oligodendrocytes during development (Romano et al., 1996; Cai et al., 2000; 
Romano et al., 2002; Luyt et al., 2006), its levels in the optic nerve were highest 
at 18-months, as were mGluR4 and mGluR7 compared to 1-month nerves, 
suggesting a role in the ageing process.  
 
A key feature of glia throughout the CNS is their expression of functional 
P2 receptors, and in the optic nerve the main transcripts were for the 
metabotropic P2Y12, P2Y6 and P2Y13 receptors and ionotropic P2X4 and P2X7 
receptors, which are the substrate for glial Ca2+ signalling (James & Butt, 2002). 
Glia can express all P2X subunits, but my results are consistent with P2X4 and 
P2X7 subunits predominating in optic nerve astrocytes, oligodendrocytes and 
microglia (Agresti et al., 2005a; Agresti et al., 2005b; Matute et al., 2007b; Butt, 
2011), and are of interest because they can cause sustained influx of Ca2+ and 
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mediate glial pathological responses, in particular the loss of oligodendrocytes 
and myelin in ischemia and demyelination (Matute & Cavaliere; Matute et al., 
2007b; Domercq et al., 2010). Notably, P2Y12 and P2Y13 receptors are prominent 
in microglia (McIlvain et al., 2010), but oligodendrocytes also express P2Y12 
where they are believed to contribute to myelination (Amadio et al., 2006; 
Amadio et al., 2010; Butt, 2011), and P2Y13 receptors in astrocytes mediate 
calcium signals (Carrasquero et al., 2009). The marked developmental 
downregulation of P2Y12R strongly suggests it is important for myelination, 
whereas the increase in P2Y13 may indicate changes in microglial and/or 
astrocyte function that are important in ageing white matter.   
 
3.3.4  Axonal genes and synaptic release mechanisms in the optic nerve  
A number of axonal transcripts were highly expressed, including 
neurofilament (Nefl), which is specific to axons, and ankyrin-3G (Ank3), which is 
an axolemmal protein that anchors sodium channels at nodes of Ranvier, 
although the key nodal sodium channel, Nav1.6 was called absent (Schafer et al., 
2006; Schafer & Rasband, 2006). These axonal transcripts were highest in the 
developing optic nerve, which is consistent with the reported prominence of 
local translation of mRNA by axonal ribosomes, and the apparent increase in Nefl 
transcripts in the ageing optic nerve may be a sign of axonal damage (Bomont et 
al., 2000). This microarray data requires further examination by qRT-PCR, but 
may be informative of the axonal transcriptome. For example, transcripts for the 
synaptic vesicle glycoprotein 2B (Sv2b) and Synaptotagmin-1 (Syt1) were 
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detected at relatively high levels in the postnatal nerve. Both Sv2b and Syt1 act 
via presynaptic calcium to regulate GABA and glutamate release regulate calcium 
is expressed at axonal terminals (Bragina et al., 2011), and their expression in the 
postnatal nerve is consistent with higher transport of their mRNA to the axon 
terminals during the postnatal period of active synapse formation. Syt1 has also 
been shown to regulate axon growth (Greif et al., 2013) and its apparent 
upregulation in the ageing nerve may indicate altered axonal growth or 
plasticity. In support of this possibility, a number of prominent transcripts that 
encode synaptic proteins were detected in the developing optic nerve. Notable 
amongst these were the high levels of transcripts for synaptobrevin-3 (Vamp3), 
Vapa (Vesicle associated protein A), SNAP proteins (Napa), and syntaxin 7 (Stx7), 
which as part of the SNAP-SNARE complex play a critical role in vesicle 
trafficking, docking and fusion, and were highest in the postnatal nerve. 
Furthermore, it is possible these mRNAs represent local translation of synaptic 
proteins, since axonal vesicular release mechanisms for glutamate have been 
described in the developing optic nerve (Alix et al., 2008). However, the main 
vesicular transporters for glutamate, GABA and ATP were called absent or barely 
detectable in the postnatal optic nerve, suggesting against local translation of 
axonal synaptic proteins. 
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3.3.5  Astrocytes as a source of synaptic neurotransmitter release in the optic 
nerve  
It is important to note that astrocytes are a potential source of 
neurotransmitters and are capable of vesicular neurotransmitter release (see 
(Zorec et al., 2012) for recent review). Notably Adk (adenosine kinase) was 
prominent at all ages and encodes for an enzyme that catalyzes ATP to 
adenosine, both intracellularly and extracellularly, consistent with the prominent 
role for ATP- and adenosine-mediated signalling in the optic nerve (Butt, 2011). 
In addition, a number of enzymes involved in the formation and breakdown of 
glutamine, GABA and glutamate were expressed at all ages. Notably, Gad1 
(GAD67) and Gad2 (GAD65) are expressed by astrocytes and required for the 
synthesis of GABA from glutamate; both were upregulated in the ageing nerve. 
An interesting feature was that the enzymes responsible for the 
endocannabinoid 2-arachidonoylglycerol (2-AG), monoglyceride lipase (Mg11) 
and diaglycerol lipase (Daglb), were differentially regulated with age: Mg11 was 
most highly expressed in the postnatal nerve and Daglb was increased in the 
mature and ageing nerve. 2-AG is produced by astrocytes, microglia and 
oligodendrocytes and, in addition to being anti-inflammatory, plays a critical role 
promoting OPC differentiation and myelin formation (Gomez et al., 2010).  
 
Vesicular release in astrocytes depends on the core SNAP-SNARE 
complex, including synaptobrevin-2 (Vamp2), its homologue cellubrevin 
(Vamp3), syntaxins and SNAP-23 (Verkhratsky and Butt, 2013). An analysis of 
 121 
synaptic terminals in the hippocampus found astrocytes abundantly express all 
three protein partners necessary to form an operational SNARE complex, but not 
the same isoforms as neighbouring neuronal synaptic terminals (Schubert et al., 
2011): astrocytes expressed SNAP23 and VAMP3, whereas neurones expressed 
SNAP25 and VAMP2, and syntaxin 1 was common to both. In the optic nerve, 
SNAP23 and Vamp3 were most enriched in the postnatal nerve, and the main 
syntaxins were syntaxin 6 and 7. Astrocytes can also express SNAP25 and VAMP3 
(Wilhelm et al., 2004; Crippa et al., 2006). Notably, in the ageing optic nerve 
there was a marked shift to SNAP25/VAMP3/syntaxin12, together with an 
upregulation of complexin-1 (Cplx1), which binds syntaxin and promotes 
vesicular release. This implies major changes in astrocyte and/or axonal synaptic 
mechanisms that may be important in the age-related decline in white matter 
function and require further investigation.  
 
3.4  Summary and conclusions 
The results of this section demonstrate that multiple neurotransmitter- 
signalling mechanisms are a prominent feature of the optic nerve, and provide a 
neurotransmitter receptor profile of optic nerve glia (Figure 3.15). There is pre-
eminence of glutamate, ATP and GABA signalling, and an important finding is 
that they were expressed at all ages, since most studies have been on postnatal 
white matter and it was suggested neurotransmitters may have been a 
developmental phenomenon. A number of signalling mechanisms were 
upregulated in the ageing optic nerve, most notably GABA signalling, mGluR5 
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and P2Y13R, and the synaptic proteins VGluT1 and SNAP25. A key function for 
neurotransmitter signalling is in the regulation of oligodendrocyte 
differentiation, and changes in the 18-month optic nerve may be relevant to the 
observed decrease in OPC genes and the reported loss of white matter in the 
ageing brain. In respect to this, the ageing optic nerve was characterized by 
increased inflammation and deregulation of proteostasis, which may be 
important in age-related pathological changes in white matter.   
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Section 4 
 
Functional expression of metabotropic 
glutamate receptors in the 
mouse optic nerve 
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4.1  Introduction and aims 
Glutamate is an important neurotransmitter in the optic nerve, with 
considerable evidence that it acts on ionotropic glutamate receptors (iGluRs) in 
oligodendrocytes and astrocytes (Butt et al., 2014a). iGluRs are ligand-gated ion 
channels permeable to K+, Na+ and Ca2+ and are classified into three groups, 
namely NMDA (N-Methyl-D-Aspartate), AMPA (α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate), and Kainate receptors, with immunohistochemical, 
functional calcium imaging, RT-PCR and western blot evidence of all subtypes 
being expressed in the optic nerve (reviewed in (Butt et al., 2014a)). There is less 
evidence for mGluRs in the optic nerve, although they are reported to be widely 
expressed in glial cells in other areas of the brain (Verkhratskiĭ & Butt, 2013). 
mGluR are seven transmembrane domain G protein-coupled receptors (GPCR) 
and are divided in three groups, based on their second messenger coupling, 
pharmacology and amino acid sequence (Pin & Bockaert, 1995). Group I mGluRs 
(mGluR1 and mGluR5) are positively coupled to phospholipase C (PLC) via Gq/11 
and inositol triphosphate (IP3) formation, whilst group II (mGluR2 and mGluR3) 
and group III (mGluR4, mGluR6, mGluR7 and mGluR8) are negatively coupled to 
adenylyl cyclase via Gi/G0. Each receptor subtype exhibits a well-defined 
expression pattern in several brain regions. In neurons, group I mGluRs are 
generally found in postsynaptic densities and modulate postsynaptic activity, 
whereas group II and III mGluRs are mainly postsynaptic and regulate 
neurotransmitter release (Ferraguti & Shigemoto, 2006). mGluRs are also 
expressed by glial cells, in which they modulate various glial functions and have a 
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role in glial-neuronal interaction. The microarray analysis in Section 3 identified 
RNA transcripts for mGluRs in the mouse optic nerve, but their functional 
expression has not previously been determined. Therefore, the aim of this 
section is to examine the protein expression of mGluRs in the mouse optic nerve 
compared to the brain, using qRT-PCR and immunocyto- and 
immunohistochemistry, and to determine their functionality by performing 
calcium imaging on intact isolated mouse optic nerves. 
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4.2  Results 
4.2.1  qRT-PCR analysis of mGluRs in mouse optic nerve and brain 
Developmental changes in the mGluR expression was analysed in the 
cortex, cerebellum and optic nerve of mice aged P9 (pre-myelination), P12 
(active myelination) and P30 (post myelination/mature), performing qRT-PCR, 
using a custom RT2 ProfilerqPCR array (Sabiosciences, Qiagen). The melt curve 
analysis shows that single amplicons are generated by qPCR (Figure 4.!) Results 
are expressed as relative gene expression using the 2^-Ct method, normalised 
to Gapdh. In the cortex, transcripts for mGluR3 (Grm3) and mGluR5 (Grm5) are 
the most abundant at P9 and are downregulated by P12 and remain at the same 
level at P30 (ANOVA and post hoc Bonferroni's tests, p values indicated on Figure 
4.1A); the other mGluR are detected at low levels, with the exception of mGluR6, 
which was not detected (Figure 4.2A). In the cerebellum, mGluR4 (Grm4) is 
markedly upregulated between P9 and P12 and is the most highly expressed 
mGluR in the P30 cerebellum (Figure4.2B; p<0.001); the other mGluRs are 
present at low levels or absent. In the optic nerve, mGluR1 (Grm1), mGluR3 
(Grm3), and mGluR5 (Grm5) are the most highly expressed and are 
developmentally upregulated (Figure 4.2C; p<0.001); mGluR4 (Grm4) and 
mGluR7 (Grm7) are also evident in P30 nerves, whereas the remaining mGluR 
are barely detectable or absent. 
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Figure 4.1 qRT-PCR melt curve analysis. Graph of the negative first derivative of 
representative melting-curves for all 8 mGluR subunits in a typical qRT-PCR 
experiment. Every trace represents a different mGluR. The presence of a single 
peak suggests that a single, specific product was amplified in the essay. 
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Figure 4.2 Expression of mGluR transcripts in cortex, cerebellum and optic nerve of P9, 
P12 and P30 mice. Tested for significance by ANOVA and post hoc Bonferroni's test 
(*p<0.05, **p<0.01, ***p<0.001).  
A 
B 
C 
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4.2.2  Group I and II mGluRs are expressed in the grey and white matter of the 
mouse brain 
In light of the qRT-PCR analysis above and the known functions of mGluR 
in glia, I focused my immunohistochemical analysis on the group I subunit 
mGluR5 and group II subunit mGluR3; mGluR1 was also examined, but the 
antibodies were not successful. Because of their high sequence homology, the 
anti-mGluR3 antibody also recognizes mGluR2, but the qRT-PCR data indicates 
that immunostaining is likely to reflect mGluR3 rather than mGluR2. It is known 
that mGluR subtypes have a specific regional pattern (Ferraguti & Shigemoto, 
2006) and my results in P8 coronal brain sections are consistent with the 
literature on immunostaining for mGluR5 and mGluR2/3 (Figure 4.3 and 4.4). An 
interesting observation is the difference in mGluR5 and mGluR2/3 
immunostaining between grey and white matter: the receptors are in fact highly 
expressed in thalamic regions, whereas their expression in the neighbouring 
corpus callosum appears significantly low in comparison (Figure 4.3 A-Aii and 
Figure 4.4 A-Aii). Because of the punctate nature of mGluR immunostaining, it is 
difficult to identify specific glial cell expression, although qualitative examination 
demonstrates the close association of mGluR with the EGFP+ astrocytes and 
NG2+ cells, these could represent close juxtaposition to neuronal synaptic mGluR 
(Figure 4.3 B-Cii and Figure 4.4 B-Cii). To address this, the Volocity 3D Image 
Analysis Software (PerkinElmer) was used to create colocalisation channels to 
investigate whether mGluRs and EGFP or dsRed reporter are present in the same 
voxels, which provides evidence of colocalization of both mGluR5 and mGlur2/3 
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with astrocytes and NG2+ cells (Figure 4.5). There is evidence of localization of 
mGluR5 and mGluR2/3 to astrocyte cell bodies, processes and endfeet 
ensheathing blood vessels (Figure 4.5A-Bii). Similarly, mGluR5 and mGlur2/3 are 
localized on pericytes, NG2-DsRed+ cells that are juxtaposed to blood vessels 
(Figure 4.5 C-Dii), as well as parenchymal NG2-DsRed+ cells with the morphology 
of OPCs (Figure 4.5 Di and Dii; data not shown for mGluR5).  
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Figure 4.3 mGluR5 expression in grey and white matter of the mouse forebrain. 
Confocal images of brain sections from P8 NG2-dsRed (A-Aii and C-Cii) and GFAP-EGFP 
mouse (B-Bii) immunolabelled for mGluR5. (A-Aii) Coronal brain section of a P8 NG2-
dsRed reporter mouse showing higher mGluR5 expression level in the thalamus 
compared to the corpus callosum. (B-Bii) High magnification confocal images ofthe 
mGluR5 staining in the thalamus of a P8 GFAP-EGFP mouse. (C-Cii) High magnification 
confocal images of the mGluR5 staining in the thalamus of a P8 NG2-dsRed mouse. 
Individual channels and the overlay are illustrated. mGluR5 immunostaining was absent 
in negative controls (not illustrated). Scale Bars: 100µm in A-Aiii and 20µm in B-Cii. 
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Figure 4.4 mGluR2/3 expression in grey and white matter of the mouse forebrain. 
Confocal images of brain sections from P8 GFAP-EGFP (A-Bii) and NG2-dsRed mouse (C-
Cii) immunolabelled for mGluR2/3. (A-Aii) Coronal brain section of a P8 GFAP-EGFP 
reporter mouse showing higher mGluR2/3 expression level in the thalamus compared to 
the corpus callosum. (B-Bii) High magnification confocal images of the mGluR5 staining 
in the thalamus of a P8 GFAP-EGFP mouse. Individual channels and the overlay are 
illustrated.  (C-Cii) High magnification confocal images of the mGluR5 staining in the 
thalamus of a P8 NG2-dsRed mouse. mGluR2/3 immunostaining was absent in negative 
controls (not illustrated). Scale Bars: 100µm in A-Aiii and 20µm in B-Cii 
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Figure 4.5 mGluR5 and mGluR2/3 colocalisation with astrocytes, pericytes and NG2 cells in grey matter of the mouse forebrain. Confocal images of brain 
sections from P8 GFAP-EGFP (A-Bii) and NG2-dsRed mouse (C-Dii) immunolabelled for mGluR5 (A-Aii and C-Cii) and mGluR2/3 (B-Bii and D-Dii). (A-Aii) 
mGluR5 immunostaining showing the colocalisation with GFAP-EGFP (Ai, colocalised voxels appear yellow) and the colocalisation channel (Aii). (B-Bii) 
mGluR2/3 immunostaining showing colocalisation with GFAP-EGFP (Bi, colocalised voxels appear yellow) and the colocalisation channel (Bii). (C-Cii) mGluR5 
immunostaining showing the colocalisation with NG2-DsRed (Ci, colocalisation appears yellow) and the colocalisation channel (Cii). (D-Dii) mGluR2/3 
immunostaining showing colocalisation with  NG2-dsRed (Di, colocalisation appears yellow) and the colocalisation channel (Dii). Scale Bars: 20µm. 
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4.2.3  Group I and II mGluR expression in mouse optic nerve glia 
mGluR5 and mGluR2/3 immunolabelling was performed on 14µm optic 
nerve cryosections from P9 GFAP-EGFP mice. Compared to the widespread 
expression observed in the brain, mGluR immunolabelling was low in the optic 
nerve (Figure 4.6), and it was barely possible to detect colocalisation of mGluR5 
or mGluR2/3 on glia, as illustrated in GFAP-EGFP+ astrocytes (Figure 4.6 Aii and 
Bii), suggesting that mGluRs are more expressed in neurons than glial cells. 
Although it was difficult to distinguish cellular expression in optic nerve sections, 
the qRT-PCR above indicated robust expression of mGluR5 and mGluR3 
transcripts in the optic nerve. Hence, to confirm that optic nerve glia express 
mGluR5 and mGluR2/3, explant cultures were prepared from optic nerves from 
P8 GFAP-EGFP and PLP1-dsRed reporter mice and examined after 5 days in vitro 
(DIV) (Figure 4.7). The results demonstrate that optic nerve astrocytes identified 
by their expression of the GFAP-EGFP reporter express mGluR5 on their cell 
somata (Figure 4.7 A-Aii) and mGluR2/3 in their cell bodies and primary 
processes (Figure 4.7 C-Cii). Oligodendrocytes identified by their expression of 
the PLP1-dsRed reporter are shown to express mGluR5 and mGluR2/3 on their 
cell somata and processes (Figure 4.7 B-Bii and D-Dii). 
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Figure 4.6 mGluR5 and mGluR2/3 immunolabelling in the mouse optic nerve. Confocal 
images of optic nerve sections from P9 GFAP-EGFP mice immunolabelled for mGluR5 (A-
Aii) and mGluR2/3 (B-Bii). (A-Aii) mGluR5 immunostaining showing colocalisation with 
GFAP-EGFP (Ai, colocalisation appears yellow), and the colocalisation channel (Aii). (B-
Bii) mGluR2/3 immunostaining showing little colocalisation with GFAP-EGFP (Ai, 
colocalisation appears yellow), and the colocalisation channel (Bii). Scale Bars: 20µm. 
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Figure 4.7 mGluR5 and mGluR2/3 immunolabelling in optic nerve glial cultures. Optic nerve explant cultures from P8 mice were analysed for mGluR5 and 
mGluR2/3 immunocytochemistry after DIV5. (A-Aii) mGluR5 immunostaining is evident mainly on the cell somata of astrocytes identified by expression of 
the GFAP-EGFP reporter, whereas mGluR2/3 immunostaining is present on the astrocytic cell body and primary processes (C-Cii). Immunolabelling for 
mGluR5 (B-Bii) and mGluR2/3 (D-Dii) is present on cell bodies and processes of oligodendrocytes identified by expression of PLP1-dsRed reporter. Individual 
channels and the overlay are illustrated. Scale Bars: 20µm. 
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4.2.4  Calcium imaging of mGluR function in optic nerve glia 
Stimulation of group I mGluR leads to the activation of phospholipase C 
(PLC), resulting in the formation of diacylglycerol (DAG) and inositol-(1, 4, 5)-
triphosphate (InsP3), which leads to the release of calcium from intracellular 
stores. We therefore examined whether group I mGluR mediate Ca2+ fluxes in 
optic nerve glia using Fluo-4 calcium imaging, as described previously (Hamilton 
et al., 2008; Hamilton et al., 2010). In brief, P7-P13 nerves were isolated intact 
and loaded with Fluo-4AM, a green-fluorescent Ca2+ dye that in its AM 
(acetoxymethylester) form is membrane permeable and, once taken up by the 
cell, cytosolic esterases remove the ester group and the dye is rendered 
membrane impermeable and thus remains intracellular (Garaschuk et al., 2006). 
Fluo-4-loaded nerves were placed in a perfusion chamber under a Zeiss LSM5 
Pascal Axioskop 2 confocal microscope and nerves imaged using a 20x/0.50 
WPh2 Achroplan water immersion lens. Fluo-4 was visualised by excitation at 
488 nm and optical z-sections were obtained, typically 7-8 sections at 2–3 µm 
intervals. Changes in Fluo-4 fluorescence were measured using the Zeiss LSM 
Image Examiner software (Zeiss, Germany) in glial cell bodies, selected as regions 
of interest (ROI). The vast majority of cells loaded in the optic nerve are 
considered to be astrocytes (Fern, 1998), although oligodendrocytes and OPCs 
may also take up the calcium indicator, and possibly the small population of 
microglia (Hamilton et al., 2010). ATP is known to mediate robust and 
reproducible [Ca2+]i elevations in optic nerve glia and hence its application 
(100μM) is used as positive control(Hamilton et al., 2008). On average, 11% of 
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the cells that responded to ATP were also responsive to the group I/II mGluR 
agonist (1S,3R)-1-Aminocyclopentane-1,3-dicarboxylic acid (ACPD). 
 
Figure 4.8A illustrates paired recordings from P9 optic nerve glia showing 
the response to ATP, glutamate and ACPD (all at 100 M; n=41 cells from 5 
nerves). The mean relative potency of action was ATP > glutamate > ACPD 
(Figure 4.7C). However, the response to the agents differed between cells, for 
example some cells displayed an equal response to all three agents, and others a 
greater response to ACPD than ATP or glutamate (Figure 4.8B). In addition, the 
primary response to the agents was characterised by a single peak, but some 
cells exhibited multiple peaks in response to glutamate and ACPD (Figure 4.8B).  
 
In an attempt to examine whether the variation in responses to ACPD 
might reflect different glial cells types, the diameter (d) of cell somata was 
measured and those with large somata (d11m) were considered putative 
astrocytes, and those with small somata (d10m) putative non-astrocytes, 
comprising mainly of oligodendrocytes, but also smaller populations of OPC and 
microglia. Interestingly, many of the smaller cells displayed the largest responses 
to ACPD, but did not respond to ATP (Figure 4.9, red traces), whereas most 
putative astrocytes had large responses to ATP and smaller response to ACPD. 
These results illustrate the need for a method of identifying glial cells in these 
experiments, but in the absence of an unequivocal method this analysis was not 
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pursued further, and in subsequent experiments cells were selected on the basis 
of a positive response to ACPD. 
 
 
 
 
Figure 4.8 Comparison of response to ATP, glutamate and ACPD in optic nerve glia. (A) 
Confocal images of Fluo-4 fluorescence intensity (illustrated in rainbow false colour) and 
(B) representative traces of individual glial cells illustrate the changes in fluorescence in 
response to ATP, glutamate and group I/II mGluR agonist ACPD (all at 100 M and 
administered for 30s). (C) Bar graph showing mean response (± SEM) expressed in 
arbitrary units (n=41 cells from 5 nerves). *p>0.5, ***p>0.001, paired t-tests. Scale bar 
15 μm. 
 
 
 
 
 140 
 
Figure 4.9 Calcium responses in optic nerve glia in response to the group I/II agonist 
ACPD. Raw traces of individual regions of interest (ROIs) illustrate the changes in Fluo-4 
fluorescence in response to 4 administrations of 100 M ACPD (30s each, with 10min 
recovery in between), followed by 100 M ATP (30s). The diameter (d) of the cells was 
measured and cells were considered putative astrocytes (d11m; black traces) and 
putative non-astrocytes (oligodendrocytes, OPC, pericytes or microglial cells; d10m; 
red traces). 
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4.2.5 Group I mGluR mediated raised [Ca2+]i in optic nerve glia 
Paired recordings from Fluo-4 AM loaded cells show that cells responding 
to ACPD also responded to the specific group I agonist DHPG (100μM) (Figure 
4.10A), and the mean rise in glial [Ca2+]i was significantly greater for DHPG than 
ACPD in paired recordings (Figure 4.9; n=13 cells from 4 nerves; p<0.01, paired t-
test). However, the response varied between cells, with ACPD evoking a larger 
response in some cells and DHPG in others (Figure 4.10B). In addition, the 
response to ACPD was generally a single or double peak, whereas DHPG evoked 
multiple peaks, characteristic of astroglial Ca2+ oscillations (Figure 4.10B). 
 
The group I mGluR antagonist AIDA (100μM) significantly inhibited the 
glial response to ACPD (Figure 4.11; n=16 cells from 4 nerves, p<0.001, paired t-
test), Interestingly, the blockade of group I mGluR alters the kinetics of the ACPD 
response, which in the presence of AIDA was characterised by multiple peaks or 
oscillations (Figure 4.11B). ACPD activates both group I and group II mGluR, 
whereas AIDA specifically blocks group I mGluR, and the variable effect of AIDA 
between cells identified cells in which AIDA completely blocked the response to 
ACPD in some cells (Figure 4.11A, ‘group I responder’), but had no effect in other 
cells (Figure 4.10A, ‘group II responder’). Although group II mGluR are coupled to 
cAMP and not Ca2+, these results raise the possibility that group II mGluR may be 
involved in glial calcium signaling. However, it was not possible to follow up 
these observations, due to malfunction of the calcium imaging equipment. 
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Figure 4.10 Group I mGluR mediate calcium signals in optic nerve glia. (A) Confocal 
images of Fluo-4 fluorescence intensity (illustrated in rainbow false colour) and (B) 
representative traces of individual glial cells illustrate the changes in fluorescence in 
response to ACPD and selective group I mGluR agonist DHPG (both at 100 M, applied 
for 30s). (C) Bar graph of mean response (± SEM) expressed in arbitrary units (n=13 cells 
from 4 nerves). **p<0.01, paired t-test. Scale bar 10μm. 
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Figure 4.11 Group I mGluR blockade significantly decreases the response to ACPD. (A) 
Confocal images of Fluo-4 fluorescence intensity (illustrated in rainbow false colour) and 
(B) representative traces of individual glial cells illustrate the changes in fluorescence in 
response to ACPD in the aCSF and in the presence of the specific group I mGluR agonist 
AIDA (both at 100 M). (C) Bar graph shows mean response (± SEM) expressed in 
arbitrary units (n=16 cells from 4 nerves). ***p<0.001, paired t-test. Scale bar 10μm. 
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4.3  Discussion 
The results of this section show that optic nerve glial cells express group I 
and group II mGluRs at mRNA and protein level, and the calcium imaging analysis 
demonstrated that these receptors are functional. 
 
4.3.1 qRT-PCR limitations 
In this study, gene expression was determined by the Relative 
Quantification method, where the quantity of genes of interest is expressed 
relative to reference genes within the same sample. The optimal way to 
determine the most appropriate reference genes with the lowest difference 
between samples would be to use RNA sequencing or to run a variety of 
candidate reference genes in triplicates for all samples and different 
experimental conditions. These methods were not feasible in my study because 
of the large number of mice that would require. The appropriate reference gene 
(Gapdh) was selected by the standard deviation method, in combination with the 
NormFinder algorithm (Casadei et al., 2011). Gapdh is the most widely used 
reference gene across the literature and has been shown to be the most stable 
gene in the mouse brain during development and in ageing (Sieber et al., 2010; 
Kraemer et al., 2012). 
 
The developmental analysis of the expression of mGluR has been 
performed on extracts of pooled whole mouse optic nerves, therefore the 
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expression profile of a specific cell type could not be determined. Nonetheless, 
the vast bulk (>90% of cells) of the RNA extracted in whole optic nerves is from 
astrocytes and oligodendrocytes (Salter & Fern, 2005). Hence, it can be 
hypothesised that the most highly expressed subunits identified in my study, 
such as mGluR1, mGluR3 and mGluR5 are in astrocytes and/or oligodendrocytes. 
This is in partial agreement with published studies that detected mRNA for 
mGluR3 and mGluR5, but not mGluR1, in hippocampal astrocytes isolated from 
young and adult rats (Schools & Kimelberg, 1999; Cai et al., 2000) and OPCs (Luyt 
et al., 2003). MGluR1 has been detected by immunocytochemistry in 10% of 
cultured astrocytes prepared from spinal cord (Silva et al., 1999) and in a 
subpopulation of reactive astrocytes in multiple sclerosis lesions (Geurts et al., 
2003). The expression of mGluR5 in astrocytes and mGluR3 and mGluR5 in 
oligodendrocyte lineage cells decreases during development (Cai et al., 2000; 
Luyt et al., 2006), similarly to that reported in neurons (Romano et al., 1996; 
Romano et al., 2002). This profile might be masked or distorted in our study 
because of the heterogeneity of the tissue and the concomitant presence of cells 
at different stages of maturation. With the exception of mGluR6, whose 
expression is restricted to retinal bipolar cells, all mGluR subunits are expressed 
in the mouse cortex, with mGluR3 and mGluR5 at the highest level. On the other 
hand, the most highly expressed in the cerebellum was mGluR4 (GRM4), which is 
expressed by granule cell axons, but also other subunits (mGluR1, mGluR2, 
mGluR5, mGluR7) are expressed in the cerebellum (Knöpfel & Grandes, 2002). It 
is likely that the most expressed transcripts in the optic nerve are the most 
important functional receptors, but it is important to take into consideration that 
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levels of mRNA do not directly correlate to the protein expression level. In fact, 
there are many different post-transcriptional and post-translational regulatory 
mechanisms that may lead to mismatches between mRNA and protein levels 
(Greenbaum et al., 2003; Vogel & Marcotte, 2012). 
 
4.3.2  mGluR5 and mGluR2/3 expression in the mouse optic nerve 
Our immunohistochemical analysis of mGluR5 and mGluR2/3 first of all 
showed a dramatic difference in expression levels between grey matter and 
white matter, suggesting that these receptors are expressed mainly by neurons. 
Nonetheless, it is known that astrocytes express mGluR5 and that its activation 
leads to an increase in intracellular calcium levels. This, in turn, results in the 
release of glutamate and other gliotransmitters, which can evoke synaptic 
responses in neighbouring neurons and glia (Pasti et al., 1997; Bezzi et al., 1998). 
This mechanism is the reason why mGluR5 is involved in a plethora or functions, 
such as learning and memory, synaptic plasticity, ion channel regulation, cellular 
excitability, anxiety and perception of pain. As a consequence, dysregulation or 
misexpression of mGluR5 is associated with major diseases, e.g. anxiety, fragile-X 
syndrome, epilepsy and AD (Niswender & Conn, 2010). Consistent with my qRT-
PCR findings, astrocytes have been shown to express mGluR3 but not mGluR2 in 
vivo (Petralia et al., 1996; Ohishi et al., 1998; Tamaru et al., 2001; Mudo et al., 
2007) and in vitro (Ciccarelli et al., 1997; Aronica et al., 2003). In addition, 
mGluR2/3 immunoreactivity has been found in microglia/macrophages in 
biopsies from patients with multiple sclerosis (Geurts et al., 2003). The activation 
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of group II mGluRs in cultured astrocytes can have a dual regulation: it reduces 
the forskolin-stimulated cAMP formation in the absence of extracellular calcium, 
but enhances it in the presence of calcium (Moldrich et al., 2002). Moreover, 
group II mGluR stimulation amplifies the stimulatory effect on cAMP formation 
mediated by 2-adrenergic receptors, and this combined activation stimulates 
the release of adenosine in cultured astrocytes (Winder et al., 1996). Adenosine 
is involved in the regulation of many glial functions, such as glial proliferation, 
glutamate transporters expression and glutamate sensitivity (Daré et al., 2007; 
Verkhratsky et al., 2009; Boison et al., 2010). 
 
Although is not clear whether mGluR5 is expressed by oligodendrocytes 
in vivo, my results demonstrate optic nerve oligodendrocytes express mGluR5 in 
explants cultures, and cultured oligodendrocyes from other brain regions have 
been shown to express mGluR1, mGluR2/3, mGluR4 and mGluR5 (Deng et al., 
2003). The expression of mGluR is developmentally downregulated in culture, 
being high in early and late OPCs and low or absent in immature and mature 
oligodendrocytes(Deng et al., 2003). This suggest that mGluR may have a role in 
oligodendrocyte differentiation and myelination (Luyt et al., 2003). mGluR3 and 
mGluR5 have also been detected in OPCs from adult human brain (Luyt et al., 
2003; Luyt et al., 2004). The activation of mGluR5 protects OPCs from 
staurosporine-induced apoptosis (Luyt et al., 2006), suggesting that its 
downregulation in premyelinating OLs increases their vulnerability. Moreover, 
consistent with my study showing that ACPD evokes raised [Ca2+]i in optic nerve 
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glia, the administration of ACPD has been shown to attenuate the loss of white 
matter myelin in P6 rats subjected to hypoxia-ischemia (Jantzie et al., 2010).   
 
4.3.3 mGluR at the gliovascular interface 
My results draw attention to the similar pattern of expression of mGluR3 
and mGluR5 at the interface between astrocytes and pericytes, both members of 
the neurovascular unit. The neurovascular unit is the point of contact on a blood 
vessel of astrocytes, endothelial cells, and pericytes. It plays a crucial role in 
neurovascular coupling. Neurovascular coupling, also referred to as functional 
hyperaemia, is the phenomenon by which an intensification of neuronal activity 
leads to a local increase in blood flow. When a rise in neural activity occurs, 
neurotransmitters are released and the metabolic demand rises, with an 
increase of O2, glucose and ATP consumption. Cerebral blood flow (CBF) 
increases to provide a continuous supply of nutrients and supports the normal 
functioning of the brain (Ventura & Harris, 1999; Simard et al., 2003). The 
functional relevance of this connection has been the subject of several studies. 
Synaptically released glutamate causes astrocytes to produce and release many 
vasoactive compounds (Petzold & Murthy, 2011), such as ATP (Queiroz et al., 
1999; Arcuino et al., 2002; Coco et al., 2003), nitric oxide (NO) (Murphy et al., 
1993; Li et al., 2003), arachidonic acid (AA) metabolic products, such as 
prostaglandin E2 (PGE2), and epoxyeicosotrienoic acids (EETs) (Pearce et al., 
1989; Amruthesh et al., 1993; Roman, 2002). These substances are believed to 
act on smooth muscle cells in arterioles or on pericytes to determine the vascular 
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tone, contraction or dilation, depending on the local O2 concentration (Zonta et 
al., 2003b; Gordon et al., 2008; Attwell et al., 2010). Specifically, the activation of 
the astrocytic mGluR5 leads to the pulsatile release of PGE2, which causes 
dilation of arterioles (Zonta et al., 2003a; Zonta et al., 2003b; Filosa et al., 2004).  
 
4.3.4 mGluR mediate calcium signals in the postnatal mouse optic nerve glia 
Calcium is a key second messenger in glial physiology and pathology, as 
astrocytes use intercellular Ca2+ waves as a mechanism for communication 
(Verkhratsky et al., 1998). The combined expression of the mRNA transcripts and 
immunostaining coupled with the response to ACPD and DHPG provide strong 
evidence for functional group I mGluR5 in optic nerve glia, in particular 
astrocytes. However, a major limitation of the calcium imaging experiments in 
the isolated intact optic nerve is that it was not possible to identify the specific 
glial cell types from which recordings were made, and experiments in the 
transgenic glial reporter mice was not successful. The vast majority of cells 
composing the optic nerve are astrocytes and oligodendrocytes(Salter & Fern, 
2005), therefore we can assume that calcium imaging measurements will include 
both cell types. However, in my analysis only 11% of cells that responded to ATP 
also responded to the group I/II mGluR agonist ACPD. This indicates that most 
optic nerve astrocytes and oligodendrocytes do not express sufficient levels of 
mGluR5 to evoke a measurable calcium response, which is consistent with the 
immunohistochemical findings. The immunohistochemistry did not support the 
possibility that mGluR5 is expressed only by a small proportion of cells, and the 
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in vitro data demonstrated both astrocytes and oligodendrocytes express 
mGluR5.  
 
The application of the group I/II mGluR ACPD agonist and group I specific 
agonist DHPG elicited arise in glial [Ca2+]i, consistent with activation of mGluR5. 
Surprisingly, the group I mGluR inhibitor AIDA did not completely abolish the 
increase in [Ca2+]i evoked by ACPD, but changed its kinetics. In expression 
systems mGluR5 elicits oscillations, whereas the closely related mGluR1 evokes 
single-peaked responses (Kawabata et al., 1996; Nakanishi et al., 1998; Kettunen 
et al., 2002). In contrast, an activation of native mGluR5 in neurons can induce 
different effects: it elicits a single-peaked response in hippocampus (Rae et al., 
2000) and it induces oscillations in the neocortex (Flint et al., 1999). Astrocytes 
can display various pattern of response, transient or oscillatory, depending on 
the species, brain regions and age of the animal (McCarthy & Salm, 1991; Müller 
et al., 1997; Cai et al., 2000). In cultured astrocytes, which like optic nerve glia do 
not express mGluR1, the activation of mGluR5 with ACPD mediates calcium 
oscillations via PKC phosphorylation (Nakahara et al., 1997). In our experiments, 
ACPD elicits mainly single-peaked responses, whereas DHPG, selective agonist 
for mGluR5, evokes an oscillatory response. ACPD does not evoke currents in 
white matter oligodendrocytes in brain slices (Káradóttir et al., 2005) although it 
elicits a rise in [Ca2+]I in cultured OPCs (Holtzclaw et al., 1995). The expression of 
mGluR5 appears to decrease during development (Cai et al., 2000), and because 
of this DHPG induces calcium oscillations in the majority of OPCs, requiring Ca2+ 
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release from intracellular stores, but only in a smaller proportion of 
oligodendrocytes (Luyt et al., 2003; Luyt et al., 2006). In OPCs, glutamate induced 
calcium oscillations could have a role in migration (Gudz et al., 2006). Although 
my calcium experiments were performed on P7-P13 optic nerves for technical 
reasons, the qRT-PCR did not support a possible down-regulation of mGluR5 with 
development in the optic nerve. 
 
4.4  Summary and conclusions 
 The results of this section provide evidence of functional expression of 
group I mGluR5 and group II mGluR3 in optic nerve astrocytes and 
oligodendrocytes. Activation of mGluR5 evokes raised [Ca2+]I in optic nerve glia, 
and there is evidence that group II mGluR may modulate these calcium 
responses. The expression of mGluR in the optic nerve is consistent with 
evidence that glutamate is an important signaling molecule and implies it has a 
physiological function; in astrocytes mGluR are implicated in their homeostatic 
functions and in oligodendrocytes in regulating differentiation and myelination. 
The source of endogenous glutamate seems likely to be axons, which release 
glutamate in response to action potentials (Kukley et al., 2007; Ziskin et al., 
2007). Extensive studies on optic nerve anatomy have shown that astrocytes, 
oligodendrocytes and OPCs make contacts with axons at nodes of Ranvier (Butt 
et al., 1994a; Butt et al., 1994b; Butt et al., 1999) and glutamate and axonal 
activity can trigger [Ca2+]i increase in optic nerve glia (Kriegler & Chiu, 1993; 
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James & Butt, 2001; Butt et al., 2004; Hamilton et al., 2008; Hamilton et al., 
2010). The results of this section show that mGluR are also involved in these 
signaling cascades. 
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Section 5 
 
A protective role for glial metabotropic 
glutamate receptors in ischaemia 
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5.1  Introduction and aims 
In Section 4, I demonstrated that optic nerve astrocytes and 
oligodendrocytes express functional mGluR. The precise functions of mGluR in 
glia are unclear, although they are implicated in oligodendrocyte differentiation 
and in the tripartite synapse in grey matter astrocytes (Ferraguti & Shigemoto, 
2006). In addition, like neurons, oligodendrocytes are highly susceptible to 
hypoxic/ischemic damage (Fern & Möller, 2000), and there is evidence that the 
activation of group I mGluRs might have a protective role in both neurons and 
oligodendrocytes exposed to ischaemic injury (Deng et al., 2003; Baskys et al., 
2005; Jantzie et al., 2010). Whilst in vitro studies have shown that cultured 
astrocytes are resilient to ischaemic injury (Goldberg & Choi, 1993), astrocytes in 
situ appear to be only slightly more resistant than neurons, and immature 
astrocytes may be more susceptible than adult (Shannon et al., 2007). 
Furthermore, OPCs in developing white matter have inadequate anti-oxidative 
defences, which make them particularly sensitive to ischaemia (Fern & Möller, 
2000; Back et al., 2001). Notably, ischaemic injury of developing white matter, 
termed periventricular leukomalacia (PVL) or periventricular white matter injury 
(PWMI), is characterized by early damage of oligodendrocytes and axons and is 
the major cause of death and neurological impairment in cerebral palsy (Banker 
& Larroche, 1962; Paneth, 1994; Volpe, 1995). In addition to oxygen and glucose 
deprivation, ischaemia is characterized by glutamatergic excitotoxicity caused by 
an increase in extracellular glutamate and the resulting over-activation of AMPA-
, KA- and NMDA-type glutamate receptors (Deng et al., 2003; Salter & Fern, 
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2005; Manning et al., 2008). In contrast, activation of mGluR in the face of raised 
extracellular glutamate is proposed to have a protective role in ischemia. The 
aim of this section is to examine the potential protective role of mGluR in 
astrocytes and oligodendrocytes in white matter ischemia, using the postnatal 
optic nerve and oxygen-glucose deprivation (OGD) model of ischemia/hypoxia 
(Fern, 1998; Shannon et al., 2007; Salter & Fern, 2008). 
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5.2  Results 
5.2.1  Group I/II mGluR activation protects optic nerve cells from ischaemia 
In order to investigate the role of mGluR in glial cells during ischaemia, 
optic nerves were subjected to OGD (Salter & Fern, 2005; Hawkins & Butt, 2013). 
Briefly, P8-P13 C57BL/6 wild-type (wt) mice and GFAP-EGFP, SOX10-EGFP, PLP1-
DsRed, NG2-DsRed reporter mice were killed humanely and the optic nerves 
rapidly isolated intact and immediately placed in aCSF (containing glucose – see 
section 2.5.4) in an incubator to stabilise for 30 min at 37C in normoxic 
conditions (95%O2/5% CO2). Optic nerves were then incubated for 1h at 37C in 
either normoxic (95%O2/5%CO2) and glucose aCSF, or in ZERO-O2 (95%N/5%CO2) 
and ZERO-glucose aCSF (OGD). All drugs were added directly to aCSF during 
incubation. At the end of the incubation, optic nerves were fixed in 4% PFA for 
1h at RT, washed and mounted on microscope slides. Surviving cells expressing 
EGFP and DsRed reporters were visualised at 488nm and 568nm, respectively, 
using a LSM 710 Zeiss confocal microscope with a x40 oil immersion lens with 
high numerical aperture (1.3nm); images were captured maintaining the 
acquisition parameters constant between samples. Two images were captured at 
the mid-point along the length of each nerve, and 15 x 1 m z-sections were 
acquired, and the number of cells expressing the reporter was counted within a 
constant 20 x 20 m field of view (FOV) in the x-y-plane. Cell counts are 
expressed as mean  SEM, where each ‘n’ value represents the number of optic 
nerves, and significance was determined by ANOVA and post-hoc Newman-Keuls 
multiple comparison analysis using Prism5.0 (Graphpad) (Hawkins & Butt, 2013). 
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Firstly, to determine whether mGluR are cytoprotective in OGD, optic 
nerves from P10 C57BL/6 wild-type mice were subjected to OGD in the presence 
of the general Group I/II mGluR agonist 1-Amino-1,3-
dicarboxycyclopentane (ACPD, 100 M) and propidium iodide (PI) was used to 
identify dead cells. Compared to normoxic control nerves incubated in 
O2+glucose (Figure 5.1A), OGD resulted in a statistically significant increase in the 
number of PI+ cells (Figure 5.1C, E; p<0.05), demonstrating that OGD induced cell 
death. Incubation with ACPD in OGD significantly decreased the number of PI+ 
cells compared to OGD in aCSF (Figure 5.1D, E; p<0.01), to a level observed in 
normoxic control conditions. Incubation with ACPD in normoxic conditions did 
not have a significant effect on the number of PI-positive cells (Figure 5.1B, E). 
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Figure 5.1 Effect of the Group I/II mGluR agonist ACPD on OGD induced cell death 
in postnatal mouse optic nerve. Optic nerves from P10 C57BL/6 mice were exposed to 1 
h OGD in the absence or presence of the Group I/II mGluR agonist ACPD (100 µM) and 
compared to normoxic controls incubated in O2+glucose (O2). (A–D) Representative 
images of PI+ cells in control O2 (A), O2+ACPD (B), OGD (C), and OGD+ACPD (D); scale 
bars = 50 m. (E) Quantification of the number of PI+ cells in constant fields of view 
(FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; *p<0.05, **p<0.01, ANOVA 
with Newman–Keuls multiple comparison post-hoc analysis).   
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5.2.2  Astrocytes in the postnatal optic nerve are susceptible to OGD and are 
protected by mGluR activation 
In order to understand which cells are protected by mGluR activation and 
examine the mGluR subtypes involved, the same experimental protocol as above 
was performed using postnatal nerves from different reporter mice to identify 
the different glial cell types, and the group I mGluR agonist DHPG ((S)-3,5-
Dihydroxyphenylglycine) and group II mGluR agonist LY379268. Analysis of 
nerves from GFAP-EGFP mice demonstrates that astrocytes are susceptible to 
OGD (Figure 5.2B), with a marked 50% decrease in GFAP-EGFP+ cells in OGD 
compared to normoxic controls (Figure 5.2A, F, p<0.001). Incubation with ACPD, 
DHPG, or LY379268 all had an equivalent protective effect against OGD in 
astrocytes (Figure 5.2C-F), rescuing astrocyte numbers to that seen in controls 
(see Figure 5.2F for details of p values). 
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Figure 5.2 mGluR activation protects postnatal optic nerve astrocytes from OGD. Optic 
nerves from P9 GFAP-EGFP reporter mice were exposed to 1 h OGD in the presence or 
absence of the group I/II agonist ACPD, or specific group I agonist DHPG and group II 
agonist LY379268 (all 100 µM), compared to control nerves incubated in normal aCSF 
with O2+glucose (O2). (A–E) Representative images of GFAP-EGFP
+ astrocytes in isolated 
intact optic nerves incubated in O2 (A), OGD (B), OGD+ACPD (C), OGD+DHPG (D), or 
OGD+LY (E); scale bars = 50 m. (F) Quantification of the number of GFAP-EGFP+ cells in 
constant fields of view (FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; 
***p<0.001, ANOVA with Newman–Keuls multiple comparison post-hoc analysis).  
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5.2.3  Oligodendrocytes in the postnatal optic nerve are susceptible to OGD 
and are protected by mGluR activation 
To analyse oligodendrocyte lineage cells, I used optic nerves from P8 
SOX10-EGFP mice (Figure 5.3) and P11 PLP1-DsRed mice (Figure 5.4). The Sox10-
EGFP reporter identifies both oligodendrocytes and OPCs, which are defined by 
their specific expression of the transcription factor Sox10, whilst the PLP1-DsRed 
reporter identifies mature oligodendrocytes and not OPC. Hence, any difference 
between SOX10-EGFP and PLP1-DsRed nerves is a measure of the changes in 
OPCs. Compared to control normoxic nerves (Figure 5.3A), OGD resulted in a 
marked loss of SOX10-EGFP+ cells (Figure 5.3B), which was statistically significant 
(Figure 5.3F, p<0.001). Incubation with ACPD, DHPG or LY379268 had a 
protective effect against OGD induced loss of Sox10-EGFP+ cells (Figure 5.3C-F; 
p<0.001); there was no significant difference between the different mGluR 
agonists, but the number of Sox10-EGFP+ oligodendrocytes in OGD+LY3799268 
was significantly less than in control normoxic conditions (Figure 5.3F; p<0.01). 
Similarly, OGD resulted in a significant loss of PLP-DsRed+ oligodendrocytes 
compared to normoxic controls (Figure 5.4A, B; p<0.001), and the mGluR 
agonists significantly protected against this (Figure 5.4C-F; p<0.001); mGluR 
agonists did not result in full recovery of PLP-DsRed+ cell numbers, which were 
significantly less than in normoxic numbers (Figure 5.4F; p<0.001). 
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Figure 5.3 mGluR activation protects postnatal optic nerve oligodendrocytes from 
OGD. Optic nerves from P8 SOX10-EGFP reporter mice were exposed to 1 h OGD in the 
presence or absence of the group I/II agonist ACPD, or specific group I agonist DHPG and 
group II agonist LY379268 (all 100 µM), compared to control nerves incubated in normal 
aCSF with O2+glucose (O2). (A–E) Representative images of SOX10-EGFP
+ 
oligodendrocyte lineage cells (Sox10-EGFP identifies all OPCs and oligodendrocytes) in 
isolated intact optic nerves incubated in O2 (A), OGD (B), OGD+ACPD (C), OGD+DHPG 
(D), or OGD+LY (E); scale bars = 50 m. (F) Quantification of the number of SOX10-EGFP+ 
cells in constant fields of view (FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; 
**p<0.01, ***p<0.001, ANOVA with Newman–Keuls multiple comparison post-hoc 
analysis).   
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Figure 5.4 mGluR activation protects postnatal optic nerve mature oligodendrocytes 
from OGD. Optic nerves from P11 PLP1-DsRed reporter mice were exposed to 1 h OGD 
in the presence or absence of the group I/II agonist ACPD, or specific group I agonist 
DHPG and group II agonist LY379268 (all 100 µM), compared to control nerves 
incubated in normal aCSF with O2+glucose (O2). (A–E) Representative images of PLP1-
DsRed+ oligodendrocytes (PLP1-DsRed identifies mature oligodendrocytes) in isolated 
intact optic nerves incubated in O2 (A), OGD (B), OGD+ACPD (C), OGD+DHPG (D), or 
OGD+LY (E); scale bars = 50 m. (F) Quantification of the number of PLP1-DsRed + cells in 
constant fields of view (FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; 
***p<0.001, ANOVA with Newman–Keuls multiple comparison post-hoc analysis). 
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5.2.4  Oligodendrocytes in the adult optic nerve are susceptible to OGD and 
are protected by mGluR activation 
In order to understand if the mGluR mediated protective effect is specific 
to developing white matter undergoing myelination, OGD experiments were 
performed on optic nerves from adult (P33) PLP1-DsRed reporter mice. After 1h 
OGD, there was a 30% loss of PLP1-DsRed+ oligodendrocytes compared to 
normoxic controls (Figure 5.5A, p<0.001). Incubation with the group I mGluR 
agonist DHPG protects oligodendrocytes from this OGD-induced loss (Figure 
5.5C, p<0.05), whilst the group II mGluR agonist LY379268 was not significantly 
protective against OGD (Figure 5.5D, p>0.05). This result demonstrates that 
oligodendrocytes are susceptible to hypoxia/ischaemia in the adult optic nerve, 
and that mGluR are protective, but the results indicate this may be preferentially 
via group I mGluR.  
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Figure 5.5 mGluR activation protects adult optic nerve oligodendrocytes from OGD. 
Optic nerves from P33 PLP1-DsRed reporter mice were exposed to 1 h OGD in the 
presence or absence of the specific group I agonist DHPG or group II agonist LY379268 
(both at 100 µM), compared to control nerves incubated in normal aCSF with 
O2+glucose (O2). (A–D) Representative images of PLP1-DsRed
+ oligodendrocytes in 
isolated intact optic nerves incubated in O2 (A), OGD (B), OGD+DHPG (C), or OGD+LY (D); 
scale bars = 50 m. (E) Quantification of the number of PLP1-DsRed + cells in constant 
fields of view (FOV) (mean ± SEM, n ≥ 5 nerves per experimental group; *p<0.05, 
**p<0.01, ***p<0.001, ANOVA with Newman–Keuls multiple comparison post-hoc 
analysis). 
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5.2.5  The protective effect of goup I mGluR on postnatal optic nerve 
oligodendrocytes in OGD requires PKC activation  
The results above indicate a cytoprotective role for group I mGluR, which 
are G-protein coupled receptors that act by an increase in phospholipase C (PLC) 
activity and subsequent formation of inositol triphosphate (IP3), which causes an 
increase of intracellular Ca2+ concentration and diacylglycerol (DAG), responsible 
for the activation of protein kinase C (PKC). In order to examine the pathways 
responsible for the group I mGluR mediated protective effect on 
oligodendrocytes, the PKC inhibitor Go6976 (10 M) was used in conjunction 
with DHPG, using the OGD model in optic nerves from P11 PLP1-DsRed reporter 
mice. The results demonstrate that the protective effect of DHPG is completely 
abolished by the inhibition of PKC (Figure 5.6, p<0.001), providing strong 
evidence that group I mGluR mediate their pro-survival effect on 
oligodendrocytes via PKC activation. 
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Figure 5.6 Protective effect of group I mGluR on postnatal optic nerve 
oligodendrocytes in OGD requires PKC activation. Optic nerves from P11 PLP1-DsRed 
reporter mice were exposed to 1 h OGD in the presence of the group I mGluR agonist 
compared to normoxic controls incubated in normal aCSF with O2+glucose (O2). (A-D) 
Representative images of PLP1-DsRed+ oligodendrocytes in isolated intact optic nerves 
incubated in O2 (A), OGD (B), OGD+DHPG (C), or OGD+DHPG+Go6976 (D); scale bars = 
50 m. (E) Quantification of the number of PLP1-DsRed + cells in constant fields of view 
(FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; *p<0.05, **p<0.01, 
***p<0.001, ANOVA with Newman–Keuls multiple comparison post-hoc analysis).  
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5.2.6  Gq coupled receptors are protective against OGD in postnatal optic 
nerve oligodendrocytes 
Group I mGluR are coupled to Gq protein (Gq/11), a heterotrimeric G 
protein subunit that activates PLC. Many G-protein coupled receptors act via Gq 
proteins, including P2Y1 receptors that are expressed by oligodendrocytes (Butt, 
2011). Therefore, to determine whether the cytoprotective effect of group I 
mGluR activation is specific to these receptors or possibly a general effect of all 
Gq-coupled receptors, I examined the effects of the P2Y1 receptor specific 
agonist (N)-methanocarba-2MeSADP (MRS2365, 10 M) (Bourdon et al., 2006). 
In P11 PLP1-DsRed optic nerves, activation of P2Y1 has a significant protective 
effect on oligodendrocytes in OGD (Figure 5.7B, D; p<0.05). The specificity of this 
effect was confirmed using the selective P2Y1 receptor antagonist 2-chloro N(6)-
methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate (MRS2279, 10 
M), which completely abolished the cytoprotective effect of MRS2365 (Figure 
5.7C, D, p<0.01). This result raises the likelihood that Gq-coupled receptors have 
a general cytoprotective role against hypoxic/ischaemic injury in 
oligodendrocytes. 
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Figure 5.7 Activation of the Gq-coupled P2Y1 receptor protects postnatal optic nerve 
oligodendrocytes from OGD. Optic nerves from P11 PLP1-DsRed reporter mice were 
exposed to 1 h OGD in the presence or absence of the specific P2Y1 agonist MRS2365 
and/or antagonist MRS2279 (both at 10 µM). (A-C) Representative images of PLP1-
DsRed+ oligodendrocytes in isolated intact optic nerves incubated in OGD (A), 
OGD+MRS2365 (B), or OGD+MRS2365+MRS2279 (C); scale bars = 50 m. (D) 
Quantification of the number of PLP1-DsRed + cells in constant fields of view (FOV) (MEAN 
± SEM, n ≥ 5 nerves per experimental group; *p<0.05, **p<0.01, ANOVA with Newman–
Keuls multiple comparison post-hoc analysis). 
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5.2.7  Role of adenylate cyclase in the protective effect of group II mGluR on 
postnatal optic nerve oligodendrocytes in OGD 
The results presented above demonstrated that group II mGluR activation 
is protective for oligodendrocytes against OGD in postnatal nerves. Activation of 
group II mGluR leads to a decrease in adenylate cyclase (AC) and consequent 
decrease in cytosolic cAMP. With the aim of understanding the role of AC and 
cAMP in the group II mediated pro-survival effect on oligodendrocytes during 
OGD, P11 PLP1-DsRed optic nerves were incubated with the lipid soluble cAMP 
analogue dibutyryl cAMP (dbcAMP, 100 M) (Figure 5.8), and the AC activator 
forskolin (100 M) (Figure 5.9), both of which act to raise cytosolic cAMP. 
Incubation in dbcAMP completely blocked the protective effect of the group II 
mGluR agonist LY379268 on oligodendrocytes in OGD (Figure 5.8C, E, F, 
p<0.001); dbcAMP alone did not alter the effects of OGD (Figure 5.8D, F). 
Similarly, incubation in forskolin, to activate AC and raise endogenous cAMP, 
significantly decreased the protective effect of LY379268 in OGD (Figure 5.9C, E, 
F, p<0.05), and had no effect on OGD-mediated loss of oligodendrocytes (Figure 
5.9B, D, F). The results provide evidence that the protective effect of group II 
mGluR is mediated by a decrease in cAMP, which can be reversed by 
pharmacologically raising cytoplasmic cAMP. 
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Figure 5.8 dbcAMP blocks the protective effect of group II mGluR on postnatal optic 
nerve oligodendrocytes in OGD. Optic nerves from P11 PLP1-DsRed reporter mice were 
exposed to 1 h OGD in the presence or absence of the group II mGluR agonist LY379268 
(100 M), together with the cAMP analogue dbcAMP (100 M). (A-E) Representative 
images of PLP1-DsRed+ oligodendrocytes in isolated intact optic nerves incubated in O2 
(A), OGD (B), OGD+LY (C), OGD+dbcAMP (D), or OGD+LY+dbcAMP (E); scale bars = 50 
m. (F) Quantification of the number of PLP1-DsRed + cells in constant fields of view 
(FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; **p<0.01, ***p<0.001, ANOVA 
with Newman–Keuls multiple comparison post-hoc analysis). 
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Figure 5.9 Forskolin blocks the protective effect of group II mGluR on postnatal optic 
nerve oligodendrocytes in OGD. Optic nerves from P11 PLP1-DsRed reporter mice were 
exposed to 1 h OGD in the presence or absence of the group II mGluR agonist LY379268 
(100 M), together with the AC activator forskolin (100 M). (A-E) Representative 
images of PLP1-DsRed+ oligodendrocytes in isolated intact optic nerves incubated in O2 
(A), OGD (B), OGD+LY (C), OGD+forskolin (D), or OGD+LY+forskolin (E); scale bars = 50 
m. (F) Quantification of the number of PLP1-DsRed + cells in constant fields of view 
(FOV) (MEAN ± SEM, n ≥ 5 nerves per experimental group; *p<0.05, **p<0.01, 
***p<0.001, ANOVA with Newman–Keuls multiple comparison post-hoc analysis). 
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5.3  Discussion 
In this chapter, I have demonstrated that the activation of group I and II 
mGluR is cytoprotective for optic nerve astrocytes and oligodendrocytes in 
hypoxia/ischaemia in situ. Ischaemic cell death is characterised by an initial loss 
of energy production and ion homeostasis, which leads to anoxic depolarisation 
(Rossi et al., 2007). These events are followed by a massive release of glutamate 
in the extracellular space, which is responsible for excitotoxicity on neighbouring 
cells. The opening of AMPA/KA and NMDA receptors on glial cells causes an 
increase in intracellular Ca2+ concentrations, which compromises the 
mitochondrial activity and activates proteolytic enzymes and death pathways. To 
my knowledge, the results of this section provide the first evidence that mGluR 
are cytoprotective against hypoxia/ischemia for immature and mature 
oligodendrocytes in situ. mGluR have been reported to be cytoprotective for 
OPCs in kainate- and OGD-induced cell death of OPCs, but not mature 
oligodendrocytes in vitro (Deng et al., 2004), and in preventing staurosporine-
induced apoptosis in OPCs in vitro (Luyt et al., 2006). Similarly, a number of 
studies have shown that mGluR are cytoprotective for cultured astrocytes 
against a wide-range of insults, including mGluR5 in OGD-induced apoptosis 
(Paquet et al., 2013), mGluR3 in NO-induced cell death (Durand et al., 2010), and 
group II/III mGluR against LPS-induced death (Zhou et al., 2006), but my results 
are the first evidence that mGluR are cytoprotective against hypoxia/ischemia 
for astrocytes in situ. Furthermore, in neurons group I and II mGluR have 
divergent effects in excitotoxic injury, group II mGluR being neuroprotective (Di 
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Giorgi-Gerevini et al., 2005), whereas group I mGluR can both facilitate and 
attenuate neuronal death (Bruno et al., 2001). The results of this section show 
that in glia, activation of both group I and II mGluR is cytoprotective against 
OGD-induced cell death. The loss of oligodendrocytes in hypoxia/ischemia is a 
primary characteristic of PVL or PWMI and is the major cause of death and 
neurological impairment in cerebral palsy (Banker & Larroche, 1962; Paneth, 
1994; Volpe, 1995). Thus, activation of mGluR may be a potential therapeutic 
target in protecting both astrocytes and oligodendrocytes in PWMI, a possibility 
supported by a study in which systemic administration of ACPD significantly 
attenuated the loss of myelin in white matter following hypoxia/ischemia in P6 
rats (Jantzie et al., 2010). 
 
5.3.1  Hypoxia/Ischemia effects on astrocytes 
My results demonstrate that postnatal optic nerve astrocytes are highly 
susceptible to ischemia/hypoxia, with a striking halving of their numbers after 60 
min OGD, indicative of massive cell death. This is consistent with evidence of 
ischemia-induced apoptosis in astrocytes (Giffard & Swanson, 2005) and OGD-
induced loss of immature astrocytes in the postnatal optic nerve (Fern, 1998; 
Thomas et al., 2004). The influx of calcium is one of the most significant events in 
ischaemia and Ca2+ overload results in mitochondrial dysfunction leading to 
death (Stys, 2004). In neonatal rat optic nerve astrocytes, the run-down of Na+-K+ 
pumps and Na+-K+-Cl- cotransport (NKCC1) during hypoxia/ischemia results in a 
rise in [Na+]i and reversal of the Na
+-Ca2+ exchanger (NCX), resulting in astrocyte 
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cell death (Lenart et al., 2004; Bondarenko et al., 2005). In addition, membrane 
depolarization and subsequent opening of voltage-operated calcium channels 
(VOCC) results in a rise in astrocyte [Ca2+]i initially through T-type VOCC within 
the first 10 minutes of ischaemia, followed by L-type Ca2+ channels (Fern, 1998). 
Activation of group I mGluR raises glial [Ca2+]i (Section 4), but this clearly does 
not induce cell death and is cytoprotective for astrocytes in hypoxia/ischaemia. It 
would be interesting in future studies to examine whether mGluR activation 
alters Na+ or Ca2+ influx during OGD by interacting with Na+-K+ pumps, NCX, NKCC 
or VOCC. An interaction between mGluR and VOCC has been described in 
neurons (Lachica et al., 1995), although in general mGluR activation appears to 
facilitate Ca2+ influx (Kato et al., 2012). 
 
In addition to these possibilities, mGluR are likely to be protective for 
astrocytes by regulating multiple downstream elements of cell death pathways 
(Vincent & Maiese, 2000; Sugiyama et al., 2007; Paquet et al., 2013). The 
application of group I and II mGluR agonists had a complete protective effect 
against the hypoxia/ischaemia induced cell death in optic nerve astrocytes. The 
group I mGluR prosurvival effect is likely to be mediated via the PI3K/Akt 
pathway, as there is evidence that mGluR5 mediates the activation of this 
pathway (Hou & Klann, 2004; Chen et al., 2012), and that oxidative stress in 
astrocytes is mediated by the regulation of PI3K/Akt, Nrf2 and NF-B pathways 
(Shah et al., 2012). A 3h OGD study on cultured astrocytes showed that the 
activation of mGluR3 also exerts a protective effect by stimulating the PI3K/Atk 
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and ERK1/2 MAPK pathways (Ciccarelli et al., 2007). Another in vitro study 
investigating the protective effect of mGluR3 in preventing nitric oxide (NO)-
induced astrocyte death shows that the activation of this group II mGluR subunit 
leads to a decrease in cAMP levels, Akt activation and interaction between 
members of the NF-B family (Durand et al., 2011). 
 
Astrocytes in ischaemia can have a dual role. They can be protective by 
buffering extracellular potassium and glutamate, scavenging reactive oxygen 
species and supporting other cells by providing substrates. On the other hand, 
astrocytes can exacerbate the damage by the propagation of death signals from 
the infarct core to the penumbra, likely through the generation of aberrant Ca2+ 
waves, and by the release of toxic substances. Notably, the uptake of glutamate 
by astrocytes leads to an intracellular accumulation up to very high levels, 
causing astrocytes to become the main source of glutamate in hypoxic 
conditions. Hypoxia itself can suppress glutamate transport via deactivation of 
NF-B (Dallas et al., 2007). Glutamate-mediated excitotoxicty is a primary cause 
of neuronal and oligodendrocyte cell death in hypoxia/ischaemia, and 
impairment of astrocyte glutamate transporters in hypoxia/ischaemia can be 
prevented by the activation of mGluR1,5 (Liu et al., 2013). Moreover, activated 
astrocytes upregulate the expression of group I/II mGluR (Aronica et al., 2001) 
and specifically mGluR5 (Ulas et al., 2000; Ferraguti et al., 2001). 
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5.3.2  Hypoxia/Ischaemia effects on oligodendrocytes 
My data on postnatal optic nerves from SOX10-EGFP reporter mice agree 
with the literature that OPCs and immature oligodendrocytes are highly 
susceptible to hypoxia/ischaemia, whilst the data from the PLP1-DsRed optic 
nerves from postnatal and adult mice demonstrates that mature 
oligodendrocytes are also susceptible to hypoxia/ischaemia, and show for the 
first time in situ a protective role for group I and group II mGluR. Expression of 
mGluR3 and 5 has been described in OPCs, immature oligodendrocytes and 
mature oligodendrocytes in vitro and in vivo, with high levels of mGluR1,5 in 
GalC+ oligodenrocytes (Luyt et al., 2006; Jantzie et al., 2010), consistent with my 
findings in Section 3. In physiology, mGluR are involved in OPC differentiation 
and myelination (Luyt et al., 2003) and prevention of apoptosis through mGluR5 
(Luyt et al., 2006). The function of mGluR in mature oligodendrocytes is 
unresolved, but in vitro studies suggest a developmental decrease in mGluR5 
expression, whereas mGluR3 remain high at all differentiation stages (Luyt et al., 
2006). My results suggest they are protective against hypoxia/ischaemia induced 
cell death, supporting a study showing a role for group I mGluR activation in the 
protection of OPCs and immature oligodendrocytes from ischaemic damage, 
which requires PKC activation (Back et al., 2002; Deng et al., 2004; Luyt et al., 
2006; Jantzie et al., 2010).  
 
Immature oligodendrocytes are more vulnerable than mature 
oligodendrocytes to oxidative stress (Back et al., 1998), because of their 
developmental lack of antioxidants (Smith et al., 2000), high levels of expression 
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of AMPA/KA-type iGluR that mediate excitotoxicity (Rosenberg et al., 2003), and 
because of their increased components of Ca2+ signalling, including VOCC, 
compared to mature oligodendrocytes (Itoh et al., 2002). Nonetheless, my data 
demonstrates mature oligodendrocytes are also lost following 
hypoxia/ischaemia, consistent with a study showing GalC+ oligodendrocytes 
exposed to 1-2 hours of ischaemia undergo Ca2+-mediated cell death involving 
AMPA/KA-type iGluR (McDonald et al., 1998). This mechanism of 
hypoxia/ischaemia induced cell death has been extensively described in OPCs in 
vitro (Deng et al., 2003) and immature oligodendrocytes in situ (Fern & Möller, 
2000). OPCs and oligodendrocytes express AMPA-, KA- and NMDA-type iGluR 
and these mediate excitotoxicity in hypoxia/ischemia (Butt et al., 2014a). Hence, 
the loss of oligodendrocytes in OGD is likely to involve a rise in extracellular 
glutamate in hypoxia/ischaemia as discussed above, due at least in part to 
impaired uptake by astrocytes and possibly reversed uptake. The protective 
effect of mGluR activation on oligodendrocytes may involve an indirect effect via 
stimulating glutamate uptake in astrocytes (Zhou et al., 2006; Liu et al., 2013). 
Furthermore, the stimulation of group I mGluR is known to cause internalization 
of AMPA- and NMDA-type iGluR in neurons (Snyder et al., 2001; Xiao et al., 
2001). An equivalent mechanism may underlie the protective effect of mGluR on 
oligodendrocytes, although an in vitro study has shown that the protective effect 
of group I mGluR in OPCs is not due to iGluR endocytosis (Deng et al., 2004). 
Furthermore, there is also evidence that the group II mGluR agonist LY379268 
can increase the expression of GluA1 and GluA2 subunits in neurons (Wang et 
al., 2013), which would counteract the protective effect I observed in 
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oligodendrocytes. Future studies should examine the role of mGluR in 
internalising iGluR in optic nerve glia and whether this is altered in 
hypoxia/ischaemia. 
 
Here, I provide evidence supporting a protective role for group I and II 
mGluR against hypoxia/ischaemia at all stages of oligodendrocyte differentiation. 
The protective effect mediated by group I mGluR requires activation of PKC, as 
demonstrated in vitro in OPCs subjected to kainate exposure and OGD (Deng et 
al., 2004). PKC is in turn activated by the coupling of Gq protein to PLC. Several G 
protein coupled receptors (GPCR) are coupled to Gq proteins and my results 
show that activation of P2Y1 receptors has a protective effect on 
oligodendrocytes exposed to OGD. Hence, it appears that the stimulation of Gq/11 
is prosurvival for oligodendrocytes, irrespective of the GPCR activated. There is 
evidence supporting that the Gq/11-coupled muscarinic receptors expressed in 
CHO cells are able to protect cells from apoptotic cell death mediated by DNA 
damage (Tobin & Budd, 2003). Further experiments are needed to investigate 
the mechanisms by which Gq/11 promotes oliogodendrocyte survival, by 
examining anti-apoptotic factors, such as Akt and Bcl-2, which was not possible 
in my PhD due to time restraints. Furthermore, depolarization of 
oligodendrocytes and a consequent rise in [Na+]i results in reversal of the NCX 
and Ca2+ influx, triggering apoptosis (Stys et al., 1991; Fern et al., 1993). Notably, 
activation of group I mGluR has been reported to activate NCX in neurons 
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(Hirono et al., 1998; Sekizawa & Bonham, 2006), which requires further 
investigation. 
 
5.4  Summary and Conclusions 
The results of this section provide novel evidence that group I and group 
II mGluR protect astrocytes and oligodendrocytes from hypoxia/ischaemia 
induced cell death in the optic nerve. These studies do not distinguish between 
direct and indirect effects of mGluR activation in specific cell types, but overall 
demonstrate that administration of mGluR agonists is glioprotective, consistent 
with the protective effects of mGluR in various nervous system disorders, 
including ischaemia-induced brain damage, traumatic brain injury, Huntington's 
and Parkinson's-like pathology or epilepsy (Flor et al., 2002). Further experiments 
are required, but the findings of this section indicate that mGluR could be useful 
therapeutic targets, with the aim of protecting astrocytes, OPCs and 
oligodendrocytes in case of ischaemic events, such as PVL, predominant in 
infants and major antecedent of cerebral palsy, and vascular dementia, second 
most common cause of dementia after Alzheimer’s disease, typically caused by a 
series of minor strokes. 
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Section 6 
 
Changes in Oligodendroglial Cells in the 
Mouse 3xTg Model of Alzheimer’s Disease 
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6.1  Introduction and aims 
The results of Section 5 demonstrated that activation of group I/II mGluR 
agonists protects glia from hypoxia/ischaemia-induced loss, which is implicated 
in multiple neuropathologies, including stroke, MS, ALS and dementia (Paquet et 
al., 2013). Specifically, mGluR5 activation is linked with the production of 
insoluble beta-amyloid (Aβ) and neurodegeneration in Alzheimer’s disease (AD) 
(Sokol et al., 2011). mGluR5 acts as a co-receptor for soluble A oligomers, 
mediating synaptic disruption and dendritic spine loss (Um et al., 2013; Haas et 
al., 2014).  Notably, activated astrocytes are reported to upregulate the 
expression of mGluR5 in neuropathology (Aronica et al., 2001), and A 
significantly increased levels of mGluR5 in cultured astrocytes and in the 3xTg-AD 
mouse model (Ronco et al., 2014). These studies suggest a potential link 
between mGluR5 and glial changes in ageing that may be altered in AD.  
 
The results of Sections 4 and 5 also demonstrated a functional role for 
mGluR5 in oligodendrocyte lineage cells, which in relation to AD is of interest, 
since mGluR5 act as a co-receptor for soluble A oligomers, and there is clear 
evidence of Aβ toxicity in oligodendrocytes (Xu et al., 2001; Desai et al., 2009). 
Indeed, the oligodendrocyte and myelin disruption has been demonstrated as an 
early feature in AD (Bartzokis, 2002; 2004; Haroutunian et al., 2014), and this is 
correlated with increased levels of Aβ in human AD (Roher et al., 2004) and 
animal models of AD (Mastrangelo & Bowers, 2008; Desai et al., 2009). 
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Furthermore, the regeneration of oligodendrocytes throughout life is the 
function of OPCs (Rivers et al., 2008), and there is evidence that mGluR5 prevent 
apoptosis of OPC and positively regulate their differentiation into 
oligodendrocytes (Luyt et al., 2003; Luyt et al., 2006). Hence, mGluR5 expression 
in oligodendrocyte lineage cells may be related to pathological changes in AD 
and the capacity of OPCs to regenerate oligodendrocytes throughout life. 
However, there is little knowledge on the expression of mGluR5 in AD and very 
little is known about the changes in OPCs in the ageing brain or in AD. 
 
The aim of this section, therefore, is to examine changes of mGluR5 and 
OPCs in AD, using the 3xTg-AD mouse, which harbours PS1 (M146V), APP (Swe) 
and tau (P301L) transgenes, which has been shown to display astroglial 
pathology and compromised glutamate homeostasis (Olabarria et al., 2010; 
Kulijewicz-Nawrot et al., 2013). To this end, analyses are performed on 6 and 24-
months old 3xTg-AD mice and age-matched controls, kindly provided by Prof J.J. 
Rodriguez (Bilbao, Spain). 
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6.2  Results 
6.2.1  mGluR5 expression in the ageing and 3xTg-AD hippocampus 
mGluR5 is widely expressed throughout the brain by neurones and glia, 
and may be deregulated in AD (Um et al., 2013). Therefore, 
immunohistochemistry was performed to examine whether mGluR5 expression 
is changed in the ageing mouse brain and whether this is altered in the 3xTg-AD 
mouse (Figure 6.1). Immunostaining was characteristically widely distributed and 
punctate, and it was not possible to resolve specific expression of mGluR5 in the 
different glial cell types, because of the intense neuronal expression of mGluR5 
and close apposition of glia with neurones. However, quantitative analysis of the 
overall level of immunofluorescence was performed on confocal z-sections, 
maintaining all parameters the same between experimental groups and 
subtracting background in negative controls; statistical significance was tested 
using ANOVA with Newman–Keuls multiple comparison post-hoc analysis. It is 
important to note that due to a lack of material and time constraints the data 
for the 24 months 3xTg-AD mouse is based on 3-4 sections from ‘n’=1 mouse 
and the results for this group are only preliminary, but in all other cases the 
data are based on 3 or more sections from ‘n’=3 or 4 mice. The results in Figure 
6.1 illustrate immunofluorescence results in the stratum oriens, pyramidal layer 
and stratum radiatum of the CA1 layer of the hippocampus of 6-months and 24-
months 3xTg-AD and age-matched controls (Figure 6.1). At the macroscopic 
level, there was no obvious difference between the experimental groups (Figure 
6.1A-D), but higher magnification (Figure 6.1, insets) and immunofluorescence 
 185 
analysis (Figure 6.1E) indicated an age-related decrease in mGluR5 levels 
between 6- and 24-months in control mice (Figure 6.1A, C, E; p<0.001, ANOVA 
with Newman–Keuls multiple comparison post-hoc analysis). There was no 
difference in mGluR5 immunofluorescence in control and 3xTg-AD at 6-months 
(Figure 6A, B, E). Interestingly, the preliminary data for the 24-month 3xTg-AD 
hippocampus indicated that mGluR5 immunofluorescence may be greater 
compared to age-matched controls (Figure 6.1C, D, E), which requires further 
analysis for corroboration.  
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Figure 6.1 mGluR5 in the 3xTg-AD mouse hippocampus and age-matched controls. (A-
D) Representative confocal micrographs of mGluR5 immunostaining in the CA1 layer of 
the hippocampus from 6-month and 24-month 3xTg-AD mice and age-matched non-Tg 
controls (NTG); image acquisition parameters were maintained constant throughout and 
insets show higher magnification of the stratum radiatum; scale bars = 50 m. (E) 
Quantification of mGluR5 immunofluorescence intensity in the CA1 measured in 
constant field of view (FOV, data are mean ± SEM from 3 areas per section, from n=3 or 
4 sections per animal, n=3 or 4 animals in all cases except for 24-month 3xTg-AD, where 
n=1 due to lack of material). ***p<0.001, ANOVA with Newman–Keuls multiple 
comparison post-hoc analysis.  
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6.2.2  Age-related changes in OPCs in the hippocampus in 3xTg-AD and age-
matched controls 
New oligodendrocytes are generated in the adult by OPCs until middle 
age in humans and this is postulated to be a mechanism by which myelination 
sustains and enhances cognitive function (Bartzokis, 2011b). However, 
myelination appears to decline in the ageing brain and studies in the mouse have 
suggested this is related to a decline in OPCs and/or their regenerative capacity 
(Sim et al., 2002). To examine this possibility, immunohistochemical analysis for 
the NG2 CSPG was used to examine OPCs in the hippocampus of 6- and 24-
month old non-Tg (NTG) mice (Figures 6.2-6.5). It is important to note that due 
to a lack of material and time constraints the data for the 24-month 3xTg-AD 
mouse is based on 3-4 sections from ‘n’=1 mouse and the results for this group 
are only preliminary, but in all other cases the data are statistically rigorous 
and based on analysis of 3 or more sections from ‘n’=3 or 4 mice.   
 
Figure 6.2 illustrates the normal distribution of OPCs in the adult 
hippocampus from 6-month mice (Figure 6.2A), and high magnification illustrates 
the characteristic multi-processed morphology of OPCs in the dentate gyrus (DG, 
Figure 6.2B), CA1 (Figure 6.2C) and CA3 (Figure 6.2D). In the DG, individual OPC 
process domains are difficult to distinguish (Figure 6.1B), whilst in the CA1 layer, 
OPC process domains overlap only at the edges (Figure 6.1C), and OPCs in the 
CA3 display a varying degree of overlap (Figure 6.1D).  
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Similar to stem cells, OPCs self-maintain by undergoing asymmetric 
divisions generating a mixed progeny of ‘sister cells’ that appear as duplets or 
triplets when recently divided (Sim et al., 2002). Sister cells either self-sustain 
OPCs or proceed to differentiate into oligodendrocytes, hence the frequency of 
duplets/triplets is an indication of the regenerative potential of OPCs (Boda et 
al., 2014). To examine this in the 3xTg-AD and ageing mouse, NG2 
immunostaining was performed together with nuclear labelling with Hoechst 
blue to highlight groups of two or more juxtaposed NG2+ sister cells (Figures 6.3 
and 6.4). As illustrated for the 6-month non-Tg mouse, sister cells were 
prominent in all three areas of the hippocampus in the DG (Figure 6.3A), CA1 
layer (Figure 6.3B), and CA3 layer (Figure 6.3C). Analysis of age-related changes 
in NG2+ sister cells shows a significant decrease between 6-month and 24-month 
in non-Tg controls in the hippocampus overall (Figure 6.4A, C, E; p<0.001, ANOVA 
with Newman–Keuls multiple comparison post-hoc analysis), and in the DG 
(p<0.01) and CA3 (p<0.01), but the decline in OPC sister cells was not statistically 
significant in the CA1 layer (Figure 6.4E). Compared to age-matched non-Tg 
controls, the number of NG2+ sister cells was significantly less in 6-month 3xTg-
AD hippocampi overall (Figure 6.4B, E; p<0.001), and in the DG and CA3 (p<0.01), 
but the decrease was not statistically significant in the CA1 layer (Figure 6.4E). 
The number of NG2+ sister cells in the 3xTg-AD hippocampus at 6-months had 
declined to the level normally seen at 24-months in the non-Tg controls (Figure 
6.4B, C, E). At 24-months in the 3xTg-AD hippocampus, the preliminary evidence 
indicated that the number of NG2+ sister cells is equivalent to age-matched non-
Tg at 24-months (Figure 6.4B, D, E), and to 6-months 3xTg-AD (Figure 6.4C, D, E). 
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The results demonstrated an age-dependent decline in OPC sister cells in the 
normal ageing hippocampus and that this is accelerated at 6-months in the 3-Tg-
AD mouse. 
 
Astrocytes have previously been shown to undergo cellular changes in 
the 3xTg-AD model (Rodríguez et al., 2013), hence this was examined in OPCs in 
the CA1 area, using the Cell Analyst programme (Chvátal et al., 2007) to measure 
cell surface area and volume in 3xTg-AD and age-matched non-Tg controls 
(Figure 6.5). The results showed that there is no difference in the morphological 
shape and size of OPCs at 6- and 24-months in non-Tg controls (Figure 6.5A, C, E-
H). In contrast, at 6-months OPCs in the 3xTg-AD hippocampi were clearly 
atrophic compared to age-matched non-Tg controls (Figure 6.5A, B), and showed 
a significant decrease in cell volume and surface area (see Figure 6E-H for ‘p’ 
values). Notably, the preliminary evidence from 24-month 3xTg-AD hippocampus 
indicated OPCs may be hypertrophic compared to age-matched non-Tg controls 
(Figure 6.5C, D), and quantification indicated a marked increase in cell surface 
area and volume compared to 6-month 3xTg-AD hippocampus (Figure 6.5E-H), 
which requires corroboration. 
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Figure 6.2 Distribution and morphology of OPCs in the hippocampus of 6-month non-
Tg mouse. Immunolabelling for the NG2 CSPG was used to identify OPCs. (A) Collage of 
confocal micrographs illustrating the overall distribution of OPCs in the hippocampus. 
(B-D) Maximum intensity projections of z-stacks of representative OPCs in the dentate 
gyrus (B), CA1 layer (C) and CA3 layer (D). Scale bars = 20 m.  
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Figure 6.3 OPC ‘sister cells’ in the hippocampus of 6-month non-Tg mouse. 
Immunolabeling for NG2 (green) and the nuclear marker Hoechst blue (blue) illustrates 
the presence of OPC duplets (highlighted by arrows), an indication of recently divided 
‘sister cells’. Maximum intensity projections of z-stacks are illustrated in the dentate 
gyrus (A), CA1 layer (B) and CA3 layer (C), together with single z-sections showing closely 
juxtaposed duplets (A’, B’, C’) and orthogonal sections through the x-x and y-y planes. 
Scale bars = 20 m in A, B, C and 10 m in A’, B’, C’.  
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Figure 6.4 Age-dependent changes in OPC sister cells in 3xTg-AD hippocampus. (A-D) 
Representative images of immunostaining for NG2 (green) and the nuclear stain Hoechst 
blue (blue) in the DG of 6-month and 24-month 3xTg-AD and age-matched non-Tg (NTG) 
mice; asterisks indicate sister cells; scale bars=50 m. (E-H) Number of sister cells per 
constant field of view (FOV) in the hippocampus overall (E), and the DG (F), CA1 (G) and 
CA3 (H) (data are mean ± SEM from 3 sections per animal, n=3 or 4 animals in all cases 
except for 24-month 3xTg-AD, where n=1). *p<0.05, **p<0.01, ***p<0.001, ANOVA with 
Newman–Keuls multiple comparison post-hoc analysis.  
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Figure 6.5 Morphological analysis of OPCs in the 3xTg-AD hippocampus and age-
matched non-Tg controls. (A-D) Representative images of OPCs in CA1 of 6- and 24-
month 3xTg-AD and age-matched non-Tg (NTG) controls, illustrating in magenta the 
outline used for analysis of individual cells using the Cell Analyst programme (Chvátal et 
al., 2007); scale bars=10 m. (E-H) Quantification of OPC total cell volume (E), total cell 
surface area (F), cell body volume (G) and cell body surface area (H); data are mean ± 
SEM from 25 cells from 3 sections per mouse, where n=3 or 4 animals in all cases except 
for 24-month 3xTg-AD, where n=1). *p<0.05, **p<0.01, unpaired t-test analysis.  
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6.2.3  Age-related changes in myelination in 3xTg-AD hippocampus and age-
matched controls 
OPCs are believed to generate oligodendrocytes throughout life to 
replace myelin lost through natural ‘wear and tear’ and to myelinate new 
connections that develop in response to new life experiences (van Wijngaarden 
& Franklin, 2013). The results above indicate that at 6-months in the 3xTg-AD, 
OPCs are hypotrophic and there is an apparent acceleration of the age-
dependent decrease in sister OPCs, which is implicated in a decrease in their 
capacity for regenerating oligodendrocytes (Sim et al., 2002; Boda et al., 2014). 
In addition, there is evidence of oligodendrocyte/myelin disruption in the 3xTg-
AD mouse brain (Desai et al., 2009; Desai et al., 2010). To examine this, MBP 
immunostaining was performed to examine age-related changes in myelination 
in the hippocampus of the 3xTg-AD compared to age-matched non-Tg controls 
(Figure 6.6). Analysis of the CA3 layer illustrates a clear age-dependent decrease 
in the intensity and pattern of MBP immunostaining in non-Tg controls between 
6-month (Figure 6.6A) and 24-months (Figure 6.6C), and that this is accelerated 
in the 6-month 3xTg-AD hippocampus (Figure 6.6B). Quantitative analysis 
confirmed that MBP immunofluorescence intensity significantly decreased 
between 6-month and 24-month non-Tg controls (Figure 6.6E; p<0.001, ANOVA 
with Newman–Keuls multiple comparison post-hoc analysis), and was 
significantly less in 6-month 3xTg-AD hippocampus compared to age-matched 
non-Tg controls (Figure 6.6E; p<0.001), equivalent to the level seen in 24-month 
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non-Tg controls. The preliminary data from 24-month 3xTg-AD suggests 
myelination may decline even further. 
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Figure 6.6 Decrease of MBP immunostaining in the 3xTg-AD hippocampus. (A-D) 
Representative images of MBP immunostaining in the CA3 layer of the hippocampus of 
6- and 24-month 3xTg-AD and non-Tg (NTG) controls mice; scale bars=50 m. (E) 
Quantification of MBP immunofluorescence intensity per constant FOV (mean ± SEM 
data from 4 sections per mouse, where n=3 or 4 mice in all cases except for 24-month 
3xTg-AD, where n=1). ***p<0.001, ANOVA with Newman–Keuls multiple comparison 
post-hoc analysis. 
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6.3  Discussion 
Previous sections have demonstrated a role for group I mGluR in 
oligodendrocyte lineage cells, which may be linked to evidence of early changes 
in myelin in AD (Bartzokis, 2011a) and to studies implicating mGluR5 in AD (Um 
et al., 2013). The results of this Section do not support early changes in mGluR5 
expression in the 3xTg-AD model, but did demonstrate significant age-dependent 
changes in OPCs that were accelerated in 3xTg-AD and correlated with early 
disruption of myelin and preceded overt A pathology. Interestingly, preliminary 
analysis of 24-month 3xTg-AD hippocampus was suggestive of an increase in 
mGluR5, consistent with evidence that activated glia may upregulate mGluR5 in 
the 3xTg-AD mouse model (Ronco et al., 2014). However, the key finding of this 
Section is of early atrophy of OPCs and a marked decrease in the number of OPC 
sister cells at 6-months in the 3xTg-AD model, which supports the possibility that 
a decrease in OPC regenerative capacity may be a key component of 
oligodendrocyte and myelin disruption that has been demonstrated as an early 
feature in AD (Bartzokis, 2002; 2004; Haroutunian et al., 2014), and animal 
models of AD (Mastrangelo & Bowers, 2008; Desai et al., 2009).  
 
6.3.1  The 3xTg-AD model 
The results of this section provide evidence of marked changes in OPCs in 
3xTg-AD mice. These mice carry the APP Swedish mutations K670N/M671L, the 
presenilin-1 M146V mutation and the tau P301L mutation in the C57BL6 mice 
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background, and were developed as an AD model by Oddo et al in 2003 (Oddo et 
al., 2003). This model progressively develops A intracellular deposits and 
plaques and tau pathology as observed in AD. A deposition starts between 3 
and 4 months of age in the neocortex, and after 6 months of age in the CA1 
subfield of the hippocampus, in both male and female mice (Rodríguez et al., 
2008). At the same age, 3xTg-AD show altered long term potentiation (LTP) and 
synaptic dysfunction. My study has been conducted in collaboration with the 
Functional Neuroanatomy Laboratory, University of the Basque Country, in 
Bilbao, Spain, directed by Prof. JJ Rodriguez, who kindly provided the 3xTg-AD 
and age-matched control tissue. For my analysis, male 3xTg-AD mice of 6- and 
24-months were selected to represent early- and late-stage of the AD pathology. 
However, for 24-month 3xTg-AD only one brain was available for analysis within 
the time available. Nonetheless, the data for the 6-month 3xTg-AD and 6- and 
24-month non-Tg controls are from n=3 or 4 mice and are based on a minimum 
of 3 sections per mouse. Hence, the clearly defined age-dependent changes in 
OPCs and myelin and the evidence these are accelerated in 3xTg-AD are 
statistically reliable. 
 
6.3.2  Changes in OPCs and impact on myelination in 3xTg-AD 
OPCs are uniformly distributed in both white and grey matter and are 
characterised by a complex stellate process arborization, which has been shown 
to form intimate and multiple contacts with neurones, astrocytes, 
oligodendrocytes and microglia (Butt et al., 2005). OPCs co-express NG2, 
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PDGFR, and O4, but not mature oligodendrocyte markers (Nishiyama et al., 
1996a; Reynolds & Hardy, 1997), and are the source of oligodendrocytes in the 
developing and adult brain (Dimou et al., 2008; Rivers et al., 2008; Zhu et al., 
2008b; Kang et al., 2010). Like stem cells, OPCs in the adult brain undergo 
asymmetric division to generate sister cells that self-sustain OPCs and 
differentiate into new oligodendrocytes (Dawson et al., 2003; Rivers et al., 2008). 
Hence, the frequency of duplets/triplets is an indication of the regenerative 
potential of OPCs (Boda et al., 2014), which the results of this section show is 
reduced between 6- and 24-months in the normal mouse hippocampus, 
consistent with evidence that OPC proliferation rate is significantly reduced with 
age (Psachoulia et al., 2009). The observation that the overall number of OPCs 
does not change significantly with age (Rivers et al., 2008) implies that half of the 
sister OPCs differentiate or die. The numerous NG2+ sister cells observed in the 
hippocampus is consistent with this being an area of rapid turnover of OPCs, but 
further studies using proliferative markers and pulse-chase techniques, e.g. with 
BrdU and EdU, are required to prove this unequivocally. Nonetheless, there was 
a significant decrease of number of sister OPCs between 6-months and 24-
months in normal non-Tg mice, and the number of sister OPCs at 6-months in 
3xTg-AD was significantly less than in age-matched non-Tg mice and equivalent 
to that observed at 24-months. These results imply the age-dependent decrease 
in OPC proliferation and regenerative capacity is accelerated in 3xTg-AD, and 
precedes overt A pathology.  
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In addition, morphological analysis of OPCs highlighted alterations at the 
early stages of the disease. At 6-months, OPCs in 3xTg-AD displayed a marked 
atrophy, manifested by a decreased cell volume and surface area compared to 
OPCs in non-Tg mice. Furthermore, this was not an accelerated ageing, since the 
cellular morphology was not altered between 6- and 24-months in non-Tg 
hippocampus. Although data in the 24-month 3xTg-AD is not statistically reliable, 
the preliminary evidence indicates that OPC are hypertrophic at later ages of the 
disease, with increased cell volume and surface area, with thicker processes and 
enlarged cell body, characteristic of the injury response in OPCs (Ong & Levine, 
1999). These results reflect similar changes described in astrocytes by Olabarria 
et al (Olabarria et al., 2010). The early atrophy of OPCs may be pathologically 
relevant, considering their role in regenerating oligodendrocytes. Indeed, 
quantification of myelination using MBP immunostaining indicates myelination is 
disrupted at 6-months in the hippocampus of 3xTg-AD, comparable to normal 
24-month old mice. This supports evidence of myelin disruption previously 
described in the cortical regions of the 3xTgAD model preceding the appearance 
of amyloid and tau pathology (Desai et al., 2009). The same group showed that 
A is toxic for oligodendrocytes and may be related to AD-related myelin injury 
in vivo (Desai et al., 2010). Loss of myelin structure and integrity would expose 
axons to damage, resulting in the decline of cognitive function in the ageing 
brain. The results of this section support a hypothesis in which accelerated 
deregulation of OPCs is a major element in the loss of myelin in AD, which is 
worthy of further study. 
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6.4  Summary and conclusions 
The results of this section demonstrate marked age-dependent changes 
in OPCs that are accelerated in 3xTg-AD and support a hypothesis in which 
disruption of OPCs and a decline in their regenerative capacity may be a 
contributor to the loss of myelin in AD. In addition, the results supported the 
possibility of an age-dependent decrease in mGluR5 in the hippocampus and 
suggested this may be reversed at 24-months in 3xTg-AD, correlating with A 
deposition and neuropathological changes in neurons, astrocytes, myelin and 
OPCs. Neurotoxic soluble A oligomers lead to neuronal death and memory loss, 
pathological features of AD. A negatively affects long term potentiation (LTP), 
the cellular mechanism that underlies learning and memory, and these effects of 
A can be reversed with memantine, a non-competitive NMDA-receptor 
antagonist. mGluR5 is coupled to post-synaptic NMDA receptors, and the 
application of both NMDA and allosteric mGluR5 antagonists restored LTP in the 
presence of soluble A in an acute murine hippocampal slice model (Rammes et 
al., 2011). Moreover, A42, the fragment with the most neurotoxic potential, 
binds to mGluR5, activating Ca2+ release from intracellular stores (Renner et al., 
2010; Sokol et al., 2011; Um et al., 2013). In turn, mGluR5 activation results in 
APP and fragile X mental retardation protein (FMRP) expression increase, 
mediated by FMRP itself, a RNA binding protein that functions as protein 
synthesis repressor at synapses (Westmark & Malter, 2007; Malter et al., 2010; 
Westmark & Malter, 2012). Another mechanism for A and mGluR5 interaction 
involves mGluR5 co-expression with A-bound cellular prion protein (PrP(C)), 
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which allows the coupling with Fyn kinases, leading to synaptic disruption (Um et 
al., 2013). Hippocampal astrocytes of AD patients show higher immunoreactivity 
for mGluR5 (Lim et al., 2013), which is supported by a study in murine cultured 
hippocampal astrocytes showing that exposure to A evoked an increase in 
mGluR5 expression (Grolla et al., 2013). Moreover, reactive astrocytes 
surrounding A plaques over-express mGluR5, and there is evidence that A 
binds to astrocytic membrane causing mGluR5 clustering and release of ATP, 
which slowed mGluR5 diffusion in astrocytes and neurons co-cultured with 
astrocytes (Shrivastava et al., 2013). My analysis of mGluR5 expression is 
consistent with these previous findings suggesting an increase in receptor 
expression in the CA1 layer of 24-month 3xTg-AD mice, but not at earlier stages 
of the disease. Furthermore, mGluR5 may be involved in OPC differentiation 
(Luyt et al., 2003), and in light of the age-related changes in OPCs and myelin in 
the non-Tg mice and their acceleration in 3xTg-Ad it will be considerable 
interesting to pursue these studies and investigate changes in the expression and 
function of mGluR5 in OPCs and their impact on disease progression and 
myelination. 
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Section 7 
 
General discussion 
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7.1  Summary of key findings 
The overall aim of this thesis was to provide insight into the expression 
and function of mGluR in optic nerve glia, with a focus on its potential 
glioprotective role in hypoxia/ischaemia. The optic nerve is widely used as a 
model tissue for studying white matter glia, because it comprises mainly 
astrocytes and oligodendrocytes, which myelinate and provide support for the 
axons of retinal ganglion cells, together with small populations of OPCs and 
microglia (Butt et al., 2004). There is abundant evidence of glutamate-mediated 
signaling in white matter, but it was unclear whether neurotransmitter signaling 
mechanisms persist after maturation, and mGluR had not been studied in this 
context. The key findings of the neurotransmitter profile of optic nerve glia are 
illustrated in Figure 7.1. It is evident from the results in Section 3 that glutamate 
receptors are most abundantly expressed in optic nerve glia and the data in 
Section 4 confirmed that mGluR in astrocytes and oligodendrocytes are 
dominated by group I mGluR5, group II mGluR3 and, unexpectedly, group III 
mGluR4. An important finding is that mGluR were expressed at all ages and were 
not developmentally downregulated, as had been suggested from previous in 
vitro studies. A key novel result was that activation of group I and group II mGluR 
protects both astrocytes and oligodendrocytes from hypoxia/ischaemia -induced 
cell death. The results of Section 6 supported the possibility of an age-dependent 
decrease in mGluR5 in the hippocampus, which correlated with a marked age-
dependent decrease in OPCs regenerative capacity (Section 6) and of key OPC 
genes and transcription factors that regulate their differentiation (Section 3). 
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Notably, however, the changes in OPCs and myelin loss are accelerated in 3xTg-
AD, whereas overall mGluR5 expressed did not appear to be decreased. This 
study provides new insight into mGluR expression and function in white matter 
glia, and supports a hypothesis in which mGluR are glioprotective and their 
disruption may be related to the decline in OPCs and their regenerative capacity 
in the ageing brain. These results are relevant to fundamental glial cell biology 
and to the pathology of hypoxia/ischaemia, stroke, demyelination and AD. 
 
 
Figure 7.1 Neurotransmitter profile of the optic nerve. 
 
 
 
7.2 Glutamatergic neurotransmission mechanisms in white 
matter 
The optic nerve does not contain neuronal cell bodies or conventional 
neuron-to-neuron synapses, and so the prevalence of multiple neurotransmitter 
receptors may be considered surprising. Notably, adenosine and adrenergic 
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receptors were expressed solely in the postnatal nerve, consistent with a specific 
role in oligodendrocyte development, but there was a preeminence of 
glutamatergic, purinergic and GABAergic signaling, in support of previous studies 
(Butt et al., 2014a). The physiological importance for glutamatergic signaling in 
glial cells is well known, ranging from stimulating astroglial homeostatic 
mechanisms and metabolic support for neurons, to promoting oligodendrocyte 
development and myelination (see Section 1). Hence, it was not surprising that 
the genomic profiling of neurotransmitter receptors identified the glutamatergic 
system as the most highly expressed in the optic nerve (Section 3). Overall, the 
majority of glutamate receptors were most highly expressed in the postnatal 
optic nerve, consistent with evidence that glutamate regulates OPC proliferation 
and differentiation. Notable amongst the developmental changes was the 
specific expression in postnatal optic nerves of transcripts for the group III 
mGlur4, which is worthy of further study, since the protein has been detected by 
immunohistochemistry in retinal ganglion cells axons (Cirone et al., 2002). There 
have been few studies of mGluR4 in glial cells, but it has been shown to be 
expressed in reactive astrocytes at edges of MS lesions, but not 
microglia/macrophages (Geurts et al., 2005), as well as in cultured astrocytes 
(Yao et al., 2005), although mGluR4 agonists did not alter cAMP in astrocytes, 
indicating they were not functional (Prezeau et al., 1994; Wroblewska et al., 
1998). There is also pharmacological evidence for group II mGluR in cultured 
microglia (Pinteaux-Jones et al., 2008; McMullan et al., 2012). 
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The source of glutamate in the optic nerve is likely to be axonal and to an 
unknown extent also astroglial. There is evidence of glutamate-loaded vesicles in 
premyelinated optic nerve axons (Alix et al., 2008), and propagation of action 
potentials along premyelinated axons in the optic nerve and corpus callosum 
leads to a rapid vesicular release of glutamate (Kukley et al., 2007; Ziskin et al., 
2007). Astrocytes are also capable of vesicular neurotransmitter release (Kreft et 
al., 2009; Zorec et al., 2012) and represent a potential source of 
neurotransmitters. This is supported by findings in Section 3, which highlighted 
the expression of the axonal transcripts for synaptic vesicles (Sv2b and Syt1), as 
well as proteins of the SNAP-SNARE complex, which is responsible for vesicular 
release in both axons and astrocytes (Verkhratskiĭ & Butt, 2013). An interesting 
finding was that the expression of the transcripts for synaptic proteins switch 
from SNAP23/Synaptobrevin2/Synaptotagmin4/syntaxin6,7 in the young nerve 
to SNAP25/Cellubrevin/Synaptotagmin4/syntaxin12 in the ageing optic nerve 
(Figure 7.2). The possible functional significance of this switch is unclear and 
further studies are required to compare mRNA and protein expression, using 
qRT-PCR and western blot, together with localization of the proteins in axonal 
and glial compartments using immunohistochemistry. In addition, it is possible 
that these changes are important in age-related changes in white matter 
integrity, which are poorly defined in rodents but have been reported in humans 
(Bartzokis, 2011). 
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Figure 7.2 Age-dependent changes in vesicular apparatus in the optic nerve. 
 
 
7.3 Purinergic neurotransmission in white matter 
The prominence of purinergic signaling in the optic nerve is well reported 
and it has been considered to be a ubiquitous ‘gliotransmitter’, since astrocytes 
both release ATP and respond to ATP via a wide range of P2X and P2Y receptors 
(Butt, 2011). The genomic profiling in the optic nerve was most interesting 
because of the low levels of the P2Y1 receptor, which on the basis of 
pharmacology has been considered the most important in optic nerve signaling 
(Hamilton et al., 2008). In addition, my results in Section 5 indicate P2Y1 
receptors are protective for oligodendrocytes in hypoxia/ischaemia. Although 
microarray analysis of mRNA is not a measure of functional protein, previous 
pharmacological studies used P2Y1 agonists that also act on P2Y12, which my 
microarray analysis shows to be highly expressed in the postnatal optic nerve 
and developmentally downregulated. This is of interest, since a decrease in P2Y12 
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is implicated in demyelination (Amadio et al., 2010), which may be relevant to 
myelin loss or to the failure of remyelination in the ageing brain. In contrast, 
P2X7 receptors, which are also implicated in oligodendrocyte/myelin loss in MS 
and hypoxia/ischaemia (Agresti et al., 2005a; Agresti et al., 2005b; Matute et al., 
2007b; Butt, 2011), were lowest in the aging optic nerve. All cells are a potential 
source of ATP in injury, but there is evidence that ATP is released under 
physiological conditions by astrocytes in the optic nerve (Hamilton et al., 2008). 
Astrocytes can release neurotransmitters by vesicular and non-vesicular 
mechanisms, including vesicular release (see above). However, the vesicular 
nucleotide transporter VNUT was called absent in the optic nerve at all ages, 
indicating ATP is released by non-vesicular mechanisms, such as via the P2X7 
receptor, which was expressed at all ages and has been implicated in ATP release 
in the optic nerve (Hamilton et al., 2008). The overall decline in P2X7 and other 
P2 receptors in the ageing nerve, including the most prominent P2Y12, raises the 
possibility that deregulation of purinergic signaling may be related to white 
matter dysfunction in the ageing brain. In this respect, the P2Y13 receptors are 
also of interest because they are the only P2 receptors increased in the ageing 
optic nerve and specifically expressed by microglia (McIlvain et al., 2010). These 
changes in P2 receptors certainly warrant further investigation. 
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7.4 Altered GABAergic and Glutamatergic neurotransmission in 
ageing white matter 
It is notable, therefore, that I observed a marked increase in the vesicular 
glutamate transporter VGLUT1 (ALC17A7) in the ageing optic nerve, and to a 
lesser extent VGLUT2 (ALC17A6), whereas the glial glutamate uptake transporter 
GLAST (EAAT1, SLC1A3) was developmentally decreased, raising the possibility 
that extracellular glutamate levels may be raised in the ageing nerve. In terms of 
glutamate receptors, mGluR5, mGluR7, and the NMDA receptor subunit GluN2B, 
were highest in the aging nerve, and the AMPA receptor subunit GluA2 and 
NMDA receptor subunits GluN1 and GluN2D were increased in the ageing nerve 
to levels observed postnatally. These results imply a shift in glutamate signaling 
in ageing white matter, with an increase in mGluR5, which I show is protective 
for oligodendrocytes, together with increases in AMPA/NMDA receptors that are 
implicated in oligodendrocyte cytotoxicity (Matute et al., 2007a). These changes 
are consistent with white matter disruption in the ageing brain and suggest this 
may be related to increased susceptibility of oligodendrocytes/myelin to 
glutamate-mediated cytotoxicity. 
 
Perhaps the most striking change in the ageing optic nerve was the 
upregulation of a number of GABAAR receptor subunits, which was coupled to an 
increase in GAD1 and to a lesser extent GAD2, which are the enzymes 
responsible for catalyzing the production of GABA from glutamate, and were 
barely expressed at other ages, together with a decrease in the GABA uptake 
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transporters GAT-1 (SLC6A1) and GAT-2 (SLC6A13). Together, these provide 
evidence of a marked increase in GABAergic neurotransmission in the ageing 
optic nerve. This is potentially very important in the observed decrease in OPCs 
and their regenerative capacity in the ageing brain, since OPCs express GABAAR 
and their function is to inhibit their proliferation (Yuan et al., 1998). It seems 
reasonable to suggest that the marked changes in OPCs and myelin observed in 
ageing white matter is related to changes in synaptic signaling and an imbalance 
between GABAergic and glutamatergic neurotransmission. Oligodendrocytes and 
OPCs express NMDA receptors lacking the glutamate binding subunit GluN2 
(Pina-Crespo et al., 2010). My microarray analysis shows instead a marked 
upregulation of GluN2B in the ageing optic nerve, suggesting a functional and 
age-related change in NMDA-R composition.  
 
7.5 mGluRs are protective for white matter 
In section 5, I provided novel evidence that group I and II mGluR protect 
astrocytes and oligodendrocytes from hypoxia/ischaemia -induced cell death in 
situ. This function had already been shown in both cell types, mainly for group I 
mGluR, in several studies in vitro (Back et al., 1998; Fern, 1998; Deng et al., 2004; 
Giffard & Swanson, 2005; Luyt et al., 2006; Jantzie et al., 2010). The 
cytoprotective mechanisms triggered by group I and II mGluR activation in 
astrocytes and oligodendrocytes are partially known and involve the recruitment 
of Gq/11 (See section 5), an increase in PKC activity (Deng et al., 2004), and the 
stimulation of the PI3/Akt pro-survival pathway (Ciccarelli et al., 2007). The 
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cytoprotective effects of mGluR agonists in astrocytes and oligodendrocytes are 
likely to involve both direct activation of cell survival pathways following 
activation of mGluR5 and mGlur3 in these cells, and also indirect effects 
involving other mGluR-mediated mechanisms. For example, hypoxia/ischaemia-
mediated loss of astrocytes results in disruption of ion homeostasis, which 
causes anoxic depolarization (Rossi et al., 2007), leading to massive release of 
glutamate, mainly from astrocytes, which in turn triggers excitotoxicity in 
oligodendrocytes by over-activation of AMPA/KA and NMDA receptors (Matute 
et al., 2007a). Hence, the cytoprotective effect of mGluR5 on astrocytes would 
alleviate these destructive changes and attenuate oligodendrocyte/myelin loss. 
In addition, mGluR5, mGluR2 and mGluR3 mRNA and protein have been 
detected in cultured microglia (Biber et al., 1999; Taylor et al., 2002; Byrnes et 
al., 2009). Application of group I mGluR agonists to microglia exposed to 
lipopolysaccharide (LPS, inflammatory stimulus) inhibits microglial activation, 
production of NO and reactive oxygen species, and neurotoxicity (Byrnes et al., 
2009). A recent study has shown that activation of mGluR3 was protective in a 
model of myelin-induced neurotoxicity(Taylor et al., 2002; Pinteaux-Jones et al., 
2008). Thus, the results of this study show that modulation of mGluR represents 
a multipotential therapeutic strategy to decrease hypoxia/ischaemia-mediated 
white matter destruction, which is relevant to hypoxia/ischaemia, cerebral palsy, 
stroke, multiple sclerosis, neurodegenerative diseases and dementia.  
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7.6  Link between ageing and hypoxia 
Aging is characterized by decreased oxygen supply to tissue, a reduction 
of tissue PO2 and of the activity of several enzymes and metabolic 
factors. Nonetheless, a reduction of cells' oxygen supply is concomitant to a 
parallel decrease in oxygen demand by tissues. Because hypoxia per se 
modulates mitochondria activity, influencing oxygen 
consumption, hypoxia and aging could share some link. Ageing can be defined as 
a decline of body functions, due to several factors that affect multiple systems in 
the brain such as memory and learning processes (Tapia-Arancibia et al., 2008). 
Over time, different theories proposed a variety of basic mechanisms that 
govern ageing. The most popular of these theories was the Mitochondrial Theory 
of Aging (MTA), first proposed by Harman in 1956 (Harman, 1956). According to 
this theory, aging results from the accumulation of oxygen free radical [reactive 
oxygen species (ROS)] damage to cellular components, including nucleic acids. 
Over the years, the theory was refined by, first, the identification of 
mitochondria as both the source and the target of the ROS (Harman, 1972), and, 
then, the identification of mitochondrial DNA (mtDNA) as most susceptible 
target of the damage (Fleming et al., 1982; Miquel et al., 1983). Damage to 
mtDNA can be converted to point mutations and deletions, which can be 
transmitted to and accumulated in daughter molecules through the process of 
replication, enabling deterioration of the integrity of hereditary information over 
time.  
Under normal physiological conditions, ROS emission (essentially, 
production minus scavenging) is considered to account for 0.25-11% of the total 
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oxygen consumed by mitochondria, depending on the animal species and 
respiration rates (Aon et al., 2012). When ROS production is not compensated 
for with their scavenging by endogenous antioxidants, ROS will rise beyond the 
physiological threshold level, causing a process conventionally called “oxidative 
stress”.  The reaction of formation of a primary ROS (superoxide only) generated 
in the respiratory chain from molecular oxygen is dependent on oxygen 
concentration. Oxygen supply influences cell metabolism and is a key factor in 
regulating cell growth, and thus, the oxygen-gradient diffusion at capillary tissue 
level is essential for the cellular survival. In hypoxic conditions, ROS are 
generated. Paradoxically, the generating ROS in mitochondria in the cell remains 
constant or even increases when PO2 drops dramatically. Elevated mitochondrial 
ROS generation in the cell in response to hypoxia is not intrinsic to the 
mitochondrial respiratory chain alone but can be attributed to some involvement 
of extramitochondrial factors (Hoffman et al., 2007). For example, hypoxia-
induced superoxide production can occur through activation of NADPH oxidase 
located in the cell membrane (Marshall et al., 1996). In addition, NO synthesis in 
mitochondria can partially block cytochrome oxidase (Brown & Cooper, 1994; 
Schweizer & Richter, 1994), thus reducing mitochondrial electron carriers and 
favoring generation of superoxide at hypoxic conditions (Turrens, 2003).  
In my study, Cox7a2 was one of the genes most expressed in the 18 
months old optic nerve (Section 3, Table 3.7). Cox7a2 encodes for a subunit of 
Complex IV, cytochrome oxidase and its expression is upregulated in cardiac 
tissue after hypoxic exposure (Everett et al., 2012). Gene expression during 
hypoxia is regulated by the HIF transcription factor family (Kenneth & Rocha, 
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2008). Under normal oxygen conditions, a subunit of the HIF transcription factor 
is hydroxylated by prolyl hydrolases, and subsequently rapidly degraded. 
However, during hypoxia the protein stabilizes and associates with its other 
subunits and enters the nucleus where it interacts with cofactors and can affect 
transcription (Kenneth & Rocha, 2008). Although the HIF gene didn’t stand out in 
the microarray study presented in Section 3, it would be interesting to examine 
its expression in the old optic nerve tissue and, in light of the glio protective 
properties of mGluRs activation shown in Section 5, investigate the correlation 
between the metabotropic glutamate receptors and HIF in astrocytes and 
oligodendrocytes. 
 
7.7 Myelination and oligodendrocytes in ageing and pathology 
 The optic nerve microarray analysis showed a decrease in 
oligodendrocytes and OPC markers in ageing tissue compared to postnatal and 
adult optic nerve. The difference does not appear to be due solely to the fact 
that the postnatal tissue is actively myelinating, because OPC differentiation 
factors such as Pdgfra, Sox10, Olig2 and Nkx2.2 were also downregulated. 
Moreover, genes associated with transcription, translation and protein folding 
were increased, suggesting an alteration in the maintenance of the homeostasis 
of the proteasome that is associated with ageing and protein aggregation-
diseases (Hipp et al., 2014). These results suggest there might be a link between 
ageing, impairment of OPC proliferation and loss of myelin, which is considered a 
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hallmark of cognitive impairment associated with the major neurodegenerative 
diseases such as AD (Sim et al., 2002; Bartzokis et al., 2003; Bartzokis, 2004). 
Thanks to a collaboration with Prof Rodriguez (Bilbao, Spain), I had the 
opportunity to test this hypothesis on brain tissue of 3xTg-AD mice. 
Unfortunately, due to lack of material and time, the data on the 24-month old 
group are only preliminary and have no statistical relevance. Nonetheless, I 
found significant age-dependent differences in adult OPCs in the other age-
groups, which were statistically valid. Adult OPCs undergo asymmetric division, 
giving rise to sister cells (Dawson et al., 2003; Rivers et al., 2008), and my results 
demonstrated a significant decrease in the number of sister cells at 6-month in 
3xTg-AD, comparable to that observed in 24-month non-Tg age-matched 
controls. The results support evidence that OPC cell division slows with age 
(Psachoulia et al., 2009), and this is accelerated in 3xTg-AD, prior to the onset of 
overt A pathology. A key feature of OPCs is that they form synapses with 
neurons, both glutamatergic and GABAergic (Bergles et al., 2000; Lin & Bergles, 
2004) and this is proposed to regulate their proliferation and hence capacity for 
regenerating oligodendrocytes (Sim et al., 2002). Deregulation of synaptic 
signaling precedes overt A neuropathology in 3xTg-AD, reflecting the situation 
in human AD (Desai et al., 2009; Desai et al., 2010), and my results demonstrated 
deregulation of glutamatergic and GABAergic neurotransmission in ageing white 
matter. Taken together, these studies put forward a hypothesis that early 
deregulation of synaptic signaling results in a decrease in OPC regenerative 
capacity, contributing to the age-dependent loss of myelin and decline in 
cognitive function. Future studies could investigate this in mouse models of AD. 
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7.8 Conclusions 
 In conclusion, this PhD thesis has provided insights into the 
neurotransmitter profile of the optic nerve and how it changes with age. I have 
provided evidence supporting the functional expression of mGluRs in glia and 
determined a cytoprotective role for mGluR5 and mGluR3 in astrocytes and 
oligodendrocytes subjected to hypoxia/ischaemia in situ. Lastly, I provided 
evidence of early changes in OPCs in 3xTg-AD. Taken together with the genomic 
profiling and functional studies on mGluR, this thesis supports a role for glial 
neurotransmission in regulating developmental oligodendrocyte differentiation 
and myelination, and suggests deregulation of neurotransmission in the ageing 
brain may be linked to oligodendrocyte/myelin loss and white matter 
destruction. Thus, my thesis provides evidence that mGluR are a potential 
therapeutic target for maintaining white matter integrity in pathology and in 
ageing. 
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Figure 8.1 Relationship between OPCs and A in 3xTg-AD. Confocal images of coronal 
brain sections from 24-month 3xTg-AD double immunostained for NG2 (green) and A 
(red). (A) Overview of the association of OPCs with A in the CA1 and CA3 layers of the 
hippocampus. (B,C) Deposition of A in the cortex and close association of OPCs with Aβ 
containing neurones (B, B’) and blood vessels (C, C’). (D, D’) OPCs closely associated with 
neurones containing Aβ in the basolateral amygdala nucleus. Scale bars = 100 m in A-D, 
10 m in B’ and 20 m in C’ and D’.  
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Figure 8.2 Relationships between OPCs and A plaques in the hippocampus of 24-
month 3xTg-AD. Confocal images of CA1 hippocampus from 24-month 3xTg-AD mouse 
double immunostained for NG2 (green) and A (red). (A) Overview of relations between 
OPCs and Aβ plaques in the CA1 region. (B-D) Intimate association of OPCs with A 
plaques in maximum intensity z-stack projection (B), single z-section and orthogonal x-x 
and y-y sections (C), and isoformed 3-D view (D). (E) Maximum intensity z-stack 
projection of OPC located between four A plaques. (F) OPC embedded within an Aβ 
plaque in maximum intensity z-stack projections (F, F’’’ and F’’’’) and orthogonal x-x and 
y-y sections (F’, F’’). Scale bars = 50 m in B and 20 m in A-A’’ and B’-F’’’’  
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Figure 8.3 Astrocytes distribution and morphology in the hippocampus of 6-month 
non-Tg control. GFAP immunostaining illustrating the overall distribution of astrocytes 
in the hippocampus (A) and maximum intensity z-stack projections of representative 
GFAP+ cells in the dentate gyrus (B), CA1 layer (C) and CA3 layer (D). Scale bars = 100 m 
in A and 20 m in B-D. 
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Figure 8.4 Interrelations between OPCs and astrocytes with A plaques in the 24-
month 3xTg-AD hippocampus. Confocal images of CA1 region triple immunostained for 
NG2 (green), GFAP (red) and A (blue). (A) OPCs and astrocytes are uniformly 
distributed in the CA1 layer with overlapping process domains. (B) OPCs and astrocytes 
are associated with the same Aβ plaques. (C-E) Higher magnification maximum intensity 
z-stacks showing OPCs and astrocyte processes intertwined within Aβ plaques (C), 
together with single z-section (D) and orthogonal x-x and y-y sections showing 
juxtaposition of their processes within the A plaque (D’-D’’). (E) Juxtapostion of OPCs 
and astrocytes in the absence of Aβ deposits. (F, G) Maximum intensity z-stack 
projection of a large A plaque containing cells co-expressing NG2 and GFAP (F, 
colocalization appears yellow) and higher magnification of individual cell (G). Scale bars 
= 100 m in A, 50 m in B’, 20 m in C, D and F, and 10 m in E and G
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